New vaccines against pneumonia: Investigating protein-specific immune responses to Streptococcus pneumoniae using Experimental Human Pneumococcal Carriage by Owugha, JT
  
New vaccines against pneumonia: 
Investigating protein-specific immune responses to                               
Streptococcus pneumoniae using Experimental                                      
Human Pneumococcal Carriage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted in accordance with the requirements of  
the University of Liverpool for the degree of Doctor in Philosophy by 
 
Jessica Taripre Owugha 
May 2017 
“Side by side in the lung 
All air is renewed 
In constant opposition”  
Eduardo Cury (verse) b. 1963  
Marco Ulgheri (artwork) b. 1970 
 
Title page image: ‘The discovery of pulmonary circulation’ bronze plaque as part of the permanent exhibition 
entitled ‘The history of medicine’, Santa Catarina Hospital, São Paulo, Brasil. Eighth of 24 panels following 
the progression of medicine along the hospital walls: from traditional religious through to contemporary 
genetic approaches, this plaque highlights the age-old history of lung disease. The text alongside describes 
the seeming juxtapositioning of gaseous exchange. For this thesis, the mention of opposition in the 
descriptive text punctuates the importance of investigating potentially beneficial immune responses at the 
site of infection, where opposition between pneumococcal infection and homeostatic function occurs, side 
by side. Photograph credit Jessica T. Owugha, 2014. 
 
~ ~ ~  
“Thought has always worked by opposition” 
Hélène Cixous b. 1937  
 
Hélène Cixous is a Jewish-Algerian-French poet and philosopher: her writings are born out of the juxtaposed 
nature of her genealogy and life story. The quote above reflects these themes of contradiction, and relates to 
this thesis in reinforcing the message of opposing pathogen and homeostatic functions in the lung, and the 
need to research, that is to think about, immune responses at this site of infection in pneumonia vaccine 
discovery efforts. 
 
 
 
 
i 
 
Declaration 
 
This thesis is the result of the original work of the author. In some instances, studies were 
conducted in collaboration with internal colleagues and external collaborators; individual roles 
are outlined overleaf. The laboratory experiments presented in this thesis were carried out 
predominantly at the Liverpool School of Tropical Medicine, United Kingdom, but in part at 
Instituto Butantan, Brasil. The contents of this thesis have not been presented, nor are 
currently being presented, wholly or in part, for any other degree or qualification. 
 
Jessica Taripre Owugha 
May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
Collaborators of/ contributors to work presented in this thesis 
 
Activity  Responsibility  
Recruitment, sample taking, inoculation, 
microbiology  
Angela D. Wright, Andrea M. Collins, 
Carole Hancock, Elena Mitsi, 
Jenna F. Gritzfeld, Stephen B. Gordon 
(Liverpool School of Tropical Medicine)  
 
PspA protein expression and purification  Adriana T. Moreno  
(Instituto Butantan)  
 
Epitope identification 
 
 
Statistical support  
Joshua Blight  
(Jenner Institute) 
 
Duolao Wang & Brian Faragher 
(Liverpool School of Tropical Medicine)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
Abstract  
 
New vaccines against pneumonia: investigating protein-specific immune responses 
to Streptococcus pneumoniae using Experimental Human Pneumococcal Carriage 
J. T. Owugha 
Infections caused by Streptococcus pneumoniae are a major cause of morbidity and mortality 
globally: S. pneumoniae is the primary bacterial agent of pneumonia, the leading cause of 
death in children under 5 years of age and a major cause of invasive disease in the elderly. 
Currently licensed vaccination strategies target pneumococcal capsular polysaccharides of 
which there are 94 known types (serotypes). Antibodies against vaccine serotypes effectively 
protect against invasive pneumococcal disease, but less so against mucosal infections 
including pneumonia. New vaccine development efforts aim to overcome these hurdles by 
targeting conserved and immunogenic pneumococcal proteins. The Pneumococcal Surface 
Protein A (PspA) is a leading candidate due to its expression across all known clinically 
relevant pneumococcal strains, and ability to protect against infection across serotypes. 
However, PspA sequence heterogeneity necessitates identification of cross-protective protein 
constructs. In this doctoral research project, I investigated pneumococcal protein-specific 
humoral and CD4+ T-lymphocyte immune responses to S. pneumoniae utilising the platform 
of Experimental Human Pneumococcal Carriage (EHPC). With an emphasis on PspA, immune 
responses to nasopharyngeal carriage - the prerequisite to pneumococcal disease and proxy 
for infection - were evaluated. 
I present the first evidence of CD4+ T-cell responses specific to an individual pneumococcal 
purified protein in the blood of healthy adults both before and after carriage. PspA-specific 
CD4+ T-cell responses to S. pneumoniae in bronchoalveolar lavage of healthy adults after 
EHPC were detected at lower levels than in blood, indicating non-immunodominance of PspA 
as a T-cell antigen in the lung, and compartmentalisation of immune response. I also describe 
from preliminary data, a potential role of PspA in protection from pneumococcal carriage re-
acquisition, and optimise an assay for the identification of linear pneumococcal protein 
epitopes with potential for inclusion in a multiple epitope protein. 
Unveiling protein-specific immune responses to S. pneumoniae using controlled and 
reproducible EHPC, may aid in our understanding of immunity towards selection of protein 
vaccine candidates for protection against human pneumococcal infection and disease. 
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General introduction 
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1     General introduction 
 
1.1 Pneumococcal disease epidemiology 
 
Infections caused by Streptococcus pneumoniae are a major cause of morbidity and mortality 
globally. With an estimated annual case fatality of 1.6 million, children in developing nations 
bear a disproportionate level of the burden (UNICEF, 2006). Childhood pneumonia of which 
S. pneumoniae is the primary bacterial aetiological agent, is estimated to cause 150 million 
episodes per year in developing nations alone, accounting for over 95% of the global burden. 
Two million children die, 2000 times more than in industrialised nations (Rudan et al., 2004). 
In Europe and the U.S.A, S. pneumoniae infections are the most common cause of bacterial 
community acquired pneumonia (CAP) in adults (Musher and Thorner, 2014). 2013/14 
surveillance data from England and Wales place CAP and non-invasive disease at an 
incidence rate of 20.6 per 100,000 adults, and invasive pneumococcal disease (IPD) at 6.85 
per 100,000 adults. The burden of IPD increases to 20.6 per 100,000 adults in the over 65 age 
stratification (Chalmers et al., 2016). 
Despite effective vaccine implementation programmes, pneumonia remains a global health 
priority as the cause of a large burden of childhood deaths (together with diarrhoea). In 2015 
alone, over 920,000 children under the age of 5 were killed by pneumonia, most victims being 
under 2 years of age (WHO, 2016), where the majority of fatalities occurred in sub-Saharan 
Africa and South Asia (Figure 1.1). This prompted the WHO and United Nations Children's 
Fund (UNICEF) to launch the integrated Global Action Plan for the Prevention and Control of 
Pneumonia and Diarrhoea (GAPPD), which sets out proposals for ending preventable 
childhood deaths due to pneumonia by the year 2025. One such initiative is the Global Vaccine 
Action Plan (WHO, 2013): the program highlights strategies for the prevention of childhood 
disease through vaccination, and its aims include development of next generation vaccines 
and their introduction.  
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Figure 1.1 Pneumonia-attributable deaths in children under 5 years of age. Estimated percentage of childhood deaths of which pneumonia was the cause in 2015. CEE / CIS – Central 
and Eastern Europe / Commonwealth of Independent States.  
Source: WHO and Maternal and Child Epidemiology Estimation Group (MCEE). 
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1.2 At risk groups 
 
Age is the primary risk factor in susceptibility to S. pneumoniae infection. People at the 
extremes of age - under 5s (particularly under 2s) and over 65s - are at an increased risk of 
pneumococcal infection (Public Health England, 2013). 
Certain medical conditions also predispose one to pneumococcal infection (Torres et al., 
2015, Rozenbaum et al., 2012). These may fall under the banner of chronic conditions such 
as: 
 respiratory disease inc. chronic obstructive pulmonary disease (COPD), bronchitis, 
emphysema 
 heart disease inc. ischemic and congenital, hypertension with cardiac complications 
 kidney disease inc. stages 4 and 5, individuals on dialysis 
 liver disease inc. cirrhosis, hepatitis 
 diabetes mellitus 
or those which alter immunity (Ricerca et al., 2009, Jain et al., 2015a, Jain et al., 2015b) 
including:  
 HIV infection 
 respiratory viral infection 
 chemotherapy patients 
 asplenia or splenic dysfunction inc. sickle cell disease, coeliac syndrome 
 malnutrition and under-nourishment 
Further still, environmental factors thought to contribute to pneumococcal infection 
susceptibility (Greenberg et al., 2006, Reisman et al., 2014) include: 
 smoke inc. indoor air pollution from biomass fuel, smoking; 
 crowded living conditions 
However, a recent cluster randomised control trial of 10,750 children comparing pneumonia 
rates associated with traditional indoor cooking methods and a cleaner burning biomass-
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fuelled cook stove intervention, revealed no difference in risk of pneumonia in a rural region of 
Malawi, South Eastern Africa (Mortimer et al., 2017). 
Taken together, it is conceivable as to why the majority of the pneumococcal disease burden 
falls onto developing nations due to the increasing burden of non-communicable chronic 
diseases, geographical co-distribution of haemoglobinopathies, increasing communicable 
infections, in addition to long-lasting struggles with undernutrition and poor living conditions, 
pneumococcal disease truly is a global burden. 
 
1.3 Clinical presentations  
 
1.3.1 Pneumococcal carriage 
Streptococcus pneumoniae is a predominantly human opportunistic pathogen and a 
constituent of the normal human upper respiratory tract microbiome. It colonises the 
nasopharynx in a state known as pneumococcal carriage (Bogaert et al., 2004): although 
usually asymptomatic in adults (Dowson, 2004), carriage has been associated with rhinitis in 
children (Rodrigues et al., 2013a). The nasopharynx, especially of colonised children, is the 
reservoir, and transmission occurs by respiratory droplets on person-to-person contact 
(Bogaert et al., 2004). 
Importantly, pneumococcal carriage is a pre-requisite to the broad spectrum of pneumococcal 
disease (Figure 1.2). Host innate and adaptive immunity affect pneumococcal colonisation 
density and clearance. Together with differential expression of S. pneumoniae virulence 
factors facilitating immune evasion and tissue breach (Miyaji et al., 2013), the range of 
pneumococcal diseases differ in severity and frequency (Figure 1.3).   
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Figure 1.2 Pneumococcal pathogenesis and the spectrum of pneumococcal disease. Streptococcus pneumoniae nasopharyngeal colonisation may result in direct spread of 
pneumococci causing acute otitis media (middle ear infection), or pneumonia (infection of the lung). Pneumococcal translocation into the bloodstream can cause 
bacteraemia/sepsis (blood and multiple organ infection), or meningitis (blood brain barrier (BBB) breach on systemic infection or CSF leakage on middle ear infection). Figure 
courtesy of Wouter deSteenhuijsen Piters [Adapted December 2016].
colonisation 
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Figure 1.3 Hierarchical chart of pneumococcal syndromes and diseases illustrating their relative associated 
levels of severity, frequency and immunological defences required to overcome. 
 
1.3.2 Mucosal disease 
Mucosal diseases such as otitis media and sinusitis are the most common non-invasive 
pneumococcal infections. Otitis media (OM) is the infection and inflammation of the middle ear 
especially common in young children. S. pneumoniae traverse the Eustachian tube from the 
site of nasopharyngeal colonisation to the middle ear where infection can be symptomatic 
(acute OM) e.g. fever, otalgia, ottorrhoea, or asymptomatic (OM with effusion).  Infection of 
the sinuses, sinusitis, can cause complications such as orbital cellulitis and abscess formation 
(Chandler, 1970). 
 
1.3.3 Invasive disease 
Invasive pneumococcal disease (IPD) includes septicaemia, meningitis and pneumonia. 
Although less common than mucosal diseases, they are more severe due to the lower immune 
tolerance capacity of the site of infection, resulting in increased tissue damage (Orihuela et 
al., 2004).  
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Direct spread of S. pneumoniae to the blood (pneumococcaemia) results in symptomatic 
bacteraemia/septicaemia. The initial hyper-inflammatory phase of infection is followed by a 
hypo-inflammatory phase: this immune dysregulation increases risk of secondary infections, 
and can progress to multiple-organ failure (Morton et al., 2014). Septicaemia can result in 
pneumococcal cerebrospinal fluid (CSF) invasion causing meningitis. Subsequent neutrophil 
CSF influx results in apoptosis and necrosis of brain tissue and resultant brain damage (Weber 
and Tuomanen, 2007). 
 
 Pneumonia 
Pneumococcal pneumonia is an invasive disease resulting from initial pulmonary infection. 
However, subsequent bacterial outgrowth results in pulmonary consolidation and infection of 
the lung alveoli, where breathing becomes laboured and painful due to limited oxygen intake 
when alveoli are filled with exudate and fluid. Additional clinical presentations of pneumococcal 
pneumonia (Centre for Disease Control, 2015) include:  
 sudden onset of fever, chills or rigors 
 pleuritic chest pain 
 productive cough with rusty-coloured sputum  
 dyspnea, tachypnea, hypoxia 
 tachycardia, malaise, weakness 
 nausea, vomiting 
 headaches 
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1.4 Streptococcus pneumoniae biology 
 
1.4.1 Identification and biochemical features 
Streptococcus pneumoniae is a facultative anaerobic, Gram positive bacterium. Colony 
morphology on defibrinated blood agar appears as alpha-haemolytic, draughtsman colonies 
(depressed centres due to partial autolysis). Microscopically, pneumococcal morphology is 
described as a lancet-shaped coccus, often observed as diplococci (pairs). Subculture onto 
chocolate blood agar for biochemical tests of catalase (negative), optochin (susceptible) and 
bile solubility (soluble) are indicative of S. pneumoniae isolation. Together, these typical 
morphological features and biochemical tests are the gold standard of S. pneumoniae 
identification. Due to their cost-effectiveness, they are a means of identification worldwide: 
isolation of a bacterium with aforementioned results from blood, cerebrospinal fluid or other 
normally sterile body sites is suggestive of pneumococcal infection (CDC, 2015).  
Further characterisation of S. pneumoniae is based upon tests to identify the predominant 
antigen, capsular polysaccharide (CPS). With over 94 known serotypes (CPS type), 
pneumococci can be classified by serotype-specific antibody to CPS (serotyping), as an 
immunochemically distinct CPS is the defining feature of a serotype, despite their wide 
antigenic variation. The gold-standard for serotyping is the Quellung reaction: a positive 
reaction is visualised as a ‘swollen’ capsule due to the refractive capsule index change on 
antigen-capsule complex formation. Other serotyping techniques centre around the 
agglutination reaction, where a positive result is visualised as ‘clumping’ of bacteria as large 
antigen-antibody complexes become insoluble and precipitate (including slide, tube and 
passive agglutination e.g. latex particles).  
Genotypic methods of characterisation provide a less subjective method of serotyping with 
greater discriminatory power, differentiating between strains that may be classed identical by 
phenotypic assays (Al-Swailem et al., 2004), or mixed serotype infection in any clinical sample. 
Use of genetic serotyping has aided more accurate strain identification and is often employed 
in surveillance operations monitoring disease burden. 
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1.4.2 Structure and function: virulence factors 
 Capsular polysaccharide 
The capsular polysaccharide (CPS) of S. pneumoniae is its major virulence factor and 
therefore, the primary target for licensed pneumococcal vaccination. The capsule primarily 
acts to prevent opsonophagocytosis by mediating complement-dependent phagocytosis 
(Hyams et al., 2010a). 
Phase variation in S. pneumoniae opacity phenotype is associated with pneumococcal 
pathogenicity:  transparent often capsule deficient strains exhibit more invasive potential than 
their opaque, often capsule rich variants (Ring et al., 1998). Reduced capsule expression 
promotes adherence molecule protrusion and access to host cells, increasing binding to 
epithelial surfaces to establish colonisation (Talbot et al., 1996). However, opacity phase 
variation is multifactorial and includes differing expression of capsule-associated genes in 
addition to capsule itself (Chai et al., 2017): an example is expression of teichoic acid, where 
increased expression has been shown to increase nasopharyngeal adherence (Kim and 
Weiser, 1998). 
 
 Proteins 
Streptococcus pneumoniae expresses numerous virulence proteins, some of the most studied 
of which are illustrated in Figure 1.4.  
Those capable of eliciting protection on immunisation are highlighted in colour, and can be 
broadly categorised as follows:  
 choline-binding proteins e.g. Pneumococcal surface proteins A (PspA) and C (PspC) 
 divalent metal-ion-binding lipoproteins e.g. Pneumococcal surface adhesin A (PsaA) 
which has manganese specificity in an ABC transport system 
 LPXTG-anchored proteins e.g. Neuraminidases (NanA) 
 enzymes e.g. pneumolysin (Ply), autolysin (LytA, B & C) 
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Figure 1.4 Streptococcus pneumoniae virulence factors. Well characterised pneumococcal virulence factors 
with protection-eliciting proteins indicated in colour. Image courtesy of Professor D. Briles [Adapted 
December 2016].   
 
Table 1.1 lists thirty of the most studied pneumococcal proteins, and summarises their roles 
in S. pneumoniae virulence. 
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Table 1.1 Well characterised pneumococcal proteins. 
 
Table 1.1 Well haracterised pneum coccal proteins 
Citations from T. 1.1 
(Balachandran et al., 2002, 
Rosenow et al., 1997, Ren et 
al., 2004) (Mitchell and 
Dalziel, 2014) (Steinfort et 
al., 1989, Ratner et al., 
2006) (Berry and Paton, 
1996) (Weiser et al., 2003) 
(Oggioni et al., 2003) 
(Batten et al., 2003, Beiter 
et al., 2006, Attali et al., 
2008)  (Ogunniyi et al., 
2009) (Sanchez et al., 2010) 
(Khan et al., 2012) (Balaban 
et al., 2014) (Nelson et al., 
2007) (Ahmed et al., 2014) 
(Bagnoli et al., 2008) (Ware 
et al., 2006, Brittan et al., 
2012) (Niu et al., 2013) 
(Dong et al., 2014) (Li et al., 
2000) (Agarwal et al., 2013, 
Blue et al., 2003) (Mirza et 
al., 2011) (Holmes et al., 
2001) (Pracht et al., 2005) 
(Yamaguchi et al., 2008) 
(Brown et al., 2001) (Ramos-
Sevillano et al., 2011, Bajaj 
et al., 2015) (Fleurie et al., 
2012, Mahdi et al., 2012) 
(Abbott et al., 2010) (Moffitt 
et al., 2014) 
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C3 – complement component 3; sIgA – secretory IgA; NET – neutrophil extracellular traps. 
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1.4.2.2.1 Pneumococcal surface protein A as a leading vaccine candidate 
 
The Pneumococcal surface protein A (PspA) is a leading vaccine candidate due to its wide 
expression across all known pneumococcal strains (Crain et al., 1990), and ability to protect 
across serotypes (Tart et al., 1996). It is a surface-exposed protein which attaches the 
pneumococcal cell wall via its C-terminal choline binding domain (approx. 200 amino acids 
(aa)). PspA extends through the pneumococcal capsule with its flexible proline-rich linker 
region (approx. 100 aa), permitting surface exposure of the N-terminal helical module (300 – 
400 aa) (Senkovich et al., 2007, Kolberg et al., 2003) (Figure 1.5a).  
Murine models of pneumococcal infection have demonstrated PspA to play a role in protection 
from colonisation, otitis media, pulmonary infection and bacteraemia (Bogaert et al., 2004, 
Briles et al., 2000a). PspA functions to inhibit C3b deposition onto the pneumococcal surface, 
in turn blocking the progression of the alternative complement pathway in mediating pathogen 
clearance (Tu et al., 1999). PspA also binds lactoferrin: this competitively inhibits antimicrobial 
peptide apolactoferrin binding and killing S. pneumoniae (Ren et al., 2004). 
PspA was first identified in monoclonal antibody screens and was found to be protective 
against fatal murine infection (McDaniel et al., 1984, McDaniel et al., 1986). Two decades on, 
PspA has exhibited safety and immunogenicity in phase I human vaccine trials (Briles et al., 
2000a, Nabors et al., 2000). However, based upon computational sequence homology to 
human cardiac myosin, concerns over induction of autoimmunity has hampered its 
development. Further challenges include the sequence variability in PspA molecules: despite 
being conserved as a virulence factor, it is heterogeneous in sequence (Hollingshead et al., 
2000). PspA has been classified into six clades and three families as per sequence homology: 
family 1 (clades 1 and 2), family 2 (clades 3 – 5) and family 3 (clade 6) (Hollingshead et al., 
2000). 44% of human S. pneumoniae isolates are family 1, 55% family 2 and 1% family 3 
(Briles et al., 2000b).  
Darrieux and colleagues (2008) have demonstrated the ability of PspA fusion proteins 
constructed from a combination of the most abundant family 1 and 2 fragments, to induce 
homologous family cross-clade protection in a lethal murine challenge model. However, to 
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harness the full capabilities of PspA as a broadly protective vaccine candidate, novel vaccine 
strategies seek to elicit cross-family heterologous protection. 
Multiple successive studies have highlighted the heterologous family protection abilities of 
immunisation strategies containing antigens from the most prevalent families 1 and 2. These 
include Briles and co-workers' (2000a) murine model demonstration of passive protection 
against lethal challenge with a heterologous PspA-expressing S. pneumoniae strain, following 
immunisation with human anti-PspA-Rx1 (clade 2, family 1)-containing serum. The following 
year, Kolberg and colleagues (2001) identified cross-family reactive monoclonal antibodies 
from S. pneumoniae strains from geographically distinct regions (Norway and The U.S.A).  
Further still, Moreno et al. (2010) conducted a study which clearly illustrated the cross-reactive 
(antibody titre), cross-functional (mediation of C3 deposition) and cross-protective (intranasal 
challenge with heterologous PspA-expressing strains) capabilities of murine serum IgG 
specific to PspA clades 4 and 5 (family 2). This aligned with earlier immunogenicity studies 
which illustrated the cross-reactive properties of anti-PspA clade 4 and 5 antibodies raised in 
mice (Darrieux et al., 2007). 
PspA from S. pneumoniae strain Rx1 (PspA/Rx1), is a well-characterised and studied protein 
by virtue of being the first PspA molecule to be sequenced and its protective domains identified 
(McDaniel et al., 1994, Talkington et al., 1991). Studies demonstrated the safety record of 
PspA/Rx1 in human volunteers, and post-immune serum contained antibodies which 
increased cross-clade functionality compared to pre-vaccination (Ochs et al., 2008, Nabors et 
al., 2000). Due to the foundation of information towards the utility of this strain, we employed 
PspA/Rx1 in protein vaccine candidate investigations.  
We harnessed PspA fragments for immunological investigations due to their potential 
employment in downstream fusion protein approaches, and mitigation of potential PspA 
structural homology to human cardiac myosin due to reported low amino acid sequence 
homology (Ginsburg et al., 2012). Original work with these 100 aa PspA fragments (Figure 
1.5b) by Vadesilho and co-workers (2014) investigated protection against pneumococcal 
pneumonia in a murine model on PspA immunisation. The protective epitopes located in the 
N-terminal alpha helical domain (Fragment 2: 79 – 178 aa) and the clade-defining region 
 - 16 - 
 
(Fragment 4: 179 – 278 aa), elicited 100% and 67% protection respectively. No protection was 
afforded on immunisation with Fragment 7 (F7) of the proline-rich region (329 – 406 aa), 
whereas 100% protection was elicited by the parent protein PspA/Rx1.  
 
 
Figure 1.5 Pneumococcal surface protein A surface localisation illustration and PspA/Rx1 assay fragments 
schematic. (a) PspA attaches the S. pneumoniae membrane by binding choline-containing lipoteichoic acid 
(LTA) of the pneumococcal cell wall, protrudes through the capsule via its flexible proline-rich linker, enabling 
exposure of its functional alpha-helical module to the extracellular environment (b) Fragments 2, 4 and 7 were 
employed as vaccine candidates in ex vivo T-cell stimulation assays. CDR – clade-defining region, PRR – 
proline rich region (P – proline block, N – non-proline block), CBD – choline binding domain. Figure 1.5(a) 
courtesy of Professor D. Briles; Figure 1.5(b) adapted from Vadesilho et al., 2014 [Adapted December 2016]. 
 
(b) 
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1.5 Natural immunity to Streptococcus pneumoniae 
 
1.5.1 Innate defences 
Innate immunity is the first line of defence against pneumococcal infection. Early and non-
specific, it works in concert with the nasopharyngeal epithelium physical barrier to prevent 
pathogen invasion.  
 
 Antimicrobial peptides 
Two abundant antimicrobial peptides involved in the respiratory epithelium innate defence 
against S. pneumoniae are lysozyme and lactoferrin (Travis et al., 2001). 
Human lysozyme is present in secretions of both the upper and lower airway. It inhibits 
pneumococcal growth by muranidase activity, hydrolysing pneumococcal cell wall 
peptidoglycan. S. pneumoniae evades this innate attack by modification of its peptidoglycan 
structure through the action of enzymes PgdA, (an N-acetylglucosamine deacetylase) and Adr 
(an O-acetyl transferase) (Davis et al., 2008). 
Lactoferrin is also present in nasal secretions: it sequesters iron necessary for bacterial 
growth, promotes bactericidal activity and immune modulation. Pneumococci evade killing by 
the toxic iron-depleted form, apolactoferrin, by competitively binding lactoferrin (Shaper et al., 
2004). 
 
 Complement factors 
Human complement deficiencies present a risk factor for invasive pneumococcal disease 
(IPD) (Picard and Casanova, 2003). C3 deficiencies result in recurrent cases of pneumococcal 
pneumonia (Buckley, 2004), demonstrating the importance of the complement system in 
preventing establishment of pneumococcal carriage and subsequent disease. 
Complement proteins exist to clear host-invading organisms by opsonophagocytosis. The 
complement system is made up of three arms: the classical, alternative and lectin pathways. 
All converge on the activation of protein C3 to C3b which together with its processed product 
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iC3b, are deposited on the pneumococcal surface as opsonins promoting assembly of a 
membrane-attack complex and subsequent neutrophil-mediated phagocytosis (Walport, 
2001a, Walport, 2001b).  
Murine models of pneumococcal infection have illuminated roles of the complement pathways 
in pneumococcal diseases prevention. The classical pathway has been described as of 
importance in the activation of complement during the innate immune response to 
S. pneumoniae in mice with systemic infection through influence of C3 deposition proportions 
(Brown et al., 2002). The alternative pathway was implicated in the innate defence during a 
murine model of mucosal middle ear infection with a critical role of factor B, a protease required 
for alternative pathway convertase generation (Li et al., 2011). The lectin pathway has been 
described as playing a role driving survival against fatal murine infection via the essential role 
of the mannan-binding lectin-associated serine protease 2 (MASP-2) for lectin pathway 
convertase formation (Ali et al., 2012). 
However, the pneumococcus has evolved numerous mechanisms to counter the three-
pronged attack of the complement system. These include: 
 Polysaccharide capsule expression - inhibition of C3 protein surface binding (Melin et 
al., 2010), prevention of C3b conversion to iC3b, and subsequent opsonisation via the 
alternative complement pathway (Hyams et al., 2010a)  
 Surface protein expression - pneumococcal proteins that bind complement factors and 
serve as a decoy for the sequential workings of the complement system include; 
o Pneumococcal surface protein A, PspA - competes for phosphocholine 
binding with host defence factor C-reactive protein (CRP). In doing so, 
pneumococcal surface binding sites for CRP are occupied, and subsequent 
C3 deposition cannot occur (Mukerji et al., 2012)  
o Pneumococcal surface protein C, PspC - mediates immune evasion by 
binding Factor H which ordinarily attaches host residues glycosaminoglycan 
(GAG) and/or sialic acids, marking as self (Dave et al., 2001, Jarva et al., 
2002). Contrarily to inhibition of C3 binding by CPS and PspA, PspC has the 
ability to bind complement protein C3, halting progression of complement 
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pathways (Cheng et al., 2000) and promoting epithelial cell adherence in the 
lung (Smith and Hostetter, 2000).  
  
 Toll-like receptors 
On S. pneumoniae invasion, an innate mechanism of defence falls to the pattern recognition 
receptors (PRRs). A major class of PRRs are the Toll-like receptors (TLRs). Expressed on 
host cell surfaces, intracellularly, or secreted, PRRs recognise pathogen-associated molecular 
patterns (PAMPs) which are conserved microbial moieties that trigger inflammatory responses 
(Murphy et al., 2008). 
Totalling ten in humans, three TLRs have been implicated in protection against pneumococcal 
colonisation and infection (Lee et al., 2007, Mogensen et al., 2006, Paterson and Orihuela, 
2010): 
 TLR2 - role in the protection against both pneumococcal carriage (van Rossum et al., 
2005) and disease (Yoshimura et al., 1999). Major ligands have been identified as cell 
membrane lipoteichoic acid (Schroder et al., 2003), and lipoproteins (Tomlinson et al., 
2014), which upregulate pro-inflammatory gene expression on binding (Krishnan et 
al., 2007).  
 TLR4 - the major pneumococcal ligand is described as pneumolysin (Malley et al., 
2003). Data on its role in protection from pneumococcal colonisation and disease is 
dichotomous. Malley and colleagues (2003) show the ability of potent pneumococcal 
virulence factor pneumolysin, to promote colonisation and invasive disease in TLR4 
knock out mice, whereas McNeela et al. (2010) demonstrate a TLR4-independent 
mechanism of immune-induction against pneumococcal infection. Paterson and 
Orihuela (2010) suggest TLR4-directed protection as restricted to airway surfaces, 
and Branger et al. (2004) earlier demonstrate a role of TLR4 in defence against 
pneumococcal pneumonia.  
 TLR9 - ligand described as unmethylated CpG repeats in DNA (Hemmi et al., 2000). 
Important in protection against pneumococcal lung infection (Albiger et al., 2007). 
Wang et al. (2008) demonstrated that morphine-induced impairment of TLR9 
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signalling dampens resident alveolar macrophage phagocytising abilities, resulting in 
a compromised immune response and greater susceptibility to pneumococcal 
infection. 
 
 Phagocytes 
The increased susceptibility to pneumococcal infections in individuals with neutropenia 
(Rolston, 2001) points towards the importance of phagocytes in the immune defence against 
S. pneumoniae. 
Circulating peripheral blood mononuclear cells (PBMCs) migrate to tissue both at steady state 
and in response to inflammation, where they develop into myeloid progenitor cells in the bone 
marrow. Myeloid progenitor cells are the precursor to multiple cell types, including phagocytic 
macrophages and neutrophils (Gordon and Taylor, 2005, Mosser and Edwards, 2008). 
Macrophages are tissue-specific: alveolar macrophages are the predominant cell in the human 
lung, and play a role in clearance of S. pneumoniae by opsonophagocytosis in the prevention 
of pneumonia (Jonsson et al., 1985, Dockrell et al., 2003), whilst splenic and liver 
macrophages are essential for systemic clearance and prevention of septicaemia (Gerlini et 
al., 2014). 
Although diverse in specificity, macrophages maintain two core innate immune functions on 
encountering S. pneumoniae: 
a) Generation of inflammatory responses to induce cellular recruitment and functions by 
cell surface TLR recognition of pneumococcal PAMPs, resulting in macrophage 
activation and inflammatory response induction (Lee et al., 2007)  
b) Phagolysosomal pneumococci killing where differentiated macrophages fuse with 
S. pneumoniae containing lysosomes and induce killing by either: 
i. generation of microbicidal molecules e.g. reactive oxygen species (ROS), 
nitric oxide (NO) and reactive nitrogen species (RNS) (West et al., 2011) 
ii. macrophage apoptosis where phagolysosomes are permeabilised and the 
lysosomal protease cathepsin D activated (Bewley et al., 2011)  
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Neutrophils exert an enhanced phagocytic action compared to macrophages: this however, is 
S. pneumoniae opsonisation-dependent, with either complement, antibody or both (Hyams et 
al., 2010b, Yuste et al., 2008). Neutrophils are the most abundant leucocyte in peripheral 
blood: rapidly recruited to the site of infection where inflammatory mediators such as TNFα 
stimulate cells, which phagocytose S. pneumoniae. However, they exert detrimental effects to 
surrounding tissue in the process by production of ROS and proteinases by-products (Standish 
and Weiser, 2009). Furthermore, neutrophil degradation releases extracellular DNA, which 
together with histones and antimicrobial compounds, form neutrophil extracellular traps 
(NETs) (Brinkmann et al., 2004) to entrap and degrade S. pneumoniae. Pneumococci resist 
NET-mediated killing by virtue of their positive surface charge generating electrochemical 
repulsion against NET-entrapped antimicrobial peptides, and endonuclease EndA NET-
degradation (Wartha et al., 2007, Beiter et al., 2006). 
Innate immune mechanisms often trigger the adaptive. Mark J. Walport uses the example of 
the complement system to describe innate immune mechanisms as: 
“… at the interface between innate and adaptive immunity” 
                          (Walport, 2001b) 
The inflammatory response that results from TLR-PAMP interaction serves too as an important 
link between innate and adaptive immunity, triggering inflammatory cytokine, chemokine and 
type I interferon secretion. This initiates the adaptive pathogen-specific and longer lasting B 
and T lymphocyte immune responses (Kumar et al., 2011). 
 
1.5.2 Adaptive immunity  
Over the time course of immunity, adaptive responses characteristically follow the initial innate. 
Adaptive immunity however, is highly pathogen specific and has memory; it is composed of 
both humoral and cellular responses. 
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 Humoral immunity 
The increased risk of pneumococcal infections amongst individuals with a human 
immunodeficiency where there are defects in immunoglobulin - such as the absence of Ig and 
depletion of circulating B-lymphocytes in X-linked agammaglobulinaemia (XLA) - provides 
insight into the important role of antibodies in the adaptive response against S. pneumoniae 
(Lederman and Winkelstein, 1985). 
The humoral response results from the production of antibodies from B-lymphocytes. In 
humans, antibody production specific to pneumococcal proteins occurs naturally over a 
lifetime as a result of exposure to S. pneumoniae during nasal colonisation, and is 
demonstrated by increases in titres of the predominant serum antibody IgG, from childhood to 
adulthood (Rapola et al., 2000). Conversely, a decline in natural pneumococcal protein and 
capsular polysaccharide IgG and IgM antibodies is observed from young to older adults (Simell 
et al., 2008): this associates with increased disease susceptibility in the elderly. 
The predominant human upper respiratory tract (URT) antibody is IgA subclass 1 (IgA1): IgA1 
ordinarily binds the pneumococcus to prevent host epithelial adherence and promote 
phagocytosis (Weiser et al., 2003). S. pneumoniae however, has evolved mechanisms to 
circumvent this immune defence, the primary being cleavage of IgA by the IgA protease 
(Janoff et al., 2014). Roche and co-workers (2015) demonstrate in a passive transfer 
experiment, that human IgA1-immunised mice challenged with S. pneumoniae producing an 
IgA-1 protease did not agglutinate bacteria: this is where agglutination was identified as a 
pneumococcal clearance mechanism. 
The role of antibodies in pneumococcal systemic and mucosal immunity after a previous 
colonisation episode has been demonstrated (Cohen et al., 2011). Circulating anti-
pneumococcal IgG in mice previously colonised was the predominant antibody response and 
associated with reduced bacteraemia, whereas antibody knock-out mice sustained lethal 
bacteraemia. Bronchoalveolar lavage fluid (BALF) IgG and IgA were elevated in previously 
colonised mice: this associated with reduced bacteraemia in the lung. 
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 T-lymphocyte cell-mediated responses 
Antibodies play a recognised role in pneumococcal natural and vaccine-induced immunity. 
However, pneumococcal-specific T-lymphocyte-directed immunity, particularly CD4+ T-helper 
cells, also play a role in pneumococcal carriage protection, mediation and clearance. Human 
T-cell deficiencies highlight the importance of the T-cell response to S. pneumoniae, where 
individuals are at an increased risk of respiratory tract infections (e.g. DiGeorge syndrome, a 
syndrome hallmarked by defective thymus development (Cole and Cant, 2010)), and 
pneumonia (e.g. Wiskott-Aldrich Syndrome (WASP) which results in a CD43 mutation 
therefore perturbed T-cell receptor signalling; and immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked (IPEX) syndrome where individuals have a FoxP3 mutation resulting in 
reduced T-regulatory function and autoimmunity (Ochs and Thrasher, 2006, Torgerson and 
Ochs, 2007).  
CD4+ T-cells are MHC class II-restricted lymphocytes, therefore preferentially recognise 
peptides 13 - 18 aa in length (Murphy et al., 2008). Antigen-specific, professional antigen 
presenting cells (APCs) e.g. dendritic cells, B-cells and macrophages, mediate peptide-MHC 
class II interaction. 
Multiple murine model studies have elucidated mechanisms of T-cell immunity to 
pneumococcal infection. Protection from the pre-requisite to disease, pneumococcal 
colonisation, is described as antibody-independent (McCool and Weiser, 2004, Trzcinski et 
al., 2005, Malley et al., 2006), CD4+ T-cell dependent (Malley et al., 2005, Basset et al., 2007) 
and antigen-specific (Trzcinski et al., 2008), whereas maintenance of the carriage state has 
been associated with T-regulatory cells (Neill et al., 2014, Zhang et al., 2011). 
 
1.5.2.2.1 T-helper 1 cell immunity 
 
T-helper 1 (Th1) immune responses are broadly pro-inflammatory and responsible for 
intracellular pathogen clearance. Characterised by the release of cytokine IFNγ, Th1 cells 
promote macrophage and neutrophil activation.  
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Humans with IFNγ deficiencies are more susceptible to S. pneumoniae infection. Kemp and 
colleagues (2002) demonstrated that patients with an S. pneumoniae infection as having a 
reduced systemic Th1 cytokine profile which improved on treatment.  
Glennie et al. (2011) reported an increase in nasopharyngeal colonisation in individuals with 
symptomatic HIV (irrespective of antiretroviral therapy): these participants had a defect in 
pneumococcal-specific T-cell IFNγ production. 
In vitro and murine experiments have further illuminated the role of Th1 responses to 
pneumococcal infection: where human monocytes and CD4+ T-cells were co-cultured, live 
pneumococci demonstrated the ability to promote a Th1-biased, monocyte-driven immune 
response (Olliver et al., 2011). In a murine model of pneumococcal pneumonia, IFNγ was 
shown to play a protective role (Rubins and Pomeroy, 1997). Furthermore, Th1-directing 
adjuvants increase protection of conjugate immunisation in a murine systemic lethal infection 
model (Lefeber et al., 2003), and a neonatal lethal bacteraemia and lung pneumococcal 
infection model (Olafsdottir et al., 2012). 
 
1.5.2.2.2 T-helper 2 cell immunity 
 
T-helper 2 (Th2) immune responses are broadly associated with the humoral response against 
extracellular pathogens, and the counter to potential Th1 response-induced tissue damage. 
The primary cytokine hallmark of a Th2 environment is IL4 presence. 
Dysregulation of Th2 responses are associated with allergy, including respiratory conditions 
such as asthma. This aligns with findings of reduced pneumococcal-antigen specific IgG titres 
in asthmatic children (Hales et al., 2012). 
A distinct IL4 signature in the lungs of a mice with pneumococcal pneumonia highlighted a 
Th2 environment as a risk factor for infection (Kang et al., 2009). In an earlier study utilising a 
murine model of sinusitis, Th2 sensitisation increased severity of S. pneumoniae sinusitis  (Yu 
et al., 2004). 
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1.5.2.2.3 T-helper 17 cell immunity 
 
The T-helper 17 (Th17) immune response is pro-inflammatory and plays a role in the clearance 
of extracellular pathogens. The IL-17 family of proteins recruit and activate neutrophils, which 
subsequently clear infections. Although Th17 cells effectively hasten bacterial clearance of 
extracellular microbial pathogens (van de Veerdonk et al., 2009), they have been negatively 
implicated in chronic inflammation of autoimmune diseases (Oukka, 2008, Ouyang et al., 
2008). 
Th17 immunity has been described at the mucosal surface where the pro-inflammatory 
cytokine products of innate cell pathogen clearance upregulate Th17 responses, recruiting 
phagocytes to the site of infection and accelerating bacterial clearance (Figure 1.6).  
Th17 responses play a role in the host’s natural response to S. pneumoniae. Schmid et al. 
(2011) demonstrated Th17 immunity as the dominant immune arm in pneumococcal protein-
specific immune response in human volunteers. On comparing two human populations 
differentially exposed to S. pneumoniae, a more robust pneumococcal protein-specific 
circulating Th17 response was found in the highly exposed population compared to the lower 
exposed population (Lundgren et al., 2012). Wright and colleagues (2013) detected human 
lower respiratory tract antigen-specific cellular responses to S. pneumoniae consistent with a 
Th17 phenotype. 
Murine studies similarly illustrating the role of pneumococcal Th17 responses in protection 
from colonisation include Lu et al. (2008) and Cohen et al. (2011). Zhang and co-workers 
(2009) demonstrated the essential role of Th17 phenotype cells in clearance of both primary 
and secondary pneumococcal colonisation episodes, whereas Malley et al. (2006) 
demonstrated a role of IL-17A in protection against lethal pneumococcal pneumonia. More 
recently, Wang et al. (2017) demonstrate a robust Th17 response in the lungs of mice 
previously colonised and hence protected from pneumonia. 
Antigens capable of inducing a Th17 response are therefore thought to be important in 
prevention of infection. Screening by Th17 induction has therefore been adapted as a selection 
method in identifying potential vaccine candidates (Moffitt et al., 2011).  
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1.5.2.2.4 T-regulatory cell immunity 
 
T-regulatory (Treg) immunity plays an important role in the prevention of immune responses 
to self-antigen, non-harmful antigens and regulation of pathogen-induced immunopathology. 
Cytokine TGFβ is necessary for Treg induction (Huber et al., 2004) and therefore serves as a 
global marker of Treg activity together with IL-10. 
Treg cells are broadly characterised by expression of transcription factor FOXP3, essential for 
phenotype development and cell function (Fontenot et al., 2003), and act to suppress the 
proliferation of CD4+ and CD8+ T-cells (Bacchetta et al., 2007). Antigen-specific Tregs (Tr1 or 
Th3 cells) are understood to play a role in prevention of disease. Treg induction has been 
demonstrated at mucosal surfaces with an inferred role in immune tolerance: this includes 
observations of Bordetella pertussis-specific responses in the respiratory tract of mice 
(McGuirk et al., 2002).  
The immunosuppressive actions of Treg cells has been associated with the persistence of 
pathogens. Elevated numbers of Tregs in patients with multi-drug resistant Mycobacterium 
tuberculosis have been observed (Fan et al., 2016), with similar effects in the persistence of 
pneumococcal infection described with S. pneumoniae-induced Tregs. Neill et al. (2014) 
demonstrated elevated TGF-β1 and IL-10 levels in nasal washes of individuals positive for 
experimental human pneumococcal carriage compared to their carriage negative 
counterparts, and mice with low density, prolonged carriage episodes were shown to have a 
higher level of TGF-β1 compared to their high density comparators. In nasal associated 
lymphoid tissue (NALT), Zhang et al. (2011) report higher levels of Treg phenotype cells in 
carriage positive children compared to carriage negative individuals.  
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Figure 1.6 Mucosal infection and Th17 host defence at the mucosal epithelium (A) pathogens activate peripheral dendritic cells. IL-23 is produced which in turn upregulates 
resident memory Th17 cell IL-17 and IL22 production. (B) Epithelial cells produce antimicrobial peptides due to the synergistic effects of IL-17 and 22 inductive action. (C) IL-
17 promotes epithelial cell expression of granulopoeitic and chemotactic factors. (D) Accumulation of innate immune cells at the mucosal epithelial surface promotes dendritic 
cell secretion of proinflammatory cytokines driving Th17 differentiation from naïve infiltrating T-cells. [Adapted from (Peck and Mellins, 2010); permission gained from 
American Society for Microbiology (ASM)].
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Treg activity is observed reciprocally to Th17 immunity. Elevated numbers of Tregs in the 
adenoids of children positive for nasopharyngeal carriage and an inverse correlation to Th17 
cells have been described (Jiang et al., 2015). Furthermore, ex vivo stimulation of NALT from 
carriage positive children has been show to yield a higher Treg: Th17 ratio than their carriage 
negative counterparts (Mubarak et al., 2016).  
 
1.6 Vaccines and vaccine-induced immunity  
 
A decreased ability to treat pneumococcal infections due to antibiotic resistance has been 
reported in the United Kingdom and worldwide (Guy et al., 2016, Appelbaum, 1992). The 
World Health Assembly resolution 67.25 on Antimicrobial Resistance calls on countries to 
develop national plans to fight antimicrobial resistance (Shallcross and Davies, 2014). The 
UK’s five-year strategic plan response was launched in 2013 (Department of Health, 2013), 
results of which demonstrate a non-significant increase in penicillin non-susceptibility of 
S. pneumoniae from blood cultures (3.1% in 2010 to 4.4% in 2014) (Guy et al., 2016). The 
English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) (Public 
Health England, 2014), report a 23% reduction in pneumococcal bloodstream infections in a 
population with relatively high vaccine uptake (e.g. 93.6% for diphtheria-tetanus-pertussis, 
polio and H. influenza type b for children under 1 year, 2015-16 (NHS, 2016)). This highlights 
the importance of vaccination in disease prevention and subsequent last-line antibiotic 
preservation. 
The first pneumococcal vaccine clinical trial was conducted amongst South African miners 
(Wright et al., 1914): highly susceptible to pneumococcal pneumonia, prophylactic treatment 
with whole pneumococci reduced pneumonia incidence and fatality. Three decades on, 
experiments by MacLeod and Hodges demonstrated that immunisation with S. pneumoniae 
capsular polysaccharide (CPS) prevented against pneumococcal pneumonia, highlighting the 
effectiveness of targeting CPS in vaccination. A clinical trial was conducted, and demonstrated 
the protective efficacy of a quadrivalent polysaccharide vaccine against pneumonia in a 
population of military recruits (MacLeod et al., 1945). However, with the co-incidental rise of 
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penicillin and antibiotic therapy, pneumococcal vaccine efforts were deserted (Klein et al., 
2017). 
Pneumococcal polysaccharide vaccination randomised clinical trials resumed in the 1970s 
(Austrian et al., 1976, Smit et al., 1977, Riley et al., 1977), and Merck licensed a 14-valent 
vaccine, expanded to a 23-valent in 1983 (Klein et al., 2017).  
There are currently 94 known pneumococcal serotypes (Song et al., 2013). Antibodies 
generated against CPS protect against infection by mediating serotype-specific complement-
dependent phagocytosis (Hostetter, 1986). Two vaccine types currently licensed are the 
purified polysaccharide and protein conjugated. 
 
1.6.1 Purified polysaccharide 
Pneumococcal polysaccharide vaccines are a preparation of purified CPS. The currently 
licensed contains twenty-three CPS serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) and is so named the Pneumococcal 
Vaccine Polyvalent or PNEUMOVAX®23 (23vP). 23vP is indicated for the active immunisation 
for prevention of pneumococcal disease by the listed serotypes, is approved for use in children 
over 2 years of age, and adults over 50 years of age who are at risk of pneumococcal disease. 
It is supplied as a single 0.5 mL dose vial, or pre-filled syringe, to be administered 
intramuscularly or subcutaneously into the deltoid muscle or lateral mid-thigh (Pneumovax, 
2017). 
Pneumococcal CPS is a T-cell independent (TI) immunogen, and therefore elicits protection 
against infection with pneumococci of the 23 vaccine serotypes by generation of opsonising 
antibodies on stimulation of mature B-lymphocytes. Without T-cell help, memory is not induced 
and immune protection subsequently short-lived (Bridy-Pappas et al., 2005). The inability to 
mount a T-cell independent response limits vaccine efficacy, and is observed in the 
immunocompromised and extremes of age (Douglas et al., 1983). 
23vP has limited effectiveness against pneumonia in the elderly (Huss et al., 2009). Booster 
doses resulted in hypo-responsiveness in adults, thought to be driven by an induced decrease 
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in memory and B1b-cell frequency, due to B1b antigens driving TI immunity (Clutterbuck et 
al., 2012). Studies on the clinical efficacy of PPV23 in HIV-infected adults have reported 
inconsistent findings, including one study where a higher risk of pneumonia was observed in 
vaccinees (Watera et al., 2004). Further still, the inability of the most vulnerable group to mount 
T-cell independent responses to immunogens (under 2s), means there is no demonstrable 
evidence of 23vP efficacy in very young children (Fedson, 1999).  
 
1.6.2 Polysaccharide conjugates 
Pneumococcal conjugate vaccines (PCV) are composed of CPS conjugated to a carrier 
protein. Proteins have included the tetanus protein, Haemophilus influenzae protein D, and 
the diphtheria toxoid (CRM-197). Conjugated CPS becomes a T-cell dependent immunogen, 
and therefore overcomes the downfalls of 23vP in that conjugate vaccines induce memory, 
protecting more effectively in vulnerable populations including healthy children under 2 years 
of age, and older at-risk children (Eskola et al., 2001, Darkes and Plosker, 2002). 
The first pneumococcal conjugate vaccine to be licensed was the Polysaccharide Conjugate 
Vaccine 7, or Prevenar®7 (PCV7), protecting against pneumococcal disease from serotypes 
4, 6B, 9V, 14, 18C, 19F and 23F (Black et al., 2000). Despite the efficacy of PCV7 in reducing 
the burden of vaccine-type disease, non-vaccine types continued to kill. Notably, where the 
disease burden was greatest in developing nations, protection against the two most common 
serotypes 1 and 5, was not included in the vaccination strategy.  Therefore, serotypes 1, 3, 5, 
6A, 7F and 19A were added to a formulation to create Polysaccharide Conjugate Vaccine 13, 
or Prevenar®13 (PCV13) (Jefferies et al., 2011).  
In addition to post-PCV introduction reductions in worldwide burden of invasive pneumococcal 
disease (Rodgers and Klugman, 2016), PCV reduces rates of pneumococcal colonisation, 
reducing transmission and creating a herd immunity effect (Dagan and Fraser, 2000). 
Consequently, conjugate vaccines have an added benefit of reducing the total incidence of 
pneumococcal disease in unvaccinated community members. 
A randomised placebo-controlled trial was conducted to evaluate the clinical benefit of PCV13 
in the prevention of pneumococcal pneumonia in older adults (CAPiTA) and demonstrated a 
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halved vaccine efficacy of PCV13 against vaccine-type pneumococcal pneumonia compared 
to invasive disease (Bonten et al., 2015). This highlights the clinical need to understand 
biological mechanisms involved in protection from pneumococcal infection to improve vaccine 
efficacy. 
Current vaccination strategies however, induce capsular polysaccharide-specific IgG which 
confers protection against pneumococcal disease in a serotype-specific manner. The 
phenomena of serotype replacement and capsular switching play a role in limiting vaccine 
effectiveness. Serotype replacement involves non-vaccine serotypes inhabiting the disease-
causing niche vacated by vaccine-targeted serotypes (Gladstone et al., 2015), whereas with 
capsular switching the pneumococcus acquires a new capsular polysaccharide by horizontal 
gene transfer (Wyres et al., 2013). Both permit vaccine escape – where immunisation does 
not protect against non-vaccine serotypes (NVT). 
Vaccine strategy has adapted to target emerging disease-causing serotypes, adding 
polysaccharides to vaccine formulation, evolving from PCV7 to the current PCV13. This 
however covers less than 15% of the potential 94 disease-causing serotypes. Together with 
the expense of conjugation, and potential of excessive polysaccharide antigens reducing the 
responsive B-cell population (Clutterbuck et al., 2012), the numbers of polysaccharides that 
can be added to formulation is limited.  
Alternative strategies are therefore still needed, with a focus on mounting lasting serotype-
independent protection. Understanding mechanisms by which the pneumococcus evades host 
immunity is important in the development of novel vaccination strategies. 
 
1.7 Experimental human pneumococcal carriage 
 
1.7.1 The model 
The ability to investigate pneumococcal disease in the primary natural host, the human, is 
invaluable. Using the state of carriage as a surrogate for infection, novel vaccine candidates 
can be tested for their ability to prevent carriage, the pre-requisite to disease. 
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The Liverpool School of Tropical Medicine-based Experimental Human Pneumococcal 
Carriage model (EHPC) has been established such that 50% of healthy volunteers acquire 
carriage when intranasally inoculated with an average of 80,000 cfu/100 µL per naris of 
S. pneumoniae strain BHN418. Volunteers are carefully selected through a screening process, 
and closely monitored throughout the duration of a study by a safety committee of clinicians 
and scientists (Gritzfeld et al., 2013). 
Individuals with immunity which prevents the carriage state can be viewed as the protected 
population, and those who become carriers, the susceptible population. This allows for probing 
of immunological factors influencing S. pneumoniae dynamics in the natural human host. 
 
1.7.2 Biological and immunological utility 
The EHPC model is a platform which has been used to investigate pneumococcal biology and 
the immunological factors regulating pneumococcal dynamics. 
Humoral immunity affected by EHPC is described as increased pneumococcal-specific 
mucosal IgG on S. pneumoniae exposure (Wright et al., 2012), and augmented on carriage 
acquisition. We have reported two humoral correlates of colonisation protection: serotype 6B 
capsular polysaccharide IgG-secreting memory B-cells (Pennington et al., 2016), and capsular 
polysaccharide-specific mucosal IgG mediating S. pneumoniae agglutination (Mitsi et al., 
2017). Elevated serum IgG with specificity to capsular polysaccharide and pneumococcal 
proteins conferred passive protection against murine lethal challenge with a heterologous 
pneumococcal strain (Ferreira et al., 2013). Cellular immune responses to carriage include 
that described by Wright and colleagues (2013) of increases in S. pneumoniae-specific 
CD4+IL-17+ T-cells in blood and the lung on carriage acquisition. 
Biological factors associated with increased susceptibility to pneumococcal carriage 
acquisition were elucidated as diversity of nasopharyngeal microbiome, whereby increased 
diversity associated with increased rates of carriage (Cremers et al., 2014), and presence of 
an upper respiratory tract virus at the time of inoculation which increased rate of colonisation 
(Glennie et al., 2016). The biological state of pneumococcal carriage is protective against re-
acquisition with a homologous S. pneumoniae (Ferreira et al., 2013). 
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Immunological mediators of S. pneumoniae carriage density and duration have been 
described. Increased nasal Factor H levels resulted in increased pneumococcal adherence 
via Pneumococcal surface protein C in an in vitro model of virus-pneumococcal co-infection 
(Glennie et al., 2016). The ability of nasopharyngeal cells to induce TGF-β1, together with T-
regulatory cells, were shown by Neill and co-workers (2014) to play a role in the acquisition 
and maintenance of pneumococcal carriage.  
The aforementioned studies contribute to our understanding of S. pneumoniae carriage as the 
pre-requisite for pneumococcal disease, and therefore inform strategies and targets of 
vaccination. 
 
1.7.3 EHPC-PCV study: licensed vaccine efficacy against experimental carriage 
The EHPC platform has been used to assess vaccine efficacy as measured by pneumococcal 
colonisation. Vaccine clinical trials are often expensive and lengthy due to the number of 
individuals required to investigate population-level efficacy against disease. To validate the 
EHPC platform for use in vaccine efficacy, Collins and colleagues (2016) determined the effect 
of the licensed PCV-13 on colonisation with vaccine serotype 6B in a double blind randomised 
controlled trial. 
During this study of 100 volunteers, the vaccinated group had a significantly reduced 
colonisation rate (risk ratio = 0.22, CI = 0.09 to 0.52, p < 0.01), and density and duration of 
colonisation (geometric mean vaccinated: 259, geometric mean placebo: 11183, p = 0.02) 
compared to the placebo vaccinated-group. Therefore, the EHPC model was demonstrated 
as an effective method of assessing the protective efficacy of novel vaccine on pneumococcal 
colonisation. 
Notably, the EHPC model has proven safe, efficient and cost-effective in investigating effects 
of the licensed vaccine PCV13 on nasopharyngeal colonisation (Collins et al., 2016): it 
therefore offers a platform to test the effect of novel vaccines on colonisation and associated 
immunological parameters.   
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1.7.4 GEN-004: new vaccine efficacy against experimental carriage 
The EHPC platform has been used to investigate the safety, immunogenicity and efficacy of 
Genocea biosciences’ novel vaccine candidate GEN-004. Containing three T-cell inducing 
universal pneumococcal proteins: maltose/maltodextrin-binding protein (SP2108), ABC 
transporter substrate-binding protein (SP0148), and hypothetical surface exposed protein 
(SP1912), GEN-004 was protective against pneumococcal carriage in murine models (Moffitt 
et al., 2014). 
During the Phase II study using the EHPC platform, GEN-004 was reported as safe and 
immunogenic as determined by antibody titres to vaccine antigens: 100% of volunteers 
responded to antigen SP2018, 97.7% to SP0148, and 83.7% to SP1912. GEN-004 was also 
demonstrated as capable of modest reductions in volunteers with experimental carriage and 
volunteer carriage density as determined by classical microbiology (day 2 colonisation rates: 
52% vaccinated, 39% placebo) and qPCR. However, no result was statistically significant 
between placebo and vaccine immunised groups (Skoberne et al., 2016). 
 
1.8 New pneumococcal vaccines 
 
1.8.1 Whole cell vaccine 
Whole cell vaccines such as the unencapsulated S. pneumoniae strain developed by PATH 
(formerly Program for Appropriate Technology in Health), expose surface proteins common to 
multiple serotypes as immunogens. Pre-clinical murine trials of PATH’s whole cell 
S. pneumoniae vaccine (wSP) have shown protection against colonisation and invasive 
disease by multiple pneumococcal strains (Malley et al., 2001, Malley et al., 2004). 
To date, two Phase I trials of PATH wSP have been completed in the U.S.A and Kenya to 
identify the optimal vaccine dose in adults and toddlers, in addition to a Phase II efficacy study 
on nasopharyngeal carriage in the paediatric Kenyan population. A third trial in the Kenyan 
cohort is underway, and is a Phase II to assess PATH wSP safety and immunogenicity as 
measured by serology (U.S. National Institutes of Health, 2014). 
 
 - 35 - 
 
1.8.2 Recombinant bacteria 
Recombinant bacteria expressing pneumococcal antigens protect mice against infection to 
varying extents. Their attraction as a vaccine strategy lies in their low-cost vaccine production, 
needle-free delivery, and induction of strong mucosal immunity (Curtiss et al., 2010). 
Xin et al. (2009) utilise a recombinant avirulent Salmonella enterica serovar Typhimurium 
vaccine system (RASV) for expression and secretion of PspA fusion proteins: immunised mice 
were protected against infection with S. pneumoniae clinical strains expressing a heterologous 
PspA. An extension of the RASV system is described and termed regulated delayed antigen 
synthesis (RDAS) (Wang et al., 2010). Protection against challenge with an S. pneumoniae 
strain expressing a heterologous PspA is enhanced on regulation of PspA expression, 
reflected in reduced IgG titres in the RASV strain constitutively expressing PspA. 
Surface expression of PspA by heterologous bacteria has also proven effective in reducing 
S. pneumoniae infection. Kothari et al. (2015) model a system of conjugation of PspA to 
Salmonella Typhi Vi capsular polysaccharide, protective against lethal challenge in murine 
models. Furthermore, Kuipers and co-workers (2015), demonstrated protection against 
S. pneumoniae colonisation upon immunisation with PspA-expressing salmonella outer 
membrane vesicles. 
An early example of a similar inducible expression system was developed by Oliveira and 
colleagues (2003), where Lactobacillus casei is the vector, and PspA the test antigen. PspC 
has also been expressed using L. casei, and exposed on the bacterial surface on nasal 
immunisation, resulting in induction of high mucosal anti-PspC IgA titres in mice protected 
from colonisation (Hernani et al., 2011). Live lactic acid bacteria are an attractive vector as 
they can be used to deliver protective antigens mucosally and have been shown to elicit 
mucosal and systemic antigen-specific immunity (Vintini and Medina, 2011). 
Optimisation of recombinant protein vaccine systems is important in the arena of new protein 
vaccines vaccine discovery: realising methods of antigen delivery for maximum protective 
effect is vital in the identification of novel, immunogenic and protective pneumococcal protein 
vaccine candidates. 
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1.8.3 Protein vaccine candidates 
Vaccine-driven changes in the pneumococcal population are challenges to lasting protection 
against pneumococcal disease. The primary hurdle is the phenomenon of serotype 
replacement, but also includes capsule switching and increase in serotype diversity. The latter 
is eloquently compared to the Red Queen hypothesis (reciprocal co-evolution of competing 
species, human beings and bacteria) (Stockmann et al., 2016). In all cases, non-vaccine 
capsular types pose an increased risk to causing infection and disease. 
The hurdle of serotype-specific, short-lived vaccination strategies together with the high costs 
of manufacture, has made the development of new cost-effective, broad coverage 
pneumococcal vaccines a global health priority (Miyaji et al., 2013). Pneumococcal protein 
vaccine approaches are designed to address this need, with the most promising candidates 
alongside their roles in pneumococcal virulence tabulated in Table 1.1. 
In addition to vaccination, S. pneumoniae protein constructs are under investigation for 
immunotherapy strategies. One such example is P4, a 28 aa construct of the Pneumococcal 
surface adhesion A protein (PsaA) (Rajam et al., 2008). Bangert and colleagues (2013) 
demonstrated efficacy towards promotion of ex vivo S. pneumoniae phagocytic killing on 
treatment of human alveolar macrophages. Furthermore, clinical samples obtained from adults 
with severe sepsis infection demonstrated the effect of P4 peptide on enhancing neutrophil 
phagocytosis of S. pneumoniae and hence, its potential use as an augmented immunotherapy 
(Morton et al., 2016).  
Protein vaccines composed of single and multiple surface antigen formulations of antigens 
widely expressed across pneumococcal strains are known to induce adaptive immunity above 
capsular polysaccharide (Moreno et al., 2010, Cohen et al., 2013). Together with the potential 
to overcome barriers of serotype replacement and lack of mucosal efficacy, we chose to 
investigate protein-specific immune responses to S. pneumoniae in healthy adult volunteers 
using the Experimental Human Pneumococcal Carriage model.  
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1.9 Study aims 
 
Our overall aims and specific objectives were to: 
1. Further our current understanding of humoral PspA-specific responses to          
S. pneumoniae 
 Investigate whether protection against re-acquisition of carriage associates with          
S. pneumoniae expressed PspA family  
 Assess if pneumococcal exposure alters heterologous PspA family IgG titre 
 Assess whether pneumococcal exposure modulates IgG binding to S. pneumoniae 
expressing heterologous PspA families 
 
2. Investigate blood PspA-specific CD4+ T-cell responses to S. pneumoniae 
 Determine whether antigen-specific CD4+ T-cell responses to S. pneumoniae are 
detectable in blood 
 Assess whether inoculation alters antigen-specific CD4+ T-cell responses to                  
S. pneumoniae 
 Compare antigen-specific CD4+ T-cell responses to S. pneumoniae post-inoculation 
across carriage status  
 Examine whether antigen-specific CD4+ T-cell responses to S. pneumoniae associate 
with colonisation intensity 
 
3. Investigate BAL PspA-specific CD4+ T-cell responses to S. pneumoniae 
 Compare non-PspA-specific pulmonary CD4+ T-cell cytokine levels across carriage 
status 
 Determine whether PspA-specific immune response to S. pneumoniae is detectable 
in pulmonary CD4+ T-cells 
 Explore if carriage augments PspA-specific responses to S. pneumoniae in pulmonary 
CD4+ T-cells 
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 Assess whether PspA-specific responses to S. pneumoniae in pulmonary CD4+           
T-cells correlate with carriage intensity 
 Investigate whether PspA-specific CD4+ T-cell responses to S. pneumoniae are of 
comparable magnitude in the lung and blood 
 
4. Investigate systemic S. pneumoniae epitope-induced lymphoproliferation 
 Identify the thirty most studied, immunogenic pneumococcal protein vaccine 
candidates by literature search 
 Determine conserved peptide sequences of functional importance (fragility islands) 
within selected vaccine candidates 
 Optimise lymphoproliferation assay conditions 
 Assess lymphoproliferation activity of selected epitopes 
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2 General methods 
 
Investigating human protein-specific immune responses to S. pneumoniae required a number 
of methods. Specifically: volunteer recruitment and ethical approval, The Experimental Human 
Pneumococcal Carriage model, obtaining and processing of clinical samples, and laboratory 
procedures. Methods and materials common to more than one study chapter are detailed 
below, with an overview recapitulated in the relevant thesis chapter. Study-specific methods 
and materials are detailed in the relevant thesis chapter. 
 
2.1 Volunteer recruitment and ethical approval 
 
All four studies in this thesis (chapters 3 – 6) required human volunteer participation. 
Therefore, participants were recruited subject to ethical approval. 
 
2.1.1 Experimental Human Pneumococcal Carriage studies 
Healthy adult volunteers were enrolled with written informed consent to an Experimental 
Human Pneumococcal Carriage study (chapters 3 to 5) with inclusion criteria:  
 18 - 60 years of age; 
 proficiency in the English language; 
 communicable by electronic means (telephone and text message). 
Volunteers were unable to participate if they fell under any exclusion criteria:  
 close contact with at-risk individuals (young children, immunosuppressed adults, 
elderly adults, individuals with chronic ill health);  
 current smoker or a significant smoking history (> 10 pack years);  
 sufferer of asthma or other respiratory disease;  
 pregnant;  
 allergic to penicillin; 
 involved in another clinical trial (unless observational or in a non-interventional phase); 
 - 41 - 
 
 unable to give full informed consent.  
Ethical approval was obtained from the National Health Service Research Ethics Committees 
(REC 12/NW/0873 (EHPC-PCV clinical trial) and 11/NW/0592 (Dose-ranging/Re-challenge 
study)), and studies sponsored by the Royal Liverpool and Broadgreen University Hospitals 
Trust. Clinical trial approval (EHPC-PCV) was granted by the Medicines and Healthcare 
products Regulatory Agency (MHRA) (EudraCT 2012-005141-20). Volunteer appointments 
took place in the Clinical Research Unit at the Royal Liverpool University Hospital.  
 
2.1.2 Epitope-induced lymphoproliferation study 
Healthy adult volunteers were recruited from the Liverpool School of Tropical Medicine blood 
donor register under the Research Tissue Bank ethics approval granted by The North West 3 
Research Ethics Committee, Liverpool East (REC 11/H1002/9) and Liverpool School of 
Tropical Medicine Human Tissue Act Research Licence number 12548. Volunteer 
appointments took place in the Department of Clinical Sciences at the Liverpool School of 
Tropical Medicine. 
 
2.2 The Experimental Human Pneumococcal Carriage model 
 
The Experimental Human Pneumococcal Carriage (EHPC) model utilised clinical isolate          
S. pneumoniae serotype 6B strain BHN418 as the inoculation strain (GenBank accession 
number ASHP00000000.1) (a gift of P. Hermans of Radboud University, Nijmegen, S. 
Normark and B. Henriques-Normark of the Karolinska Institute, Stockholm). An animal 
product-free medium, Vegitone Infusion broth (Fluka, Buchs, Switzerland), was used to grow 
the inoculum stock, and its serotype, penicillin sensitivity, and purity independently confirmed 
by the Public Health England reference laboratory. Each inoculum was prepared on the day 
of inoculation and dose quantified to an average 80,000 colony-forming units (cfu)/ 100 µL per 
naris, as quantified by Miles and Misra (Miles et al., 1938). 
Nasal carriage was determined before and after inoculation by nasal wash sampling (Gritzfeld 
et al., 2013). Volunteers seated in a semi-recumbent position had 5 mL sterile saline inserted 
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into their anterior nasal space, which was immediately expelled by rapid exhalation and 
collected into a foil bowl. Saline insertion-exhalation cycles were repeated until 20 mL saline 
had been washed through the nose.  
Pooled samples were pelleted and plated onto chocolate blood agar (CBA) for pneumococcal 
carriage determination. Gentamicin (4 μg/mL) CBA was used to negatively select against 
commensal microbial flora. Suspected S. pneumoniae colonies were subcultured for purity, 
Gram stain, optochin sensitivity and bile solubility. S. pneumoniae serotype was determined 
by latex agglutination (Statens Serum Institute, Denmark), and density in cfu/mL of returned 
nasal wash (Gritzfeld et al., 2013).  
The Dose-ranging/Re-challenge study pneumococcal preparation, inoculation and 
subsequent detection was carried out as described above, with the modification of five extra 
doses. Six groups of 10 volunteers were inoculated with increasing target doses of                          
S. pneumoniae strain BHN418: 1, 2, 4 and 8 x104, 1.6 and 3.2 x105 cfu/100 µL per naris. 
 
2.3 Clinical samples: obtaining and processing 
 
2.3.1 EHPC-PCV clinical trial 
Nasal wash samples were obtained for determination of natural pneumococcal colonisation at 
5 days before inoculation. Experimental carriage was determined by classical microbiology at 
days 2, 7 and 14 following inoculation with a single intranasal target dose of 80,000 cfu/100 µL 
per naris S. pneumoniae serotype 6B (strain BHN418).  
Blood samples were obtained 5 days before and 21 days after S. pneumoniae inoculation. 
Peripheral blood mononuclear cells (PBMCs) were isolated by density-mediated centrifugation 
using Ficoll-Paque PLUS (GEHealthcare, Uppsala (Sweden)) according to the manufacturer’s 
instructions. PBMCs were washed twice in PBS, re-suspended in complete media [RPMI + 20 
mM L-glutamine supplemented with antibiotics (penicillin 40 U/mL, streptomycin 40 µg/mL, 
neomycin 80 µg/mL) and 10% Foetal Calf Serum (FCS) (Invitrogen)], and seeded into a 24-
well plate in a volume of 1 mL and concentration of 1 x 106 PBMCs/mL. 
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Research bronchoscopy and Bronchoalveolar lavage (BAL) was offered to participants 
between weeks 9 – 21 on completion of the study. This followed administration of a 3-day 
course of Amoxicillin 500 mg if they were carriage positive (Figure 2.1a).  
  
Figure 2.1 Timeline for sample collection relative to inoculation with S. pneumoniae strain BHN418 (serotype 
6B expressing PspA1) (a) EHPC-PVC clinical trial: blood samples were taken 5 days pre- (t = -5d) and 21 days 
post-inoculation (t = 21d). Nasal washes taken at intermediary days (d) 2, 7 and 14 for monitoring of 
pneumococcal carriage (carriage negative, c-, = 32; carriage positive, c+, = 8). Bronchoscopy offered (week 9 
– 21) after unblinding for carriage status (c- = 6, c+ = 8). (b) Dose-ranging/Re-challenge study: serum samples 
obtained from blood 5 days pre- (t = -5d) and 14 days post-inoculation (t = 14d).  Cohort A (c- = 16, c+ = 12); 
Cohort B (natural carriers at baseline) pre-inoculation samples obtained after clearance of natural carriage 
episode (post-inoculation c- = 4, c+ = 4). Natural carriage isolates molecularly typed to identify PspA clade 
and family. 
 
 - 44 - 
 
Whole BAL samples were filtered through muslin to remove mucus plugs and 5 mL of 
unprocessed BAL stored at −80°C (Figure 2.2). Whole sample was pelleted at 470 x g for 10 
minutes; supernatant was stored at −80°C for subsequent humoral analysis, and the cellular 
fraction taken forward for ex vivo stimulation. Cells were re-suspended in complete media and 
differentially counted to note macrophage and lymphocyte yield, plated into standard 6-well 
tissue culture plates at a concentration of 5 x 105 macrophages/mL, and incubated at 37°C, 
5% CO2 for 3 hours to promote macrophage adhesion. Non-adherent cells were collected, 
washed in complete media, and plated at a count of 200 – 500,000 cells/mL in a 96-well plate. 
 
Figure 2.2 Whole BAL cytospin differential stain to demonstrate immune cells found in the lung. Alveolar 
macrophages represent one of the most abundant immune cells in the lung which were extracted by 
adhesion, and lymphocytes (inset) a population of non-adherent cells. Horizontal bar represents 10 µm in 
length. 
 
2.3.2 Dose-ranging/Re-challenge study 
Nasal wash samples were obtained for determination of natural pneumococcal colonisation 5 
days before inoculation. Experimental carriage was determined by classical microbiology, 14 
days after inoculation with S. pneumoniae strain BHN418. 
10 µm 
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Serum samples were obtained from blood 5 days before and 14 days after S. pneumoniae 
inoculation. Healthy adult volunteers were stratified into two groups and inoculated with a 
target dose of 40,000 cfu/100 µL per naris: Cohort A, negative for carriage on presentation, 
and Cohort B, who were naturally colonised with S. pneumoniae at presentation (re-inoculated 
after clearance of their natural carriage episode) (Figure 2.1b).  
 
2.3.3 Epitope-induced lymphoproliferation study 
Blood samples were collected at a single time-point for PBMC isolation and subsequent 
lymphoproliferation experiments. Peripheral blood mononuclear cells (PBMCs) were isolated 
by density-mediated centrifugation using Ficoll-Paque PLUS (GEHealthcare, Uppsala 
(Sweden)) according to the manufacturer’s instructions. PBMCs were washed twice in PBS, 
re-suspended in complete media [RPMI + 20 mM L-glutamine supplemented with antibiotics 
(penicillin 40 U/mL, streptomycin 40 µg/mL, neomycin 80 µg/mL) and 10% Foetal Calf Serum 
(FCS) (Invitrogen)], and seeded into a 24-well plate in a volume of 1 mL and concentration of 
1 x 106 PBMCs/mL. 
 
2.4 Laboratory procedures 
 
To investigate protein-specific immune responses to S. pneumoniae, we synthesised 
pneumococcal proteins and peptides. A leading vaccine candidate, Pneumococcal surface 
protein A (PspA), and derivative fragments were employed as stimulants in CD4+ T-cell assays 
of chapters 4 and 5. 
 
2.4.1 Recombinant protein expression and purification 
The PspA of S. pneumoniae strain Rx1 (PspA/Rx1) (GenBank accession number M74122.1) 
was selected as it is well characterised having been the first PspA molecule to be described 
(Kolberg et al., 2003, McDaniel et al., 1994). The 100 aa fragments, with a 50 aa overlap 
covering the mature N-terminal region of the proline-rich region, were constructed and purified 
as previously described (Vadesilho et al., 2014).  
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 Bacterial strains and plasmids  
Escherichia coli BL21/DE3 (Sigma-Aldrich®, St Louis (USA)) was used as the host strain for 
all protein expression experiments. His-tagged PspA/Rx1 fragments originating from 
S. pneumoniae strain Rx1 were engineered into ampicillin-selectable and IPTG-inducible 
expression vector pAE (Ramos et al., 2004) to produce plasmids pAE-pspARx1 (1,011 bp), 
pAE-frag 2 (300 bp), pAE-frag 4 (300 bp) and pAE-frag 7 (243 bp) (Vadesilho et al., 2014).  
Recombinant E. coli was cultured in Luria Bertani (LB) broth (Sigma-Aldrich®, St Louis (USA)) 
supplemented with 1 μg/mL ampicillin. Incubation at 37°C at an agitation of 180 rotations per 
minute (rpm) for 18 – 24 hours constituted an overnight (O/N) culture.  
 
 Transformation of heat competent E. coli  
Competent BL21(DE3)-T1R cells (Sigma-Aldrich®, St Louis (USA)) of 50 μL were thawed on 
ice for 15 minutes, 5 μL of PspA/Rx1 DNA added and left on ice for 30 minutes. Cells were 
given a thermal shock at 42°C for 2 minutes and recovered in 500 μL of Super Optimal broth 
with Catabolite repression (SOC) [0.5% yeast extract (Sigma-Aldrich®); 2% Tryptone (Sigma-
Aldrich®); 10 mM NaCl (Sigma-Aldrich®); 2.5 mM KCl (BDH); 10 mM MgCl2 (BDH); MgSO4 
(Sigma-Aldrich®); 20 mM glucose (BDH)] at 37°C and 180 rpm for 1 hour. Dilutions of 50, 100 
and 300 μL were plated onto ampicillin-selective LB agar plates, and incubated at 37°C O/N 
to confirm successful transformation. 
 
 Induction of His-tagged protein  
O/N cultures of each bacterial clone were subcultured in a 1:10 dilution of LB broth (Sigma-
Aldrich) supplemented with 1 μg/mL ampicillin, and grown to an optical density (OD) of 0.6 – 
0.7 at wavelength 600 nm (OD600). Protein expression was induced by addition of 1M IPTG 
and incubated at 37°C for 3 hours. Cells were isolated by centrifugation at 1,300 x g for 20 
minutes, supernatants discarded and pellets stored at -20°C. 
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 Cell lysis  
Bacterial cell pellets containing expressed protein were thawed on ice and underwent cell lysis 
by one of two methods: mechanical disruption (proteins used in Chapter 4) or enzymatic lysis 
(proteins used in Chapter 5).  
2.4.1.4.1 Mechanical disruption 
 
Cells were re-suspended in equilibration buffer [50 mM Tris pH 6 - 8 (FischerScintific), 150 
mM NaCl (Sigma-Aldrich®), 5 mM imidazole (Sigma-Aldrich®)]. Cells were then disrupted at 
a pressure of 130 bars (1885.5 psi) using the PandaPLUS 2000 system (GEA Niro Soavi, 
Parma, Italy).  
2.4.1.4.2 Enzymatic lysis 
 
Lysozyme and Benzonase® Nuclease supplemented lysis buffer (Qiagen) was used to lyse 
cells by incubation at 4°C for 30 minutes. 
 
 Protein purification and dialysis 
Cell lysis cellular debris was removed by centrifugation at 14,000 x g and the resultant soluble 
expressed fraction purified using Ni-NTA Resin (Qiagen) according to a previously described 
QIAexpress® Ni-NTA Fast Start Handbook protocol (June 2006) using in-house wash buffers 
of varying imidazole concentration [stock: 15 mL 1M Tris pH 8.0 (FisherScientific), 9 mL 5M 
NaCl (Sigma-Aldrich®), 1M imidazole (Sigma-Aldrich®) (1.5 mL for 5 mM wash buffer; 6 mL 
for 20 mM; 12 mL for 40 mM; 18 mL for 60 mM; 75 mL for elution buffer) completed to 300 mL 
with MilliQ H2O]. 
Purified proteins were dialysed using 7K MWCO SnakeSkin™ dialysis tubing 
(ThermoScientific, Rochford, (USA)) to remove imidazole and other contaminant salts 
according to a previously described manufacturer’s protocol (2013), and quantified by 
densitometry using SDS gel electrophoresis reads and GelAnalyzer2010® software (Lazar, 
2017). 
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2.4.2 Ex vivo stimulation 
Purified proteins were used as stimulants in investigation of PspA-specific CD4+ T-cell 
responses to S. pneumoniae in blood (chapter 4) and BAL (chapter 5).  
 
 Blood 
Isolated PBMCs were left unstimulated (for background subtraction of non-specific cytokine 
secretion), or separately stimulated with 4 µg/mL PspA antigens (PspA/Rx1, Fragments 2, 4 
and 7), or 0.5 µg/mL positive assay control staphylococcus enterotoxin B (SEB). PBMCs were 
incubated at 37°C, 5% CO2 for 120 hours and in the final 16 hours of stimulation, 1 µL of a      
3 mM monensin stock (BD Biosciences, San Diego (USA)) and 1 µL of a 1mg/mL brefeldin 
stock (BD Biosciences) were added to each well, preventing release of induced cytokines from 
the endoplasmic reticulum and Golgi apparatus of lymphocytes. 
 
 BAL 
Non-adherent cells were left unstimulated (for background subtraction of non-specific cytokine 
secretion), or separately stimulated for 16 hours with 8 µg/mL PspA antigens PspA/Rx1, 
Fragments 2, 4 and 7.  After incubation for 2 hours at 37°C, 5% CO2, 1 µL of a 3mM monensin 
stock (BD Biosciences, San Diego (USA)) and 1 µL of a 1mg/mL brefeldin stock (BD 
Biosciences) were added to each well, preventing release of induced cytokines from the 
endoplasmic reticulum and Golgi apparatus of lymphocytes. 
 
2.4.3 Flow cytometry 
Intracellular cytokine staining (ICS) was employed to monitor PspA-specific CD4+ T-cell 
responses to S. pneumoniae (Chapters 4 and 5). 
Cells were harvested by centrifugation and stained for surface phenotyping and intracellular 
cytokine production. 300,000 lymphocyte cell events (blood) and 100,000 (BAL) were acquired 
using a BD LSRII Flow Cytometer (Becton Dickinson). Cells were viewed using FacsDiva 
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software version 6.1 (BD Biosciences) in the LSTM Flow Cytometry Facility.  Viable 
CD3+CD4+CD69+ T-cells (hereafter described as activated CD4+ T-cells) and IL-17A, IL-22, 
TNFα, IFNγ and TGFβ secretors were identified and profiled. The gating strategy is described 
in Figure 2.3. 
 
2.4.4 Statistical analysis 
Cytokine-secreting CD4+ T-cells measured in ICS assays were quantitively analysed (chapters 
4 and 5). Raw percentage cytokine-secreting CD4+ T-cell data underwent initial analysis by 
One-way ANOVA with Dunnett’s post-hoc testing. Subsequent exploratory analysis employed 
normality testing on percentage cytokine-secreting CD4+ T-cell data, by Sharipo-Wilk analysis 
(Kolomogorov-Smirnov for smaller datasets). Cohort data following a Gaussian distribution 
underwent parametric analysis, namely unpaired t and Pearson’s correlation tests. Graphical 
representation and statistical analyses were performed using GraphPad Prism v5.0 
(California, USA). Differences were considered significant at p < 0.05 (two-tailed).
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Time Lymphocytes Live cells CD3+ CD4+ CD69+
IL-17A/IL22 TGFβ/TNFα IFNγ
Figure 2.3 Gating strategy for detection of lung mucosal intracellular cytokine responses PspA/Rx1 and derived fragments were used in antigenic stimulation of immunological 
responses ex vivo. Multi-parameter flow cytometry was employed to compare intracellular cytokine responses between constructs. Surface receptors were labelled to distinguish 
CD3+, CD4+, CD8+ and CD69+ cell populations. Intracellular cytokine staining of IL-17A, IL-22, TNFα, TGFβ and IFNγ was used to compare percentage of cells expressing cytokines after 
stimulation with each candidate fragment. FSC – forward scatter (measure of cell size); SSC – side scatter (measure of cell granularity/ internal complexity). 
- 51 - 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
Humoral PspA-specific responses to   
S. pneumoniae 
 
 
 
 
 
 
 
 
 - 52 - 
 
3 Humoral PspA-specific responses to S. pneumoniae 
 
3.1  Introduction 
 
Antibodies against the Pneumococcal surface protein A (PspA) have been shown as cross-
reactive, cross-functional and cross-protective in mice (Moreno et al., 2010, Miyaji et al., 2002). 
Murine studies have spearheaded our understanding of PspA as a pneumococcal vaccine 
candidate, although with an emphasis on protection from invasive disease. Studies dissecting 
PspA’s role in carriage, generation of mucosal immune responses, or implications for human 
pneumococcal immunity include demonstration of intranasal immunisation with PspA 
protecting against both carriage and invasive disease with a heterologous pneumococcal 
strain (Wu et al., 1997). Another study demonstrated that human serum PspA antibodies 
passively protect moribund mice infected with pneumococci expressing heterologous PspAs 
(Briles et al., 2000a). 
The acquisition of the state of nasopharyngeal pneumococcal carriage is a pre-requisite for 
disease susceptibility. Studying carriage is important to understanding pneumococcal disease 
as it functions as a reservoir for S. pneumoniae, and so plays a role in its transmission. 
Therefore, dissecting the role of anti-PspA IgG responses in the prevention of carriage and its 
modulation of mucosal immunity is worth investigation. Limited studies have been conducted 
in humans on this front, but include observations of an increase in serum PspA antibodies 
following pneumococcal inoculation in individuals that acquired carriage (McCool et al., 2002), 
and an increase in naturally acquired serum PspA antibodies with age and therefore exposure 
(Rapola et al., 2000).  
Using the platform of Experimental Human Pneumococcal Carriage (EHPC), we aimed to 
further current understanding of the role of serum antibodies and investigate PspA-specific 
family and clade cross-reactivity, associating with susceptibility to experimental carriage and 
re-acquisition of carriage following natural colonisation. Specifically, our research questions 
were: 
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1. Does colonisation protect against re-acquisition of carriage with heterologous PspA 
family-expressing S. pneumoniae? 
2. Does pneumococcal exposure alter IgG levels to heterologous PspA families? 
3. Does pneumococcal exposure modulate IgG binding to S. pneumoniae expressing 
heterologous PspA families? 
This knowledge will allow for further understanding of PspA’s ability to mediate carriage and 
affect mucosal immunity. 
 
 
3.2 Materials and Methods 
 
3.2.1 Volunteer recruitment  
Healthy adult volunteers from the dose-ranging study (PspA sequencing and antibody level 
data) were stratified into two groups: Cohort A, negative for carriage pre-inoculation, and 
Cohort B, naturally colonised with S. pneumoniae on presentation. Both groups were 
inoculated with a single intranasal dose of S. pneumoniae serotype 6B, PspA clade and family 
1 (strain BHN418), and monitored for nasopharyngeal carriage by nasal wash and classical 
microbiology as previously described (Section 2.3.2). 
Healthy adult volunteers from the EHPC-PCV clinical trial (serum IgG purification and binding 
experiments), were stratified according to resultant carriage status following inoculation with a 
single intranasal dose of S. pneumoniae strain BHN418, and monitored for nasopharyngeal 
carriage as previously described (Section 2.3.1). 
 
3.2.2 Detection of anti-pneumococcal antigen immunoglobulin   
Anti-pneumococcal protein antibody levels were determined as previously described (Ferreira 
et al., 2013). Briefly, NUNC 96-well plates (Thermo Scientific (UK)) were coated overnight with 
1 µg/mL of capture antigen (PspAs 1 – 5: from pneumococcal strains 435/96, 371/00, 259/98, 
255/00 and 122/02 respectively; PspA2 strain Rx1 and daughter fragments 1 – 7: fragment 
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length 1011, 300, 300, 300, 300, 300 and 243 base pairs respectively) (Figure 1.5) (Vadesilho 
et al., 2014); blocked with 1% phosphate buffered saline-bovine serum albumin (PBS-BSA) to 
prevent non-specific binding (Sigma), samples incubated at a starting dilution of 1:80, and 
bound antibodies detected using anti-human IgG alkaline phosphatase (Sigma), 5 mg para-
Nitrophenylphosphate (PNPP) (Sigma) and absorbance measured at 405 nm. The standard 
sample was a reference pooled human serum source of known anti-PspA concentration, kindly 
provided by Professor D. Briles (University of Alabama, USA). Anti-pneumococcal protein IgG 
levels were measured using a FLUOstar Omega microplate reader (BMG Labtech, UK), and 
analysis conducted with the MARS Data Analysis software v. 1.20 (BMG Labtech).  
 
3.2.3 Statistical analysis 
Graphical and statistical analyses were performed using GraphPad Prism version 5.0 
(California, USA). The Fisher’s exact test was used to determine the exact probability of a role 
of natural isolate PspA type in protection from re-acquisition of carriage. One-way ANOVA with 
Tukey’s (parametric) or Dunn’s (non-parametric) post-hoc testing for multiple comparisons and 
unpaired t-tests were performed on log transformed antibody levels to compare PspA antigen 
immunogenicity. An alpha level of 0.05 was used for all statistical tests (two-tailed). Flow 
cytometry data were analysed using FlowJo software version 7.6.5 (Treestar, Oregon, USA).  
 
3.2.4 Pneumococcal DNA extraction, PspA clade typing and 6B-specific qPCR 
Pneumococcal DNA was extracted from strains isolated from natural carriers by a modification 
of the QIAGEN DNA mini kit, and genomic DNA amplified as previously described (Carvalho 
et al., 2007). For PspA clade typing, genomic DNA was amplified with primers LSM12A (5' 
TAG CTC GAG ACC ATG ATC TTA GGG GCT GGT TT 3') and LSM9A (5' TAG TTA TCT 
AGA TTT TGG TGC AGG AGC TGG 3’) (Invitrogen), based on primers previously described 
by McDaniel et al. (1994). Amplified DNA was cloned into a pGEM-T Easy vector (Promega, 
Madison, USA) and sequenced by Sanger sequencing using Universal M13F and Universal 
M13R primers (Invitrogen).  
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For 6B-specific qPCR, genomic DNA was amplified with primer wciP(cpsS) (5’ 
GCTAGAGATGGTTCCTTCAGTTGAT/CATACTCTAGTGCAAACTTTGCAAAAT 3’) and 
Taqman minor groove binder (MGB) probe St6B VIC (5’ ACTGTCTCATGATAATT 3’) using 
the Mx3005P system (Stratagene) as previously described by (Tarrago et al., 2008). Data 
were analysed using the instrument's software. A negative-extraction control (parallel 
extraction of sample buffer), a negative control (serotype 6A), two positive controls (serotype 
6B), and two extractions of the sample isolate, were amplified. A cycle threshold (CT) value of 
> 35 was considered positive. 
 
3.2.5 Total IgG purification from serum 
Serum from ten individuals inoculated with S. pneumoniae serotype 6B-PspA1 was pooled. A 
1:1 ratio of Protein G sepharose (GEHealthcare, Uppsala, Sweden) to pooled serum was 
used; the sepharose column was packed by centrifugation in a 15 mL conical centrifuge tube 
for 8 minutes at 900 x g (all centrifugation conditions the same), washed and equilibrated in 
two resin-bed volumes of binding buffer [20mM sodium phosphate, pH 7.0: 11.54 mL dibasic 
Na2HPO4 (in house) + 8.46 mL monobasic NaH2PO4 + 180 mL distilled H2O] by re-suspending 
in binding buffer and centrifugation (baseline wash). 
Serum was applied to the sepharose column at a 1:1 ratio, and mixed on an end-over-end 
rotator at room temperature for 2 hours to promote sample antibody binding. Unbound 
antibody was removed by four cycles of washing and centrifugation in binding buffer, or until 
absorbance of the wash fraction approached that of the baseline wash (at 405 nm), 
demonstrating absence of free antibody.  
Bound IgG was released from the sepharose column by addition of a two-bed resin volume of 
elution buffer [0.1M Glycine-HCl, pH 2.7 (in-house)] and gentle mixing on an end-over-end 
rotator for 10 minutes followed by centrifugation. To ensure complete IgG elution and a 
concentrated recovery, elution buffer addition-mix-centrifugation steps were repeated using a 
one-bed resin volume. To neutralise the pH of the IgG elution fraction, 1M Tris-HCl, pH 9.0 (in 
house) was added to reach a pH of approximately 7.0. 
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3.2.6 Antigen-specific IgG purification from serum 
A CNBr-activated sepharose column 4B (GEHealthcare) was prepared by re-suspension of 1 
part lyophilised sepharose (mg) in 5 parts 1mM HCl (in-house) (mL), followed by four cycles 
of re-suspension in 1mM HCl (vortexing and centrifugation at 3,500 rpm for 20 seconds). The 
protein ligand to be column-coupled (CRM-197, PspA/Rx1 or Fragment 4) was dissolved in a 
ratio of 1 mg ligand: 1.5 mL coupling buffer [0.1M NaHCO3, pH 8.3 (containing 0.5M NaCl) (in-
house)], and bound to the column by mixing on an end-over-end rotator at 4°C overnight. 
Excess ligand was removed by centrifugation and three cycles of washing in coupling buffer 
and remaining active CNBr-groups blocked by addition of 0.1M Tris-HCl pH 8.0 followed by 
incubation for 2 hours at room temperature. The column was washed with 3 cycles of 
alternating pH to ensure no free ligand remained ionically bound to the immobilised ligand: 
acetate buffer solution pH 4.0 and 0.1M Tris-HCl pH 8.0 were used, both solutions containing 
0.5M NaCl2 as to minimise protein-protein adsorption and formation of protein aggregates. 
The serum sample was then added to the column, and incubated with rotation for 2 hours at 
room temperature, with unbound antibody removed by centrifugation. The column was washed 
with excess phosphate buffered solution (PBS) (in-house), and bound IgG extracted by 
addition of elution buffer: 50mM glycine, pH 2.8 (in-house) and incubation for 2 minutes at 
room temperature. Elution fractions were neutralised to pH 7.0 with 0.5 M Tris buffer (in-
house).  
 
3.2.7 Visualisation of IgG by dot blot and SDS-PAGE  
Total IgG wash and elution fractions were spotted onto a nitrocellulose membrane in 4 µL 
volumes. To prevent non-specific binding, the membrane was incubated with 5% bovine serum 
albumin (BSA) in Tris-Buffered Saline and 0.1% Tween 20 (TBS-T) (in house) for 45 minutes. 
The membrane was washed in TBST-T for 10 minutes, thrice over. Bound IgG was detected 
with a 1:5000 dilution of α-human IgG alkaline phosphatase (Sigma) in TBS-T 2.5% BSA for 
2 hours. The membrane was washed three times in TBST-T for 10 minutes and developed 
using a BCIP-NBT kit (Promega) until the colorimetric reaction became visible. 
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Samples were run on a 10% gradient SDS gel (in-house) for IgG visualisation and assessment 
of sample purity. Protein bands were visualised with Coomassie blue stain. 
 
3.2.8 Pneumococcal growth and antibody binding assays  
Four S. pneumoniae strains were employed in antibody binding assays: un-encapsulated 
pneumococcal Rx1 strains expressing native PspA2 (strain STR R1 – streptomycin resistant), 
Janus-cassette constructed PspA knock out Rx1 ΔpspA, and subsequent recombinant strains 
Rx1 pspA1 (St435/96) and Rx1 pspA4 (St255/00) (Miyaji et al., 2015).  
Pneumococcal strains were grown in Todd-Hewitt broth supplemented with 0.5% yeast extract 
(THY) to OD600 0.4 at 37°C in 5% carbon dioxide. Bacteria were concentrated 10-fold, and 
employed in antibody binding assays as previously described (Moreno et al., 2012) with 
modifications. Namely, the use of purified heat-inactivated IgG from a pool of 10 individuals in 
place of total serum for each test condition (carriage negative/positive before/after 
pneumococcal inoculation), and anti-human IgG FITC (Sigma) as the detection antibody.  
To account for the occasional variation in distribution of pneumococcal population size and 
therefore detection of IgG binding, geometric mean fluorescence intensity (GMFI) of the FITC 
positive population was computed. Subsequent fold changes (FC) in GMFI were calculated, 
either in relation to controls (for optimisation assays) or inoculation time-point (ratio of post: 
pre IgG binding). 
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3.3 Results 
 
3.3.1 Pneumococcal carriage and re-acquisition of S. pneumoniae expressing homologous 
and heterologous PspA families 
We investigated whether the PspA type expressed by S. pneumoniae natural carriage strains 
associated with cross-protection from re-acquisition with S. pneumoniae serotype 6B 
expressing PspA clade 1 (6B-PspA1). We molecularly typed the PspA clade of isolates 
recovered from volunteers naturally colonised with different pneumococcal strains (Cohort B), 
and following clearance of their colonisation episode inoculated volunteers with 6B-PspA1, 
monitoring whether they re-acquired carriage (Table 3.1). 
 
Table 3.1 Natural carriers PspA type and carriage reacquisition following pneumococcal inoculation 
S. pneumoniae isolates from volunteers who presented with natural carriage had PspA molecularly typed. After 
clearance of their colonisation episode, volunteers were inoculated with S. pneumoniae 6B-PspA1 and carriage re-
acquisition monitored. Volunteers previously colonised with a PspA family 1 pneumococcus had a non-significant 67% 
risk reduction of re-acquiring carriage with a pneumococcus expressing a homologous family PspA (Fisher’s exact 
test, p = 0.49, RR 0.33). The corresponding odds ratio was 0.11.  
 
Amongst individuals previously colonised with S. pneumoniae expressing a homologous 
family PspA to that of the 6B-PspA1 inoculation strain (clades 1 and 2), we observed a 25% 
rate of re-colonisation after inoculation (n = 1 out of 4). However, in those previously colonised 
Table 3.1 Natural carriers PspA type and carriage re-acquisition following 
pneumococcal inoculation 
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with a non-family 1 PspA (clades 3 - 6), we recorded a 75% rate of re-colonisation (n = 3 out 
of 4).  
We noted a natural carriage isolate typed as serogroup 6 for volunteer number 4: to investigate 
whether protection observed was serotype-specific, we performed a 6B-specific capsular 
qPCR. No CT value was measured, qualifying the isolate as a non-serotype 6B (Figure 3.1). 
Therefore, we observed a 67% reduction in risk of re-acquiring carriage with S. pneumoniae 
expressing a homologous family PspA (Risk Ratio = 0.33) in individuals previously colonised 
with a PspA family 1 pneumococcus (corresponding Odds Ratio = 0.11). This result was not 
statistically significant (Fisher’s exact test, p = 0.49) and to this end we note the limited sample 
size of this dataset (n = 8). However, taking the expected carriage rate of 50% on inoculation 
with S. pneumoniae 6B-PspA1 in a population of unknown carriage history (Gritzfeld et al., 
2013), a halving to 25% was indicative of a potential role of homologous family PspA immunity 
in protection from carriage re-acquisition. 
To investigate whether the observed protective potential of PspA type associated with serum 
IgG levels, we measured IgG levels to homologous and heterologous PspAs in carriage 
negative and positive healthy adult volunteer serum. 
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Figure 3.1 Serotype 6B-specific qPCR amplification plot. A serotype 6B-specific qPCR was conducted to identify whether volunteer 4’s serogroup 6 natural carriage isolate 
was positive or negative for serotype B. Blue horizontal line, fluorescence detection threshold; grey triangle, no DNA control; blue diamond, serotype 6A negative control; 
orange triangle and purple square, serotype 6B positive controls; red square and green diamond, natural carriage isolate DNA.
 - 61 - 
 
3.3.2 Pneumococcal exposure and IgG levels to homologous and heterologous PspA 
families 
We have previously reported pneumococcal carriage in healthy adults to be an immunising 
event generating serum IgG to PspA clades of the same family. Inoculation with 6B-PspA1, 
leads to increased IgG levels to PspA clade 2 (PspA2, family 1, strain UAB055) but not clade 
3 (PspA3, family 2, strain UAB099) (Ferreira et al., 2013).  
We investigated whether exposure to S. pneumoniae 6B-PspA1 modulated heterologous 
family PspA IgG level to other family 2 clades. We also investigated whether S. pneumoniae 
6B-PspA1 exposure altered homologous family, cross-clade PspA serum IgG reactivity. We 
measured anti-PspA IgG levels against PspA clades 1 to 5, in serum samples of volunteers 
uncolonised at baseline (Cohort A) pre- and post-inoculation with 6B-PspA1. 
Study participant data were stratified by subsequent carriage status, and pre-inoculation IgG 
levels against PspAs 1 to 5 measured by ELISA (Figure 3.2a). Serum IgG levels to PspAs 1 
to 5 varied irrespective of carriage status, significantly so in the carriage negative cohort 
(carriage negative, n = 16, p < 0.01; carriage positive, n = 12, p = 0.19) (One-way ANOVA with 
Tukey’s multiple comparisons). Irrespective of carriage status (carriage negative: (c-), carriage 
positive: (c+)), IgG levels to PspAs 1 and 5 were high [mean value ± standard deviation - 
PspA1: 2.62 ± 0.70 (c-), 2.61 ± 0.46 (c+); PspA5: 2.44 ± 0.27 (c-), 2.69 ± 0.37 (c+)], and lowest 
to PspAs 3 and 4 [PspA3: 2.20 ± 0.26 (c-), 2.33 ± 0.34 (c+); PspA 4: 2.07 ± 0.46 (c-), 2.33 ± 
0.34 (c+)]. The difference between carriage negative volunteer anti-PspA1 and PspA4 IgG 
levels was statistically significant on post-hoc testing (mean difference 0.55 [95% CI of 
difference: 0.12 to 0.98]). Although pre-inoculation PspA1 levels were elevated in carriage 
negative volunteers compared to levels of other PspAs, this did not differ from those who were 
carriage positive (difference between means: 0.01 ± 0.23 [95% CI: -0.48 to 0.49] p = 0.98) 
(unpaired t-test). Similarly, no difference was observed between carriage negative and positive 
volunteers IgG levels to PspA2 (p = 0.10), PspA3 (p = 0.15), PspA4 (p = 0.11) or PspA5 
(p = 0.07). These results suggest that neither pre-inoculation homologous nor heterologous 
PspA-specific IgG protect against S. pneumoniae carriage. The ratio of post: pre-inoculation 
anti-PspA serum IgG levels was calculated for each PspA clade (Figure 3.2b). There was a 
universal increase in IgG levels irrespective of carriage status or PspA clade (ratio > 1). 
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Figure 3.2 Serum IgG levels to PspA clades 1 – 5 in individuals negative and positive for experimental 
carriage. Antibody levels were determined by ELISA using serum from volunteers negative (n = 16, open bars) 
and positive (n = 12, filled bars) for experimental carriage with S. pneumoniae serotype 6B expressing PspA1 
(6B-PspA1).  (a) IgG levels against PspAs 1-5, 5 days before 6B-PspA1 inoculation (b) Ratio of PspA IgG levels 
before and after inoculation with 6B-PspA1. Samples obtained 14 days following inoculation were assayed 
for IgG levels to PspA, and the proportional fold difference plotted. *p < 0.05, One-way ANOVA with Tukey’s 
post-hoc testing for multiple comparisons intra-group analysis; unpaired t-test cross-group comparisons on 
log transformed antibody titres. 
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However, this was not statistically significant for neither carriage negative (p = 0.34), nor 
carriage positive (p = 1.00) volunteer groups (One-way ANOVA with Dunn’s multiple 
comparisons). Although carriage positive volunteers mounted a higher PspA1-specific IgG 
response on inoculation compared with carriage negative volunteers, this difference was not 
statistically significant (-0.62 ± 0.47 [-1.59 to 0.36] p = 0.20, unpaired t-test). 
Pneumococcal exposure therefore modulated PspA family IgG levels in both carriage negative 
and positive volunteers: S. pneumoniae inoculation increased PspA-specific IgG levels to 
homologous and heterologous PspAs although this was not statistically significant. 
Furthermore, pre-inoculation IgG levels did not associate with protection from carriage.  
To investigate whether cross-reactive antibody level reflected in functional activity, we 
employed antibody binding assays. 
 
3.3.3 Purity of pooled serum IgG extraction  
Immunoglobulin G is the predominant antibody in human serum with a high antigen specificity 
(Vidarsson et al., 2014). To assess whether increases detected in levels of cross-reactive IgG 
reflected in functional activity, we purified antibody from a serum pool of ten carriage negative 
and ten carriage positive volunteers per group:  
 carriage negative volunteers pre-inoculation 
 carriage negative volunteers post-inoculation 
 carriage positive volunteers pre-inoculation 
 carriage positive volunteers post-inoculation 
Figure 3.3 illustrates detection of IgG extracted in two columns (y-axis), and probed for in 
column washes 2 – 5 and elution fractions 1 & 2 (x-axis). Sample IgG was released in elution 
2 (dark purple). The negative control (NC) of sample buffer was free of IgG, and positive 
control (PC) of originating pooled serum positive for IgG.  
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Figure 3.3 Total IgG purification dot blot to detect elution fraction. Purification conducted in two stages 
(Columns 1 & 2). Negative control (NC) – sample buffer; Positive control (PC) – originating pooled serum. 
Colorimetric reaction denotes IgG presence. 
 
Eluted IgG was assessed for purity of sample by SDS gel electrophoresis. Three clear bands 
were evident in each sample: a 25 kDa IgG light chain, 50 kDa IgG heavy chain, and 66.5 kDa 
human serum albumin band (Figure 3.4).  
Pooled serum IgG was extracted from each volunteer group and time point. Elutions were of 
high purity and used for downstream extraction of protein-specific IgG. 
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Figure 3.4 SDS-PAGE of IgG elution fractions to assess sample purity. IgG bands (red arrows) – heavy chains 
(50 kDa), light chains (25 kDa). Human serum albumin (black arrow) - 66.5 kDa. Duplicate pre- and post-
inoculation samples correlate IgG purification columns 1 and 2 respectively. The white line between lanes 1 
and 2 indicates where the gel was spliced to remove irrelevant lanes from the original gel for simplification 
of represented data. 
 
3.3.4 Protein-specific IgG extraction from purified serum IgG 
To investigate PspA-specific IgG pneumococcal binding, we attempted to extract these 
antibodies from the purified IgG fraction. Protein CRM-197 was adopted as a positive control 
as it is a carrier protein for multiple routine immunisations this cohort of volunteers would have 
received (e.g. Meningitec®, Menjugate™). For the PspA-specific IgG extraction, the parent 
molecule PspA/Rx1 and Fragment 4 were selected as initial antigens to pull out IgG in carriage 
positive samples, as previous work had demonstrated elevated binding to S. pneumoniae 
compared to other PspA fragments on immunisation with homologous protein (Vadesilho et 
al., 2014). 
In the carriage positive volunteer cohort (Figure 3.5), purification with all three proteins 
CRM197, PspA/Rx1 and Fragment 4 (F4), yielded IgG in two fractions: pre-inoculation 
unbound IgG supernatant (black brackets) and post-inoculation protein-specific elution (red 
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brackets). In the carriage negative cohort (Figure 3.6), IgG was detected in pre and post-
inoculation unbound IgG supernatant (black brackets). 
 
Figure 3.5 Carriage positive volunteer cohort SDS-PAGE of protein-specific IgG fractions. Protein-specific 
purification fractions where IgG was detected in pre-inoculation unbound IgG supernatant (black brackets) 
and post-inoculation CRM197, PspA/Rx1 and Fragment 4 (F4)-specific elutions (red brackets). The white lines 
between lanes indicate where the gel was spliced to re-order lanes from the original gel for simplification of 
represented data. 
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Figure 3.6 Carriage negative volunteer cohort SDS-PAGE of protein-specific IgG fractions. Protein-specific 
purification fractions where IgG was detected in pre- and post-inoculation unbound IgG supernatant fractions 
(black brackets) for CRM197, PspA/Rx1 and Fragment 4 (F4)-specific purifications. The white lines between 
lanes indicate where the gel was spliced to re-order lanes from the original gel for simplification of 
represented data. 
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Therefore, IgG was eluted in protein-specific fractions from carriage positive post-inoculation 
samples alone. Sample concentrations were calculated by densitometry analysis:  
 CRM197 – 1.50 µg/µL 
 PspA/Rx1 – 2.05 µg/µL 
 F4 – 1.52 µg/µL 
Due to achieving IgG purification from the protein-specific fraction of only 1 out of 4 
experimental groups, we utilised an alternative method to interrogate PspA-specific IgG 
binding. Unencapsulated S. pneumoniae strain Rx1 and its PspA isogenic mutants were 
employed to investigate IgG binding in carriage negative and positive volunteer groups, in pre 
and post-inoculation sample pools. 
 
3.3.5 Purified IgG binding assay optimisation 
Preliminary analysis showed demonstrable binding of carriage negative volunteer pre-
inoculation IgG to S. pneumoniae pspA4 Rx1. Therefore, we titrated human anti-IgG FITC 
against this set-up to elucidate the optimal detection antibody concentration. 
A sequential two-fold degradation in binding fluorescence was observed from a 1:10 dilution 
(Fold change - FC - 71.52) through to 1: 10,000 (FC 10.87) (Table 3.2). The cell count of the 
1:10 dilution was 7 times less than the average of the remaining three titrations, therefore 
excluded. We observed an adequate separation in negative control and fluorescent peaks for 
the remaining dilutions, therefore we selected the practical working dilution in which the 
highest number of cells was recovered - 1: 1,000 FITC. 
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Table 3.2 Purified IgG binding detection antibody titration. 
 
GMFI = geometric mean fluorescence intensity. Fold change = stained: un-stained GMFI. 
 
3.3.6 Effect of pneumococcal exposure on IgG binding to S. pneumoniae expressing 
homologous and heterologous PspA families at 50 µL/test 
We measured IgG binding of purified IgG samples to four isogenic S. pneumoniae Rx1 strains 
in triplicate assays to investigate whether detected cross-reactive IgG levels reflected in 
functional activity. The strains employed were Janus-cassette constructed PspA knock out 
S. pneumoniae Rx1 ΔpspA, resulting recombinant strains Rx1 pspA1 (St435/96) and Rx1 
pspA4 (St255/00), and native Rx1 expressing PspA2 (strain STR R1) (Miyaji et al., 2015). 
Binding of IgG was undetectable in both homologous and heterologous PspA family-
expressing S. pneumoniae to that of the inoculation strain 6B-PspA1: S. pneumoniae Rx1 
pspA1, pspA4, and ΔpspA fluorescence values were below that of their respective negative 
controls (Table 3.3). Where binding was measurable against homologous family-expressing 
S. pneumoniae Rx1 pspA2, pneumococcal exposure had a minimal effect on IgG binding in 
carriage negative volunteers (FC = 1.23), but was reduced in carriage positive volunteers (FC 
= 0.44) (Figure 3.7). 
Due to purified IgG binding largely being undetectable above negative control levels, we 
concluded that the reaction may not have reached saturation due to varying purified IgG yields 
(Figure 3.4). Therefore, as an initial step to optimise assay conditions, we adjusted purified 
IgG reaction volumes to an equalised concentration. 
 
Table 3.2 Purified IgG binding detection ntibody titration. 
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Table 3.3 PspA binding fluorescence intensities of pre and post-inoculation purified IgG at 50 µL/test. 
GMFI = geometric mean fluorescence intensity. Fold change = post: pre-inoculation GMFI. Data presented graphically 
in Figure 3.7. 
 
 
 
Table 3.3 PspA binding fluorescence intensities of pre and post-inoculation purified IgG 
at 50 µL/test. 
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Figure 3.7 Purified IgG binding to pneumococci of varying PspA type, before and after S. pneumoniae 6B-
PspA1 inoculation at 50 µL/test. Carriage negative and positive volunteer serum IgG binding to 
S. pneumoniae strain Rx1 expressing PspAs 1, 2, 4 or ΔPspA, before (dashed) and after (solid line) 
inoculation with                    S. pneumoniae serotype 6B expressing PspA1 (6B-PspA1). Binding in the absence 
of pooled purified IgG (grey), served as a negative control. Data presented numerically in Table 3.3. 
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3.3.7 Effect of pneumococcal exposure on IgG binding to S. pneumoniae expressing 
homologous and heterologous PspA families at 10 µg/test 
To ensure investigation of antibody function without bias of purified IgG yields, we adjusted 
the concentration of samples to 10 µg/test and assayed for IgG binding to S. pneumoniae Rx1 
strains. 
Purified IgG concentrations were calculated by densitometry from SDS page gels of protein 
purifications. Post-inoculation IgG from carriage positive volunteers was an order of magnitude 
less concentrated than the other three cohorts: 
 Carriage negative pre-inoculation: 0.23 µg/µL 
 Carriage negative post-inoculation: 0.16 µg/µL 
 Carriage positive pre-inoculation: 0.22 µg/µL 
 Carriage positive post-inoculation: 0.06 µg/µL 
Where purified IgG binding to S. pneumoniae was detectable, we observed pneumococcal 
exposure increased binding to pneumococci expressing each or no PspA clade. This was 
except for binding of purified IgG from carriage negative volunteers on binding the PspA4 
variant (Figure 3.8). The greatest increase in post-inoculation binding was observed for 
carriage negative volunteer IgG binding to S. pneumoniae expressing PspA1, the homologous 
clade to the inoculation strain 6B-PspA1 (FC = 10.83) (Table 3.4).  
Carriage positive pre-inoculation IgG binding to S. pneumoniae Rx1 pspA1 and pspA2 was an 
order of magnitude higher in carriage positive compared to negative volunteers, at comparable 
levels to S. pneumoniae pspA4, and diminished to S. pneumoniae ΔpspA. Post-inoculation 
IgG binding was greater in the carriage positive cohort, to all S. pneumoniae Rx1 strains 
expressing heterologous clades (Table 3.4). 
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Table 3.4 PspA binding fluorescence intensities of pre and post-inoculation purified IgG at 10 µg/test. 
GMFI = geometric mean fluorescence intensity. Fold change = post: pre-inoculation GMFI. Data presented graphically 
in Figure 3.8. 
 
Table 3.4 PspA binding fluorescence intensities of pre and post-inoculation purified IgG at 
10 µg/test. 
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Figure 3.8 IgG binding to pneumococci of varying PspA type, before and after S. pneumoniae 6B-PspA1 
inoculation at 10 µg/test. Carriage negative and positive volunteer serum IgG binding to S. pneumoniae strain 
Rx1 expressing PspAs 1, 2, 4 or ΔPspA, before (dashed) and after (solid line) inoculation with S. pneumoniae 
serotype 6B expressing PspA1 (6B-PspA1). Binding in the absence of pooled purified IgG (grey), served as a 
negative control. Data presented numerically in Table 3.4. 
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Therefore, we observed that pneumococcal exposure modulated IgG binding to 
S. pneumoniae expressing heterologous PspA families: inoculation increased purified IgG 
binding to S. pneumoniae expressing both heterologous and homologous PspA families at 
10 µg/test. Carriage was immunising and PspA IgG served as a marker: carriage positive 
volunteer S. pneumoniae binding was higher compared to carriage negative volunteers. 
Multiple other pneumococcal proteins were observed as immunising: S. pneumoniae ΔpspA 
binding increased post-inoculation, where GMFI and hence IgG binding was notably higher 
than for homologous and heterologous PspA-expressing strains. We note that these data are 
from a single biological experiment, and pneumococcal populations grew heterogeneously. 
 
 
3.4 Discussion 
 
We observed a 50% reduction in expected colonisation rate with family-specific protection 
against re-colonisation in individuals previously naturally colonised: this aligned with our 
findings of a marked increase in clade 1-specific binding capabilities of IgG purified from 
carriage negative volunteers inoculated with S. pneumoniae 6B-PspA1. We found that 
pneumococcal exposure led to increased cross-reactive IgG levels to both homologous and 
heterologous PspA family types. However, the fold change in post: pre-inoculation IgG binding 
to S. pneumoniae with heterologous PspA families was highest in carriage positive individuals, 
therefore may serve as a marker of carriage and hence, disease susceptibility. 
 
3.4.1 Questions answered: study in field context 
Cross-reactivity and functionality of PspA clade 4 and 5-specific IgG has been previously 
reported and leads to cross-protection in a murine intranasal lethal challenge model (Moreno 
et al., 2010). Similarly, immunisation with PspA4 and intranasal lethal challenge with a 
heterologous family PspA2-expressing strain has demonstrated greater levels of protection 
than immunisation with homologous family PspA1, highlighting the cross-protective nature of 
PspA4 (Miyaji et al., 2015). We did not observe a difference in pre- and post-inoculation IgG 
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binding to S. pneumoniae Rx1 pspA4 in a protected population. We note that this observation 
is based on a single biological replicate. 
Our observations of protection against pneumococcal carriage re-acquisition conferred by 
carriage being restricted to a homologous PspA family, corroborate previous work in mice. 
Miyaji and colleagues (2002) demonstrated a lack of cross-protection between PspA families 
after PspA1 immunisation and heterologous lethal challenge in mice, despite observed cross-
reactivity of PspA antibodies. 
A higher cross-family post: pre-inoculation fold change in carriage positive compared to 
carriage negative volunteer serum IgG binding to S. pneumoniae expressing different PspA 
types, contrasted the clade-specific nature of carriage negative volunteer post: pre-inoculation 
fold change in serum IgG binding. From this preliminary finding, we observed an increased 
antibody cross-functionality conferred by nasopharyngeal colonisation, re-affirming 
pneumococcal carriage as immunising, and serum IgG binding as a marker of prolonged 
exposure and disease susceptibility in humans.  
The ability to purify PspA fragment-specific IgG and assess pneumococcal binding to strains 
expressing various PspA clades may have provided insight into fragment-specific IgG cross-
functionality, adding to our understanding of the therapeutic potential of these PspA fragments. 
We have previously demonstrated that older adults have reduced levels of IgG to PspA 
fragments when compared to younger adults. This finding was Fragment 2 (F2) and 7 (F7)-
specific: F2 located in the alpha helical domain, and F7 the proline-rich region (Owugha et al., 
in preparation). This highlighted their potential as unique markers of increased susceptibility 
to pneumococcal infection in at risk groups. Further still, Simell et al. (2008) report decreased 
IgG titres to PspA in the elderly, with evidence of waning PspA immunity over a lifetime, in a 
population known to have low pneumococcal carriage rates (Almeida et al., 2014), and high 
disease susceptibility (Regev-Yochay et al., 2004). This strengthens the case of PspA as a 
probe of pneumococcal exposure, and therefore disease susceptibility. 
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3.4.2 Questions raised: study limitations 
Our founding observations of natural carriage with pneumococci expressing homologous but 
not heterologous PspA families playing a potential role in protection against re-acquisition is 
notably limited by sample size (n = 8). However, taking our expected carriage rate of 50% in 
a population of unknown carriage history (Gritzfeld et al., 2013), a halving to 25% is suggestive 
of a role of homologous family PspA immunity in protection from carriage re-acquisition. 
Our initial purified IgG functional binding experiments with S. pneumoniae strain Rx1 pspA2 
and isogenic variants pspA1, pspA4 and ΔpspA at 50 µL serum IgG/ test, demonstrated no 
difference in antibody binding before and after S. pneumoniae inoculation. We concluded that 
the reaction may not have reached saturation for each of the conditions due to the varying 
purified IgG yields, and therefore adjusted the experiment to investigate binding at an 
equalised purified serum IgG concentration of 10 µg/test to separate questions of observed 
binding due to IgG levels versus functionality. We note as a limitation that subsequent assay 
results were derived from a single experiment. 
Although we measured increased functionality of carriage negative volunteer IgG compared 
to their carriage positive counterparts on binding S. pneumoniae expressing PspA1, the 
homologous clade to inoculation strain 6B-PspA1, we note that the pneumococcal populations 
represented were at different growth stages. A distinct negative population would allow for 
better discrimination between fluorescence peaks, resolving the truest binding differences. 
Again, we note that this data was from a single experiment, with observations only remaining 
valid if reproducible. 
We sought to investigate PspA fragment-specific IgG binding to S. pneumoniae. It has been 
reported that immunisation of mice with conformational epitopes of PspA2 (PspA fragments) 
protected mice against lethal challenge with a pneumococcus expressing a homologous clade 
(strain A66.1, PspA2) (Vadesilho et al., 2014). Fragments 4, 5 and parent protein PspA/Rx1 
induced the highest protection, therefore we attempted purification of Fragment 4 and 
PspA/Rx1 serum IgG in addition to the immunogenic vaccine conjugate control, CRM197. We 
have recently demonstrated that fragments in the alpha-helical and proline-rich regions of 
PspA (Fragments 1, 2 and 7) displayed elevated IgG levels on nasal S. pneumoniae exposure 
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in healthy adults (Owugha et al., in preparation). These regions have been identified to contain 
protective epitopes (McDaniel et al., 1994, Daniels et al., 2010). Furthermore, Fragments 2 
and 7 were shown to be uniquely elevated in younger compared to older adults, implicating 
them as markers of pneumococcal exposure (Owugha et al., in preparation): these fragments 
may have served as more efficient probes for pulling down PspA fragment-specific IgG. 
Although we could detect IgG in the protein-specific post-inoculation elution fractions from the 
carriage positive volunteer cohort for each protein, we were unable to detect protein-specific 
IgG in elution fractions for carriage negative volunteers. Therefore, to compare pneumococcal 
binding by carriage status, we investigated total IgG binding to S. pneumoniae of varying PspA 
type, in place of protein-specific IgG to S. pneumoniae.  
 
3.4.3 Questions posed: further work and study implications 
Although PspA has been studied to determine whether it is a broadly protective antigen and 
vaccine candidate, it is now widely accepted that for its success, formulations must include 
antigens across the two major PspA families (family 1 and 2). Further still, multiple 
pneumococcal vaccine formulations now focus on combining fragments of multiple antigens 
(Katsura et al., 2014, Lu et al., 2015), so investigating smaller PspA constructs is of utility for 
incorporation into aforementioned strategies. 
We demonstrated binding of serum IgG from individuals exposed to 6B-PspA1, to 
S. pneumoniae ΔpspA from both carriage negative and positive groups, pre and post-
inoculation. Fluorescence IgG binding values were largely higher for the knock out strain 
compared to PspA-expressing strains, despite possessing the same genetic backbone 
(S. pneumoniae Rx1). My explanatory hypothesis is that PspA molecules expressed on the 
surface of Rx1 strains pspA1, pspA4 and wild type expressing PspA2, hindered IgG binding 
to other pneumococcal proteins. This hypothesis reflects the molecular structure of PspA 
where its flexible proline-rich region enables its extension through the capsule above other 
proteins, and the abundance of PspA expression on the pneumococcal surface resulting in a 
measurable cumulative effect of reduced non-PspA protein binding site access on PspA 
expression. This data again highlighted the involvement of other pneumococcal proteins in 
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humoral response to S. pneumoniae, and merits further investigation into protein vaccine 
candidates. 
It is important to note that humoral immunity is solely one aspect of immune defence against 
pneumococcal colonisation, with PspA-specific immunity being one of multiple proteins 
involved. The importance of CD4+ T-cells in protection from pneumococcal carriage has been 
demonstrated in mice (Malley et al., 2004), with particular emphasis placed on the role of the 
Th17 cell subset in recent years (Bogaert et al., 2009). Importantly, Trzciński and colleagues 
show both the CD4+ T-cell mechanism of infection protection as antigen-specific (Trzciński  et 
al., 2008), and anti-PspA IgG correlating to, but not be required for protection from colonisation 
in a murine model (Trzciński  et al., 2005). Therefore, it is imperative to dissect both the roles 
of humoral and CD4+ T-cell responses to PspA fragments to better understand their potential 
for inclusion in multiple-epitope vaccine formulations in broad protection against 
pneumococcal disease. 
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Blood PspA-specific CD4+ T-cell 
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4 Blood PspA-specific CD4+ T-cell responses to S. pneumoniae 
 
4.1 Introduction 
 
Cellular immune responses to Streptococcus pneumoniae act to limit pneumococcal carriage 
density: Lu et al. (2008) demonstrated a role of the Th17 subset of CD4+ T-cells, and 
subsequent neutrophil-directed pneumococcal clearance. As a high pneumococcal 
nasopharyngeal colonisation density has been correlated clinically with pneumonia 
susceptibility (Wolter et al., 2014), it is pertinent to investigate immunological mechanisms 
involved in protection against carriage acquisition and reduction of colonisation density and 
duration as a precursor to disease.   
Single and multiple surface antigen formulations of virulence factors known to induce adaptive 
immunity whilst being widely expressed across pneumococcal strains, are deemed good novel 
vaccine candidates (Miyaji et al., 2013). These are necessary to overcome current vaccine 
limitations, particularly serotype-specificity. A leading antigen is the Pneumococcal surface 
protein A (PspA): however, despite PspA being conserved as a virulence factor across all 
known pneumococcal strains (Crain et al., 1990), it is heterogeneous in sequence and is 
classified into six clades and three families: family 1 (clades 1 and 2), family 2 (clades 3 - 5) 
and family 3 (clade 6) (Hollingshead et al., 2000). Vaccine design efforts have shifted toward 
alternative PspA constructs capable of inducing antibodies cross-reactive with strains 
expressing PspAs of the most prevalent families, 1 and 2 (Darrieux et al., 2007, Darrieux et 
al., 2008). Vadesilho and colleagues (2014) demonstrated protection against pneumonia in a 
murine model on immunisation with 100 amino acids (aa) PspA fragments. Protective epitopes 
were located in the N-terminal alpha helical domain (Fragment 2: 79 - 178 aa) and the clade-
defining region (Fragments 4: 179 - 278 aa), eliciting 100% and 67% protection respectively. 
No protection was afforded on immunisation with Fragment 7 of the proline-rich region (329 - 
406 aa), whereas 100% protection was elicited by the parent protein PspA/Rx1. 
Protection from pneumococcal carriage acquisition has been shown in murine studies to be 
CD4+ Th17 dependent (Malley et al., 2005, Bogaert et al., 2009) and antigen-specific 
(Trzciński  et al., 2008). Wright et al. (2013) demonstrated the ability to measure 
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pneumococcal-specific CD4+ T-cell responses in human volunteers. Here we investigate 
whether PspA (Fragments 2, 4, 7 and parent protein PspA/Rx1)-specific CD4+ T-cell immune 
response to S. pneumoniae is detectable in blood, and if so, whether it associates with 
protection from carriage in healthy adults exposed to S. pneumoniae in our Experimental 
Human Pneumococcal Carriage (EHPC) model. Specifically, our research questions were: 
1. Are antigen-specific CD4+ T-cell responses to S. pneumoniae detectable in blood? 
2. Does inoculation alter antigen-specific CD4+ T-cell responses to S. pneumoniae? 
3. Do changes to pre-existing antigen-specific CD4+ T-cell responses to S. pneumoniae 
post-inoculation associate with carriage status? 
4. Do post-inoculation antigen-specific CD4+ T-cell responses to S. pneumoniae 
associate with colonisation intensity (area under the curve analysis of density and 
duration)? 
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4.2 Materials and Methods 
 
4.2.1 Volunteer Recruitment and the Experimental Human Pneumococcal Carriage (EHPC) 
Model  
Study approval was granted by the Liverpool Central NHS Research Ethics Committee [REC 
12/NW/0873]. Written informed consent was obtained from each healthy adult volunteer to 
enrol in the EHPC-PCV study (EudraCT 2012-005141-20). Pneumococcal inoculation and 
subsequent detection was carried out as previously described (Gritzfeld et al., 2013). In short, 
volunteers were inoculated with a single intranasal dose of 80,000 cfu/ 100 µL per naris 
serotype 6B (BHN418 strain), and acquisition of carriage determined by microbiological culture 
of nasal wash. 
 
4.2.2 Expression of recombinant proteins  
PspA fragments originating from S. pneumoniae strain Rx1 (PspA/Rx1) were engineered into 
ampicillin-selectable and IPTG-inducible expression vector pAE (Ramos et al., 2004) to 
produce plasmids pAE-frag 2 (300 bp), pAE-frag 4 (300 bp), pAE-frag 7 (243 bp) and pAE-
pspARx1 (1,011 bp) as previously described (Vadesilho et al., 2014). Constructs were 
expressed in Escherichia coli BL21/DE3 (Studier and Moffatt, 1986) as His-tagged PspA/Rx1 
fragments, and purified from the soluble expressed fraction using Ni2+ affinity chromatography 
(Qiagen). Resultant proteins were dialysed using 7K MWCO SnakeSkin™ dialysis tubing 
(ThermoScientific, Rochford, (USA)) and quantified by densitometry using SDS gel 
electrophoresis reads and GelAnalyzer2010® software (Lazar, 2017). 
 
4.2.3 Tissue processing and ex vivo stimulation  
Blood samples were obtained 5 days before and 21 days after S. pneumoniae inoculation. 
Peripheral blood mononuclear cells (PBMCs) were isolated by density-mediated centrifugation 
using Ficoll-Paque PLUS (GEHealthcare, Uppsala (Sweden)) according to the manufacturer’s 
instructions. PBMCs were washed twice in PBS, re-suspended in complete media [RPMI + 20 
mM L-glutamine supplemented with antibiotics (penicillin 40 U/mL, streptomycin 40 µg/mL, 
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neomycin 80 µg/mL) and 10% Foetal Calf Serum (FCS) (Invitrogen)], and seeded into a 24-
well plate in a volume of 1 mL and concentration of 1 x 106 PBMCs/mL Cells were left 
unstimulated (for background subtraction of non-specific cytokine secretion), and separately 
stimulated with 4 µg/mL PspA antigens (PspA/Rx1, Fragments 2, 4 and 7), and 0.5 µg/mL 
positive assay control staphylococcus enterotoxin B (SEB). PBMCs were incubated at 37°C, 
5% CO2 for 120 hours and in the final 16 hours of stimulation, 1 µL of a 3 mM monensin stock 
(BD Biosciences, San Diego (USA)) and 1 µL of a 1mg/mL brefeldin stock (BD Biosciences) 
were added to each well, preventing release of induced cytokines from the endoplasmic 
reticulum and Golgi apparatus of lymphocytes.  
 
4.2.4 Flow Cytometry  
Cells were harvested by centrifugation at 533 x g for 20 minutes, stained for surface 
phenotyping and intracellular cytokine production, and acquired on a BD LSR II flow cytometer. 
Viable CD3+CD4+ CD69+ T-cells (hereafter described as CD4+ T-cells) and IL-17A, IL-22, 
TNFα, IFNγ and TGFβ secretors, were identified using FlowJo software v10 (Treestar, 
Oregon, USA). Pestle v1.7 and SPICE v.5.2 software (Mario Roederer, Vaccine Research 
Centre, NIAID, NIH) were employed for background subtraction and data mining respectively.  
 
4.2.5 Statistical Analysis  
Data analysis was conducted as previously described (Section 2.4.4). Briefly, stimulus-specific 
cytokine secreting CD4+ T-cell data underwent initial analysis by One-way ANOVA with 
Dunnett’s post-hoc testing, calculation of geometric mean percentage cytokine-secreting CD4+ 
T-cells and subsequent fold change (FC) relative to unstimulated control. Mean volunteer FC 
across all stimuli (average FC all stimuli) is presented.  
Subsequent exploratory analysis employed log-transformed percentage cytokine-secreting 
CD4+ T-cell data which followed a Gaussian distribution. Therefore, parametric tests were 
employed, namely t-tests both paired and unpaired, and Pearson’s correlation tests. Graphical 
representation and statistical analyses were performed using GraphPad Prism v5.0 
(California, USA). Differences were considered significant at p < 0.05 (two-tailed). 
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4.3 Results 
 
4.3.1 Detection of PspA-specific CD4+ T-cell responses to S. pneumoniae in healthy adults 
The ability to detect whole cell pneumococcal-specific CD4+ T-cell responses in blood has 
been described (Wright et al., 2012). In order to harness the EHPC model to test novel 
serotype-independent vaccine candidates, we assessed the sensitivity of our assay to detect 
induction of single pneumococcal antigen-specific CD4+ T-cell responses to S. pneumoniae in 
blood. 
We observed detectable PspA-specific CD4+IL-17A+, IL22+, TNFα+, IFNγ+ and TGFβ+ cytokine 
responses to S. pneumoniae above unstimulated levels (US) both pre- and post-
pneumococcal inoculation, with average fold change measurements (all stimuli) > 1 (Table 
4.1).  
Pre-inoculation, the greatest measurable differences in proportion of CD4+ T-cells secreting 
cytokine in response to protein stimulation were in CD4+IL-17A+ T-cells (p = 0.02), TNFα+ (p = 
0.03) and TGFβ+ (p = 0.01) (One-way ANOVA with Dunnett’s post-hoc test, p < 0.05) (Figure 
4.1a). Fragment 7-specific CD4+ T-cell induction was consistently detected at each of the 
measurable cytokine outputs after post-hoc corrections (mean difference [95% CI of 
difference]: IL-17A (-0.10 [-0.17 to -0.02]); TNFα (-0.03 [-0.05 to -0.01]); TGFβ (-0.10 [-0.18 to 
-0.02])). Levels of CD4+ T-cell secreting IL22 (p = 0.42) and IFNγ (p = 0.15) were not 
significantly different from their unstimulated controls. 
To investigate whether PspA-specific CD4+ T-cell responses were detectable after 
pneumococcal exposure, we measured post-inoculation PspA-specific CD4+ T-cell responses 
to S. pneumoniae. All average combined stimulus CD4+ T-cell responses (all stimuli) were 
detectable, that is above their unstimulated control (FC > 1, Table 4.1). Levels of post-
inoculation PspA-specific CD4+ T-cells secreting TGFβ were significantly increased (p = 0.01) 
(One-way ANOVA with Dunnett’s post-hoc test, p < 0.05). Overall protein responses were not 
statistically significant for IL-17A (p = 0.06), IL22 (p = 0.06), TNFα (p = 0.73), or IFNγ (p = 
0.06) (Figure 4.1b). 
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Therefore, antigen-specific CD4+ T-cell responses to S. pneumoniae were detectable in blood: 
we demonstrated the ability to detect PspA-specific CD4+ T-cell responses to S. pneumoniae 
in the blood of healthy adults both pre-and post-inoculation using the EHPC platform.   
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Table 4.1 Fold changes in pre- and post-inoculation blood unstimulated to stimulated PspA-specific CD4+ T-cells. 
 
Average percentage cytokine secreting CD4+ T-cells – geometric mean [95% confidence interval of geometric mean]. US – unstimulated; Fn – fragment n. Average fold change all stimuli 
– mean fold change from unstimulated to stimulated for F2, F4, F7 and PspA/Rx1 stimuli.
Table 4.1 Fold changes in pre- and post-inoculation blood unstimulated to stimulated PspA-specific CD4+ T-cells. 
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Figure 4.1 Detection of PspA-specific CD4+ T-cell responses to S. pneumoniae (a) Pre-inoculation and (b) Post-
inoculation. Percentage cytokine-secreting CD4+ T-cells unstimulated (open circles) and PspA/Rx1 fragment-stimulated 
(closed circles). IL-17A, IL22, TNFα, IFNγ and TGFβ-secretion profiles per panel. PspA Fragments 2 (F2), 4 (F4), 7 (F7) 
and parent protein (PspA/Rx1) stimuli. One-way ANOVA with Dunnett’s post-hoc test, * = p < 0.05. Horizontal bar 
represents mean ± SEM. 
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4.3.2 Post-inoculation changes to pre-existing PspA-specific CD4+ T-cell responses to 
S. pneumoniae and association with carriage status 
We have observed that pneumococcal carriage with S. pneumoniae expressing one PspA type 
increases levels of IgG that are cross-reactive and cross-functional to heterologous PspAs (Section 
3.3.7). To investigate whether the boosting effect of carriage on humoral immunity was seen in altered 
CD4+ T-cell immunity, we compared pre- and post-inoculation proportions of PspA-specific CD4+ T-cells 
to S. pneumoniae in carriage negative and positive individuals (Figure 4.2). We note that overall 
volunteer post-inoculation PspA-induced responses (carriage negative and positive volunteers) were 
not significantly different to pre-existing responses for TNFα (FC > 1, p > 0.05), whereas they were 
significantly increased for IL-17A, IL22, IFNγ and TGFβ (Section 4.3.1).  
In carriage positive individuals, we observed a boost in post-inoculation PspA-specific CD4+TNFα+ T-
cell response compared to pre-inoculation (Figure 4.2c). This was significant for F2 (difference in means 
[95% CI] -0.98 [-1.85 to -0.12] p = 0.03) and F7-specific (-0.49 [-0.91 to -0.07] p = 0.03) CD4+TNFα+ 
responses (Paired t-test) (Section 4.3.1). Pre-existing PspA-specific CD4+IL-17A+, IL22+, IFNγ+ and 
TGFβ+ T-cell responses to S. pneumoniae remained unchanged post-inoculation in both carriage 
negative and positive volunteers (p > 0.05) (Figure 4.2a, b, d and e). 
Therefore, pneumococcal inoculation altered antigen-specific CD4+ T-cell responses to S. pneumoniae: 
post-inoculation Fragment 2 and 7-specific CD4+TNFα+ inflammatory responses were boosted in 
carriage positive volunteers alone, highlighting these responses as markers of pneumococcal carriage.  
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Figure 4.2 (a) Post-inoculation changes in PspA-specific CD4+ IL-17A T-cell responses to S. pneumoniae in carriage negative and positive volunteers. Background-corrected 
(unstimulated discounted) CD4+ T-cell responses in carriage negative (open circles) and positive (closed circles) volunteers. PspA Fragments 2 (F2), 4 (F4), 7 (F7) and parent 
protein (PspA/Rx1) stimuli. Paired t-test on log transformed data, all data * p > 0.05. Horizontal bar represents mean ± SEM. 
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Figure 4.2 (b) Post-inoculation changes in PspA-specific CD4+ IL22 T-cell responses to S. pneumoniae in carriage negative and positive volunteers. Background-corrected 
(unstimulated discounted) CD4+ T-cell responses in carriage negative (open circles) and positive (closed circles) volunteers. PspA Fragments 2 (F2), 4 (F4), 7 (F7) and parent 
protein (PspA/Rx1) stimuli. Paired t-test on log transformed data, all data * p > 0.05. Horizontal bar represents mean ± SEM. 
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Figure 4.2 (c) Post-inoculation changes in PspA-specific CD4+ TNFα T-cell responses to S. pneumoniae in carriage negative and positive volunteers. Background-corrected 
(unstimulated discounted) CD4+ T-cell responses in carriage negative (open circles) and positive (closed circles) volunteers. PspA Fragments 2 (F2), 4 (F4), 7 (F7) and parent 
protein (PspA/Rx1) stimuli. Paired t-test on log transformed data, * p < 0.05. Horizontal bar represents mean ± SEM. 
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Figure 4.2 (d) Post-inoculation changes in PspA-specific CD4+ IFNγ T-cell responses to S. pneumoniae in carriage negative and positive volunteers. Background-corrected 
(unstimulated discounted) CD4+ T-cell responses in carriage negative (open circles) and positive (closed circles) volunteers. PspA Fragments 2 (F2), 4 (F4), 7 (F7) and parent 
protein (PspA/Rx1) stimuli. Paired t-test on log transformed data, all data * p > 0.05. Horizontal bar represents mean ± SEM. 
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Figure 4.2 (e) Post-inoculation changes in PspA-specific CD4+ TGFβ T-cell responses to S. pneumoniae in carriage negative and positive volunteers. Background-corrected 
(unstimulated discounted) CD4+ T-cell responses in carriage negative (open circles) and positive (closed circles) volunteers. PspA Fragments 2 (F2), 4 (F4), 7 (F7) and parent 
protein (PspA/Rx1) stimuli. Paired t-test on log transformed data, all data * p > 0.05. Horizontal bar represents mean ± SEM. 
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4.3.3 Colonisation intensity and correlation with PspA-specific CD4+ T-cell responses to      
S. pneumoniae  
To investigate whether there was an association between PspA-specific CD4+ T-cell cytokine 
responses to S. pneumoniae and a continuous measure of pneumococcal carriage, 
colonisation intensity, we calculated a compound measure of carriage density and duration 
(area under the curve analysis of density of pneumococcus recovered in nasal wash (log10) 
and duration of colonisation in days) (Table 4.2). This measure of extent of colonisation was 
adopted to conduct a correlation analysis with baseline-corrected post-inoculation PspA-
specific CD4+ T-cell cytokine-responses to S. pneumoniae in carriage positive volunteers for 
which there was reliable microbiology and flow cytometry data: two volunteers were excluded 
from this analysis (n = 6). Where combined total volunteer post-inoculation responses (IL-17A, 
IL22, IFNγ and TGFβ) were significantly greater than their unstimulated control, cytokines are 
emboldened (Figure 4.4).  
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Table 4.2 Colonisation intensity of carriage positive volunteers.  
Colonisation intensity = Area Under the Curve (AUC) analysis of density and duration of pneumococcal carriage 
episode. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 Colonisation intensity of carriage positive volunteers 
 
 - 98 - 
 
Figure 4.3 Colonisation intensity correlation with PspA-specific CD4+ T-cell responses to S. pneumoniae (a) 
by PspA stimulus response (full figure legend for Fig 4.3 panels (a) and (b), page 100). 
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Figure 4.4 Colonisation intensity correlation with PspA-specific CD4+ T-cell responses to S. pneumoniae (a) 
by PspA stimulus response (b) total PspA response. Microbiology data from carriage positive volunteers (n 
= 6) used to calculate intensity of colonisation episode (area under the curve analysis of density of 
pneumococcus recovered in nasal wash (log10) and duration of colonisation in days), and a correlation 
analysis conducted against PspA-specific CD4+ T-cell responses to S. pneumoniae post-inoculation (pilot 
dataset baseline-corrected combined total volunteer responses - IL17A, IL22, IFNγ, TGFβ - are in bold). 
Carriage negative volunteer data (n = 32) plotted alongside carriage positive data for descriptive analyses. 
Stimulation with PspA Fragments 2 (circles), 4 (squares), 7 (triangles) and parent protein, PspA/Rx1 
(diamonds). Carriage negative volunteers (open symbols), carriage positive volunteers (closed symbols). 
Pearson’s correlation test performed on log transformed data: % CD4+ TGFβ-colonisation intensity 
correlation alone, p < 0.05.
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We plotted both carriage negative (open symbols) and carriage positive (closed symbols) 
volunteer PspA-specific cytokine-secreting CD4+ T-cell responses to enable descriptive 
exploratory analysis of the relationship between carriage and immune response to 
S. pneumoniae (Figure 4.4). Correlation analysis tests were performed on colonisation 
intensity and carriage positive volunteer CD4+ T-cell responses to S. pneumoniae post-
inoculation (baseline corrected). Fragment-specific responses were plotted (Figure 4.4a), but 
overlapped. Therefore, analysis was performed on combined all stimulus CD4+ T-cell 
responses to S. pneumoniae (Figure 4.4b). 
We did not observe a correlation between combined antigen-specific CD4+ Th17-associated 
(cytokines IL-17A and IL22), inflammatory (TNFα), and Th1-associated (IFNγ) responses to 
S. pneumoniae and colonisation intensity post-inoculation (p > 0.05) (Figure 4.4). However, 
we observed a significant weak negative correlation between post-inoculation PspA-specific 
CD4+TGFβ+ T-cells (T-regulatory cell-associated) and colonisation intensity (r = -0.23, p = 
0.04). We note the limited number of carriage positive volunteer data points with which we 
conducted correlation analyses (n = 6). 
Therefore, antigen-specific CD4+ T-regulatory cell-associated responses to S. pneumoniae 
correlated with colonisation intensity: we observed a weak negative correlation between 
CD4+TGFβ+ T-cell responses and post-inoculation carriage intensity, reiterating a role in 
regulation of colonisation in healthy adults. 
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4.4 Discussion 
 
We have demonstrated the ability to detect PspA-specific CD4+ T-cell responses to                     
S. pneumoniae in the blood of healthy adults pre-and post-inoculation. Post-inoculation 
Fragment 2 and 7-specific CD4+TNFα+ responses were boosted from pre-existing levels in 
carriage positive volunteers alone, highlighting these responses as markers of pneumococcal 
carriage and therefore disease susceptibility, playing a role in response to carriage. PspA-
specific CD4+TGFβ+ responses to S. pneumoniae displayed a weakly negative correlation to 
post-inoculation carriage intensity (compound measure of density and duration), reiterating a 
role in regulation of colonisation in healthy adults. 
 
4.4.1 Questions answered: study in field context 
Moffitt and colleagues (2011) demonstrated antigen-specific Th17 immunity as a factor in 
prevention of pneumococcal colonisation in mice. Similarly, Gray et al. (2014) implicated an 
elevated pneumococcal antigen (pneumolysin domain 4)-mediated Th17 immunity in 
protection from pneumococcal presence in nasal-associated lymphoid tissue of children. In 
this study, we did not assess a role of pre-existing pneumococcal antigen-specific CD4+ T-cell 
responses in protection from carriage acquisition in healthy adults due to this study being 
carried out within a PCV vaccine trial (Collins et al., 2015). Although PCV vaccination does 
not impact PspA immunity (Ditse et al., 2013) the predominant vaccine-induced protective anti-
polysaccharide IgG precluded our ability to investigate potential baseline protective PspA-
specific CD4+ T-cell immune responses to S. pneumoniae.  
A similar finding to ours however, was demonstrated in a murine study: Cohen et al., (2011) 
showed that pneumococcal exposure primed for an inflammatory Th17 response during 
challenge, but this was not required for the prevention of invasive disease. This finding is in 
line with what Wright and colleagues (2013) and we (Section 3.3) have previously described: 
although nasal inoculation with S. pneumoniae boosts immunity as demonstrated by 
increased cross-reactive, cross-functional IgG to PspA, this does not play a role in protection 
against heterologous strain carriage re-acquisition. Boosted PspA-specific immunity to 
S. pneumoniae therefore could serve as a marker of pneumococcal exposure. 
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The carriage positive volunteer boost in post-inoculation F2 and F7-specific inflammatory 
CD4+TNFα+ immune response to S. pneumoniae points towards a role in response to carriage, 
and highlights boosted PspA fragment-specific CD4+TNFα+ responses as potential markers of 
prolonged pneumococcal exposure and therefore infection susceptibility. These data align with 
our previous observations of a reduced Fragment 2 and 7-specific IgG in older adults 
compared to younger adults (Owugha et al., in preparation), where older populations are 
known to have a lower rates of carriage (Almeida et al., 2014). 
The parent regions of PspA strain Rx1 fragments 2 and 7 have been previously reported as 
playing a role in pneumococcal immunity. Fragment 2 is located within the alpha-helical PspA 
region, a highly studied domain due to early identification that immunisation with epitopes in 
this region protect against fatal murine pneumococcal infection (McDaniel et al., 1994). Further 
work confirming the protective properties of immunity to the alpha helical regions of PspA 
include: observations of genetic immunisation encoding the alpha helical region protecting 
mice against lethal challenge (Bosarge et al., 2001), and observations of murine infection 
protection on immunisation (Roche et al., 2003). 
Fragment 7 originates from the proline-rich region of PspA. The ability of F7-including non-
proline block binding monoclonal antibody MAb 1A4.7, to protect mice against morbidity from 
pneumococcal infection has been reported (Daniels et al., 2010). Additionally, in children 
colonised by S. pneumoniae, the generation of proline-rich region-specific antibodies has 
been observed (Melin et al., 2012). 
The importance of Th17 and Th1 immunity in S. pneumoniae infection (marked by cytokines 
IL-17A and IFNγ respectively) has been previously demonstrated. Examples include 
observations of an inverse correlation between IL-17A levels and pneumococcal density in 
Fijian children (Hoe et al., 2015), and up-regulation of IFNγ-related defence genes which 
associated with protection from pneumococcal pneumonia in mice (Marques et al., 2012). We 
did not identify PspA as a generator of robust Th1 and Th17-associated responses with a role 
in reduction of pneumococcal carriage density and duration in healthy adults. It is important to 
note here that the negative correlation observed between pneumococcal density in humans 
and IL-17A levels by Hoe and co-workers (2015) was not identified as originating from CD4+ 
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T-cells: the cellular source may have been from other T-cell subsets e.g. CD8+ and γδ T-cells, 
or a range of innate immune populations including neutrophils (Cua and Tato, 2010).
We propose that PspA-specific CD4+TGFβ+ responses may play a role in regulating or 
controlling carriage intensity, furthering pneumococcal-specific observations of Treg-mediated 
control of and association with, pneumococcal density in upper respiratory tissue of humans 
and mice (Neill et al., 2014, Zhang et al., 2011). Our demonstration of PspA-specific 
CD4+TNFα+ response as a marker of carriage aligns with previous findings of TNF playing a 
role in regulation of infection severity in mice (Kirby et al., 2005). 
 
4.4.2 Questions raised: study limitations  
The nature of investigating immune responses to S. pneumoniae in the human host compared 
to murine models is complex, as no individual is naïve: previous pneumococcal exposure is 
difficult to account for, and therefore factor into immunological analyses. Additionally, sampling 
circulating tissue and not that of the site of colonisation may not be optimal to explore 
protective responses against nasal pneumococcal carriage. However, the advantage of a 
controlled, measurable and equal pneumococcal inoculation dose is a distinct advantage of 
the EHPC model, and current investigations are focussed on sampling at the site of 
inoculation, proximal to that of colonisation at the nasal mucosal tissue (Jochems et al., 2017). 
Here we demonstrate for the first time, a correlation between pneumococcal antigen-specific 
CD4+TGFβ+ T-cell responses to S. pneumoniae, and regulation or control of experimental 
pneumococcal colonisation in humans.  A notable limitation however, was the number of 
pneumococcal carriers available to conduct the analysis (n = 6), and therefore limited range 
of colonisation intensities. This study was carried out within a PCV vaccine trial with high 
efficacy against pneumococcal colonisation, hence the low availability of carriage positive 
volunteers. An increase in sample size and range of inoculation doses would allow for a larger 
distribution of carriage positive volunteer density measurements, and therefore more confident 
conclusions of immune regulators of colonisation intensity.  
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4.4.3 Questions posed: further work and study implications  
The ability to detect protein-specific CD4+ T-cell responses to S. pneumoniae and dissect 
biological relevance relating protection against pneumococcal disease via its precursor 
nasopharyngeal carriage (using the EHPC model), is key for the testing of novel, broadly-
protective vaccine candidates in the natural host. Various pneumococcal vaccines under 
development take a multiple protein target approach to minimise and slow pneumococcal 
vaccine escape (Kothari et al., 2014, Uraki et al., 2015): the ability to measure whether PspA 
constructs stimulate CD4+ T-cell responses to S. pneumoniae is of importance for potential 
inclusion in these strategies. Additionally, the ability of PspA fragments to induce a greater 
measurable CD4+ T-cell responses compared to the whole molecule, not only avoids potential 
structural barriers of similarities to human cardiac myosin, but provides examples of PspA 
peptide constructs to be included in multiple pneumococcal protein vaccination strategies 
which look to include T-cell immunogens. 
Pneumococcal carriage in healthy adults is immunising and results in increased IgG levels to 
several protein antigens including PspA (Ferreira, 2013, Wright et al., 2013, Ferreira et al., 
2013). Pneumococcal inoculation alone without carriage induces a pneumococcal-specific 
Th17-associated cellular immune response (Wright et al., 2012). Here we demonstrated that 
pneumococcal carriage increased PspA-specific CD4+TNFα+ recall responses to 
S. pneumoniae, therefore played a component role in CD4+ T-cell-mediated inflammatory 
response to carriage.  
Pneumococcal protein-specific CD4+ T-cell responses to S. pneumoniae in peripheral blood 
of humans is of utility as S. pneumoniae causes blood-borne diseases. However, the tissue-
specific nature of pneumococcal CD4+ T-cell immunity (Jambo et al., 2011), highlights the 
need to investigate CD4+ T-cell responses at relevant sites. With respect to vaccines against 
pneumonia, this implicates measuring protein-specific CD4+ T-cell responses in the lung. 
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5 BAL PspA-specific CD4+ T-cell responses to S. pneumoniae  
 
5.1 Introduction 
 
Streptococcus pneumoniae is the causative organism of a range of mucosal syndromes and 
diseases including otitis media, sinusitis and pneumonia. The existing 23-valent 
pneumococcal polysaccharide vaccine (23-PPV) recommended for use in adult groups and 
the elderly, does not protect against pneumonia (Bonten et al., 2015). The conjugate vaccines 
protect well against invasive pneumococcal disease (IPD) in children, but less well against 
mucosal diseases including pneumonia (Cutts et al., 2005) and otitis media (Rodrigues et al., 
2013b). 
The lung is a specialised immune-regulated environment with a large mucosal surface. 
Pneumococcal-specific immune responses have been demonstrated as important in defence 
against S. pneumoniae at several mucosal sites including the upper respiratory tract/nasal 
associated lymphoid tissue (Pido-Lopez et al., 2011, Zhang et al., 2011). Although we know 
pneumococcal-specific CD4+ T-cell responses are generated in the human lung (Wright et al., 
2013), little is known about protein-specific CD4+ T-cell immunity to the pneumococcus at this 
mucosal site in humans. 
Understanding pulmonary immune memory is important as pneumococcal-specific CD4+ T-
cell responses have been shown to be compartmentalised (Jambo et al., 2011), and vaccine 
efficacy may be dependent on tissue-specific effector memory. Furthermore, an understanding 
of beneficial immune responses to S. pneumoniae will aid in identification of human 
populations in which these are lacking, and consequently suffer from critical exacerbations, 
such as chronic lung disease patients (Chodosh, 1987). Targeting vaccination towards these 
at risk groups may further reduce the morbidity and mortality associated with pneumococcal 
lung disease. Therefore, the ability to detect antigen-specific CD4+ T-cell responses in the lung 
within the EHPC model, is pertinent in the testing of novel vaccine candidates at this important 
and relevant mucosal site. 
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Here we investigate PspA-specific CD4+ T-cell immune responses to S. pneumoniae in the 
adult lung, and associate them with recent pneumococcal nasopharyngeal carriage status in 
healthy adults exposed to S. pneumoniae in the EHPC model.  
Specifically, our research questions were: 
1. Do non-PspA-specific pulmonary CD4+ T-cell cytokine levels associate with carriage 
status? 
2. Are PspA-specific immune responses to S. pneumoniae detectable in pulmonary 
CD4+ T-cells? 
3. Does carriage augment PspA-specific responses to S. pneumoniae in pulmonary 
CD4+ T-cells? 
4. Do PspA-specific responses to S. pneumoniae in pulmonary CD4+ T-cells correlate 
with carriage intensity? 
5. Are PspA-specific CD4+ T-cell responses to S. pneumoniae of different amplitude in 
the lung and blood? 
 
 
5.2 Materials and methods 
 
5.2.1 BAL tissue sample collection, processing and ex vivo stimulation 
Bronchoalveolar lavage (BAL) samples were collected as previously described (Collins et al., 
2014). The non-adherent cell fraction containing lymphocytes, was isolated and stimulated as 
previously described (Section 2.4.2). Briefly, BAL samples were obtained an average of 67 
days post-inoculation by bronchoscopy, filtered to remove mucus and whole BAL separated 
by centrifugation at 470 x g for 10 minutes. The resultant cellular pellet was re-suspended, 
seeded and incubated at 37°C, 5% CO2 for an average of 3 hours to promote macrophage 
adhesion.  
Non-adherent cells were collected, washed and plated at a count of 200 – 500,000 cells/mL 
into a 96-well plate. Cells were left unstimulated (for background subtraction of non-specific 
cytokine secretion), and separately stimulated for 16 hours with 8 µg/mL PspA antigens 
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(PspA/Rx1, Fragments 2, 4 and 7). After 2 hours of incubation, protein secretion was inhibited 
as previously described (Section 2.4.2.2), for intracellular cytokine secretion analysis by Flow 
cytometry (Section 5.2.3).   
 
5.2.2 Blood sample collection, processing and ex vivo stimulation 
Blood samples were collected at a matched time point to BAL. Peripheral blood mononuclear 
cells were isolated and stimulated as previously described (Section 2.4.2). Briefly, PBMCs 
were isolated by density-mediated centrifugation, washed twice and re-suspended in complete 
media. Cells were seeded for stimulation (with 4 µg/mL pneumococcal antigens PspA/Rx1, 
Fragments 2, 4 and 7, and 0.5 µg/mL positive control Staphylococcus Enterotoxin B) at a 
concentration of 1 x 106 PBMCs/mL, in addition to a negative unstimulated assay control (for 
background subtraction). Cytokine secretion was prevented by addition of monensin and 
brefeldin. 
 
5.2.3 Flow Cytometry  
Cells were harvested, stained and analysed for intracellular cytokine production as previously 
described (Section 2.4.3) Briefly, cells were harvested by centrifugation, stained for surface 
phenotyping and intracellular cytokine production, and acquired on a BD LSR II flow cytometer. 
Viable CD3+CD4+CD69+ T-cells (hereafter described as CD4+ T-cells) and IL-17A, IL-22, 
TNFα, IFNγ and TGFβ secretors, were identified using FlowJo software v10 (Treestar, 
Oregon, USA). Pestle v1.7 and SPICE v.5.2 software (Mario Roederer, Vaccine Research 
Centre, NIAID, NIH) were employed for background subtraction and data mining respectively. 
The gating strategy is presented in Figure 2.3. 
 
5.2.4 Statistical Analysis  
Data analysis was conducted as previously described (Section 2.4.4). Briefly, stimulus-specific 
cytokine secreting CD4+ T-cell data underwent initial analysis by One-way ANOVA with 
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Dunnett’s post-hoc testing, and calculation of the average geometric mean fold change (FC) 
per volunteer across each stimulus (average fold change all stimuli).  
Subsequent exploratory analysis employed log-transformed percentage cytokine-secreting 
CD4+ T-cell data which followed a Gaussian distribution, therefore parametric tests were 
employed, namely t-tests both paired and unpaired, and Pearson’s correlation tests. Graphical 
representation and statistical analyses were performed using GraphPad Prism v5.0 
(California, USA). Differences were considered significant at p < 0.05 (two-tailed). 
 
 
5.3 Results 
 
5.3.1 Non-PspA-specific pulmonary CD4+ T-lymphocyte cytokine levels and association 
with carriage status  
To investigate whether non-PspA-specific CD4+ T-cell cytokine levels associated with post-
inoculation carriage status, we compared unstimulated pulmonary CD4+ T-cell cytokine 
secretion in carriage negative and positive individuals. 
We observed no statistical difference in non-PspA-specific CD4+ T-lymphocyte cytokine-
secretion between carriage negative (n = 6) and positive volunteers (n = 8) (Figure 5.1). 
However, volunteer numbers were few, therefore our ability to detect small differences 
between groups was low. Hence, we note a reduced level of non-PspA-specific CD4+ IL-17A+ 
secretion in the carriage positive cohort compared to the negative (difference between means 
[95% CI]: 0.49 ± 0.54 [-0.67 to 1.66] p = 0.37), and the reverse trend on measurement of non-
PspA-specific CD4+ TGFβ+ secretion (-0.74 ± 0.47 [-1.76 to 0.29] p = 0.14). Carriage negative 
and positive CD4+ T-cell secretion levels were similar for IL22 (0.18 ± 0.30 [-0.54 to 0.90] p = 
0.57), TNFα (-0.71 ± 0.56 [-1.93 to 0.50] p = 0.23) and IFNγ (0.09 ± 0.69 [-1.42 to 1.60] p = 
0.89). 
Therefore, we did not detect significant non-PspA-specific pulmonary CD4+ T-cell cytokine 
levels associated with carriage status. However, we detected higher carriage positive 
volunteer CD4+ TGFβ+ secretion compared to carriage negative volunteers, where CD4+ IL-
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17A+ secretion was reciprocally lower in carriage positive compared to negative volunteers. 
This reflected the immune paradigm of an inverse relationship between inflammatory Th17/T-
regulatory responses, and may indicate a mechanism of preventing excessive inflammation in 
the lung of a population with increased risk of pneumococcal aspiration to the lung (carriage 
positive volunteers). 
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Figure 5.1 Non-PspA-specific CD4+ T-cell cytokine levels in the human lung. Unstimulated CD4+ T-lymphocyte 
cytokine secretion in carriage negative (n = 6) and positive (n = 8) volunteers in the lung post S. pneumoniae 
inoculation. Unpaired t-test on log transformed data (all data p > 0.05). Horizontal bars represent mean ± SEM. 
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5.3.2 PspA-specific CD4+ T-lymphocyte responses to S. pneumoniae in the lung  
In order to harness the EHPC model to test novel serotype-independent vaccine candidates 
at a relevant mucosal site, we assessed the sensitivity of our assay to detect induction of single 
pneumococcal antigen-specific pulmonary CD4+ T-cell responses to S. pneumoniae. 
Fourteen volunteers underwent bronchoscopy an average of 67 days post-inoculation for 
obtaining BAL. There was no difference in time elapsed between inoculation and BAL 
procedure in carriage negative (n = 6, 76.83 ± 27.37 days) and carriage positive volunteer 
groups (n = 8, 64.63 ± 21.39 days) (p = 0.37, unpaired t-test) (Table 5.1). 
 
Table 5.1 Time elapsed between pneumococcal inoculation and bronchoscopy procedure. 
 
Average time elapsed measured as mean number of days ± SD. 
 
Table 5.1 Time lapsed between pneumococcal inoculation and bronchoscopy procedure. 
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We detected PspA-specific CD4+ T-cell responses to S. pneumoniae in BAL: CD4+ IL-17A+, 
IL22+, TNFα+ and IFNγ+ T-cell proportions had an average fold change (all stimuli) > 1 (Table 
5.2). The highest differences in cytokine secretion on PspA-stimulation were observed for Th1 
cytokine IFNγ (FC = 2.38) and inflammatory cytokine TNFα (FC = 1.88) whereas no overall 
difference was observed on PspA-specific CD4+TGFβ+-secretion (FC = 0.99). 
 
Table 5.2 Fold change in pulmonary post-inoculation unstimulated to stimulated PspA-specific CD4+ T-cells. 
 
Average percentage cytokine secreting CD4+ T-cells – geometric mean [95% confidence interval of geometric mean]. 
US – unstimulated; Fn – fragment n. Average fold change all stimuli – mean fold change from unstimulated to 
stimulated for F2, F4, F7 and PspA/Rx1 stimuli. 
 
However, differences between unstimulated and combined PspA-specific CD4+ T-cell 
responses to S. pneumoniae were not statistically different at any one of five cytokines 
measured: IL-17A, p = 0.80; IL22, p = 0.11; TNFα, p = 0.11; IFNγ, p = 0.22; TGFβ, p = 0.43 
(One-way ANOVA) (Figure 5.2a). On PspA stimulation, a number of volunteer CD4+ T-cell 
responses fell to undetectable levels: 81% of undetectable cytokine secretion cases were in 
carriage positive volunteers (n = 13 of 16) (Figure 5.2b). 
On employing Dunnett’s post-hoc testing to correct for multiple comparisons between the 
constant unstimulated control measurements and variant antigen-specific conditions, 
differences in means were detected on F2-specific CD4+ IL22 secretion (mean difference [95% 
Table 5.2 Fold change in pulmonary post-inoculation unstimulated to stimulated           
PspA-specific CD4+ T-cells. 
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confidence interval]: -0.36 [-0.69 to -0.03]), and F4-sepcific CD4+ TNFα secretion (-0.29 [-0.56 
to -0.02]) (Figure 5.2a). We did not detect a difference between unstimulated and antigen-
stimulated cytokine secretion when data were stratified by carriage status (p > 0.05) (Figure 
5.2b).  
Therefore, PspA-specific immune response to S. pneumoniae in pulmonary CD4+ T-cells was 
not statistically different to unstimulated levels. This may reflect the lack of immunodominance 
of PspA as an antigen in the lung. Consequently, subsequent analyses were exploratory, 
primarily using data of conditions where CD4+ responses were significant, as a pilot dataset 
addressing outlined research questions.
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Figure 5.2 PspA-specific CD4+ T-cell responses to S. pneumoniae in the human lung. CD4+ IL-17A, IL22, TNFα, 
IFNγ and TGFβ secretion in the lung post S. pneumoniae inoculation. (a) all volunteers - unstimulated (open 
circles), PspA-stimulated (closed circles). One-way ANOVA with Dunnett’s post-hoc corrections, * = p < 0.05 
(all ANOVA data p > 0.05). (b) by carriage status – carriage negative (open circles), carriage positive (closed 
circles), unstimulated (small circles), stimulated (large circles). Horizontal bars represent mean ± SEM. 
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5.3.3 Carriage status and association with PspA-specific pulmonary CD4+ T-cell responses 
to S. pneumoniae  
We investigated whether post-inoculation pulmonary PspA-specific CD4+ T-cell responses to                   
S. pneumoniae differed between carriage negative and positive individuals. We note that these 
analyses are against a background of inability to detect a significant PspA-specific CD4+ T-
cell cytokine response to S. pneumoniae in a small dataset (carriage negative: n = 6; carriage 
positive: n = 8) (Section 5.3.2). Therefore, we present these data as a descriptive analysis to 
defined research questions. We highlight a pilot dataset where pulmonary PspA-specific CD4+ 
T-cell cytokine secretion was significant (F2-specific CD4+IL22+ and F4-specific CD4+TNFα+ 
responses) (Figure 5.2). 
We observed no association between carriage status and proportion of PspA-specific 
pulmonary CD4+ T-cells secreting IL-17A, IL22, TNFα, IFNγ or TGFβ (p > 0.05, unpaired t-
test) (Figure 5.3). Where there was a previously detected significant PspA-specific CD+ T-cell 
response to S. pneumoniae, we maintained inability to associate carriage status with immune 
response: percentage F2-specific CD4+ T-cells secreting IL22+ (difference between means 
[95% CI]: 0.45 ± 1.24 [-2.45 to 3.37] p = 0.73), and F4-specific CD4+ T-cells secreting TNFα 
(0.15 ± 0.78 [-1.58 to 1.87] p = 0.86) were not statistically different between carriage negative 
and positive groups (Figure 5.3).  
Therefore, carriage did not augment PspA-specific responses to S. pneumoniae in pulmonary 
CD4+ T-cells. This supports our observation that PspA may not be an immunodominant 
antigen in the lung. 
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Figure 5.3 Carriage status and PspA-specific CD4+ T-cell responses to S. pneumoniae in the human lung. 
Unstimulated-corrected PspA-specific CD4+ IL-17A, IL22, TNFα, IFNγ and TGFβ-secretion in the lung of 
carriage negative (open circles) and positive (closed circles) volunteers post S. pneumoniae inoculation. 
Significant pulmonary PspA-specific CD4+ T-cell responses boxed. Unpaired t-test on log-transformed data 
(all data p > 0.05). Mean value plotted, horizontal bars represent ± SEM.  
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5.3.4 Correlation of pneumococcal colonisation intensity with PspA-specific pulmonary 
CD4+ T-cell responses to S. pneumoniae  
We calculated a compound, continuous measure of carriage density and duration (area under 
the curve analysis of density of pneumococcus recovered in nasal wash (log10) and duration 
of colonisation in days) (Table 5.3) to investigate whether PspA-specific CD4+ T-cell cytokine-
responses to S. pneumoniae correlated with extent of colonisation (colonisation intensity). We 
note that overall, we did not detect a significant pulmonary PspA-specific CD4+ T-cell response 
to S. pneumoniae (unstimulated to stimulated cells, Section 5.3.2), therefore highlight data for 
statistically significant conditions as a pilot analysis as per defined research questions (F2-
specific CD4+IL22+ and F4-specific CD4+TNFα+ responses). 
 
Table 5.3 Colonisation intensity from microbiology carriage density and duration data. 
 
Colonisation intensity = Area Under the Curve analysis of density and duration per pneumococcal carriage episode. 
 
We did not detect a correlation between colonisation intensity and F2-specific CD4+IL22+ T-
cell responses to S. pneumoniae (r = 0.15, p = 0.78) or F4-specific CD4+TNFα+ responses 
(r = 0.29, p = 0.56) (Figure 5.4). We also did not detect a correlation between IL-17A, IFNγ 
and TGFβ-secreting PspA-specific CD4+ T-cells to S. pneumoniae (all stimuli combined) 
(Figure 5.5), notably against a background of non-statistical difference in detection of 
differences between unstimulated and stimulated cells.  
able 5.3 Colonisatio  intensity fr m microbiology carriage density and duration data. 
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Therefore, PspA-specific responses to S. pneumoniae in pulmonary CD4+ T-cells did not 
correlate with carriage intensity. This further strengthens observations that PspA may not be 
an immunodominant antigen in the human adult lung. 
 
 
Figure 5.4 Colonisation intensity and PspA-specific CD4+ T-cell responses to S. pneumoniae in the human 
lung. Unstimulated-corrected (a) Fragment 2-specific CD4+IL22+ and (b) Fragment 4-specific CD4+TNFα+ 
pulmonary T-cell responses to S. pneumoniae post-inoculation. Open symbols - carriage negative 
volunteers; closed symbols - carriage positive volunteers. Pearson’s correlation on log transformed carriage 
positive volunteer CD4+ T-cell responses (all data p > 0.05). 
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Figure 5.5 Colonisation intensity and PspA-specific CD4+ T-cell responses to S. pneumoniae in the human 
lung. PspA-stimulated CD4+ IL-17A, IL22, TNFα, IFNγ and TGFβ-secretion in the lung of individuals post 
S. pneumoniae inoculation. Pearson’s correlation analysis on log transformed CD4+ T-cell data of carriage 
positive volunteers (all data p > 0.05). 
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5.3.5 PspA-specific CD4+ T-cell responses to S. pneumoniae in the lung and blood  
To investigate whether post-inoculation PspA-specific CD4+ T-cell responses to                            
S. pneumoniae were of a similar amplitude in the lung and systemically, we compared CD4+ 
T-cell response levels at matching time points in BAL and blood. Where pulmonary responses 
were significantly detected, we employed data for a pilot analysis of pre-defined questions. 
Although pilot dataset F2-specific CD4+ IL22 secretion did not significantly differ across BAL 
and blood tissue (mean of differences [95% CI]: -0.53 [-1.82 to -2.89] p = 0.56), F4-specific 
CD4+TNFα secretion was significantly lower in BAL compared to blood (-2.13 [-3.69 to -0.57] 
p = 0.01) (Figure 5.6). Carriage negative volunteer F4-specific CD4+TNFα+ T-cell responses 
to S. pneumoniae were significantly lower in BAL compared to blood (-2.78 [-4.01 to -1.56] 
p < 0.01) (Figure 5.6).  
 
Figure 5.6 Detectable PspA-specific CD4+ T-cell responses to S. pneumoniae in BAL and blood. Unstimulated-
corrected F2-specific CD4+IL22+ and F4-specific TNFα+ T-cell responses to S. pneumoniae in the lung and 
blood of volunteers at matched time-points. Carriage negative (open circles) and carriage positive (closed 
circles) volunteers. Paired t-test on log transformed data, *p < 0.05. Horizontal bars represent mean ± SEM.  
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We observed a lower combined PspA-specific CD4+TNFα secretion in the lung as compared 
to the blood of volunteers (-1.39 [-2.11 to -0.67] p < 0.01) (Figure 5.7): this difference was most 
marked for carriage positive volunteers (-1.78 [-2.61 to -0.94] p < 0.01). We note this result 
was against a background of non-statistical difference between unstimulated and stimulated 
blood CD4+ T-cells post-inoculation (Figure 5.8), and comparable cytokine detection in 
matched unstimulated controls (FC = 0.93) (Table 5.4).  
 
Table 5.4 Matched BAL time-point blood fold changes in unstimulated to stimulated PspA-specific CD4+ T-
cells. 
 
Average percentage cytokine secreting CD4+ T-cells – geometric mean [95% confidence interval of geometric mean]. 
US – unstimulated; Fn – fragment n. Average fold change all stimuli – mean fold change from unstimulated to 
stimulated for F2, F4, F7 and PspA/Rx1 stimuli. 
 
Similarly, we observed a lower combined PspA-specific Th17-associated immune response in 
the lung compared to blood: CD4+IL-17A secretion was lower in BAL (-0.71 [-1.37 to -0.05] p 
= 0.04) (Figure 5.7): this difference too was most marked for carriage positive volunteers (-
0.98 [-2.00 to 0.04] p = 0.06). Carriage positive volunteer CD4+IL22 secretion was similarly, 
but not significantly, lower in BAL compared to blood (-0.25 [-1.92 to 1.42] p = 0.73). We note 
these observations are against a background of detectable, but not significant differences in 
unstimulated to stimulated CD4+ T-cells in blood at the same time-point (IL-17A: FC = 3.33, p 
= 0.73; IL22: FC = 1.11, p = 0.48) (Table 5.4, Figure 5.8). 
Table 5.4 Matched BAL time-point blood fold changes in unstimulated to stimulated 
PspA-specific CD4+ T-cells. 
 - 125 - 
 
 
Figure 5.7 PspA-specific CD4+ T-cell responses to S. pneumoniae in BAL and blood. Unstimulated-corrected 
PspA-stimulated (all stimuli) CD4+ IL-17A, IL22, TNFα, IFNγ and TGFβ-secretion in the lung and blood of 
volunteers at matched time-points. Paired t-test on log transformed data, *p < 0.05. Horizontal bars represent 
mean ± SEM. 
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Although the non-statistically significant trend in low BAL, high blood CD4+ T-cell cytokine 
secretion was evident for carriage negative IFNγ (-0.55 [-1.53 to 0.43] p = 0.25) and TGFβ-
secretion (0.68 [-0.39 to 1.76] p = 0.20), BAL and blood cytokine levels were similar for carriage 
positive volunteers [IFNγ: (0.18 [-0.78 to 1.14] p = 0.69); TGFβ:(-0.04 [-1.48 to 1.40] p = 0.95)]. 
Again, we note that these observations are against a background of non-significant differences 
in matched time-point blood CD4+IFNγ+-secretion (FC = 1.90, p = 0.34) and undetectable CD4+ 
TGFβ+-secretion (FC = 0.73, p = 0.44) (Figure 5.7, Table 5.4). 
 
Therefore, PspA-specific CD4+ T-cell responses to S. pneumoniae differed in the lung and 
blood: where responses were significant, PspA-specific CD4+TNFα+ response levels were 
lower in BAL compared to blood. This further still may reflect the reduced immunodominance 
of PspA in the lung compared to blood.  
 - 127 - 
 
 
 
 - 128 - 
 
 
Figure 5.8 Matched BAL time-point blood PspA-specific CD4+ T-cell responses to S. pneumoniae. CD4+ IL-
17A, IL22, TNFα, IFNγ and TGFβ secretion in the blood (matched BAL time point) post S. pneumoniae 
inoculation. (a) all volunteers - unstimulated (open circles) and PspA-stimulated (closed circles) (b) by 
carriage status – carriage negative (open circles), carriage positive (closed circles), unstimulated (small 
circles), stimulated (large circles). One-way ANOVA with Dunnett’s post-hoc corrections (all data p > 0.05). 
Horizontal bars represent mean ± SEM. 
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5.4 Discussion 
 
Post-inoculation PspA-specific CD4+IL-17A+, IL22+, TNFα+ and IFNγ+ T-lymphocyte 
responses to S. pneumoniae in the lung did not significantly differ from their unstimulated 
controls. Two exceptions to this however, were observed on PspA functional helical region-
specific responses: pulmonary Fragment 2-specific CD4+IL22+ and Fragment 4-specific TNFα+ 
T-cell responses to S. pneumoniae were significantly detected. These stimulation parameters 
were employed as a pilot dataset for exploratory analysis of pre-defined research questions 
and revealed no effect of carriage and colonisation intensity on PspA-specific CD4+ T-cell 
responses to S. pneumoniae, but revealed reduced levels of F4-specific CD4+TNFα-secretion 
in BAL compared to blood. All data suggest a non-immunodominant role of PspA in the healthy 
adult lung, subject to study limitations. 
 
5.4.1 Questions answered: study in field context 
The lung has historically been considered as a sterile site. However, it is now known to have 
its own distinct microbiome, where perturbations to its homeostatic state of microbial entry, 
elimination and regional growth are thought to contribute to disease susceptibility (Dickson 
and Huffnagle, 2015). 
Pre-exposure to S. pneumoniae through nasopharyngeal colonisation results in aspiration into 
the lungs (Mizgerd, 2012). This leads to the generation of antigen-specific memory T-cells, 
lung resident and primed to prevent disease on re-infection (Purwar et al., 2011). The 
presence of lung resident effector memory CD4+ T-cells necessitates measurement of antigen-
specific responses in situ to accurately characterise recall responses specific to novel protein 
vaccine candidates in the lung. This may inform pneumococcal vaccine design strategies with 
a focus on creation of constructs with a directional immune response against pneumococcal 
pneumonia. Our overall inability to detect a significant pulmonary PspA-specific CD4+ T-cell 
response suggests PspA is not an immunodominant pulmonary CD4+ T-cell antigen, subject 
to the limitations discussed. 
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Previous studies investigating pneumococcal-specific CD4+ T-cell responses in the human 
lung have similarly to this study used a stimulant concentration of 8 µg/mL, but in place of a 
single pneumococcal protein antigen, stimulated with a pneumococcal cell culture supernatant 
(Jambo et al., 2011, Sepako et al., 2014). Together with our findings, this indicates that PspA 
of strain Rx1 alone may be of insufficient potency to stimulate a pulmonary CD4+ T-cell 
response. This supports previous findings in BAL of no induction of anti-PspA (clade 1) IgG 
on exposure to S. pneumoniae serotype 6B (strain BHN418, PspA clade 1) (Wright et al., 
2012). 
Further still, on comparing pilot dataset PspA F4-specific CD4+TNFα+ T-cell responses in the 
lung and blood at the same time-point, we observed that cytokine secretion was lower in BAL. 
These data align with murine studies which have demonstrated at the genetic level, that the 
virulence of PspA is such that there are reduced levels of pspa microRNA (mRNA) expression 
in the lungs of mice compared to the blood (LeMessurier et al., 2006, Oggioni et al., 2006), 
again indicative of the reduced immunodominance of PspA in the lung. This further 
strengthens our observations of a less prolific role of PspA-immune response in the lung 
compared to blood. 
The human lung is a challenging immune environment: the primary site of pathogen targeting, 
a delicate balance between sterility and inflammation is crucial to maintain the essential and 
normal functioning of gaseous exchange. Treg-associated cytokine TGFβ plays a role in both 
normal lung function, and the pathogenesis of disease. Prevention of lung homeostatic 
dysregulation includes regulation of local immunomodulation, cell proliferation, differentiation, 
and control of tissue repair (Bartram and Speer, 2004). Where these processes are perturbed 
in magnitude or temporally, there is a risk of development of lung pathology with fibrosis: (Neill 
et al., 2012) demonstrated that mice with high levels of TGF-β1-associated with a T-regulatory 
phenotype were less likely to develop pneumococcal pneumonia. It is therefore conceivable 
as to why non-PspA-specific CD4+TGFβ+ responses were elevated in carriage, reciprocally so 
to the CD4+IL-17A+ responses, although not significantly different to carriage negative 
volunteers: this may reflect the regulation of an inflammatory response in a population at 
increased risk of lung injury, on aspiration of pneumococci during carriage to the lung. This 
observation aligns with pneumococcal-specific observations of a reciprocal relationship 
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between T-regulatory and Th17 cell activity in pneumococcal infection at a mucosal site, where 
Tregs are more abundant in adenoids of children positive for pneumococcal carriage 
compared to those negative for carriage (Jiang et al., 2015, Mubarak et al., 2016). 
 
5.4.2 Questions raised: study limitations 
Our observation of a global non-robust nature of pulmonary CD4+ T-cell responses post-
inoculation points towards PspA as non-immunodominant in long-lived CD4+ T-cell recall 
responses in the lung, or methodological limitations of sampling. 
BAL and matched blood samples were taken an average of 46 days later than day 21 post-
inoculation blood samples, therefore it is possible recall responses were dampened and 
consequently not robust. This finding is in line with the rationale for administration of vaccine 
boosters to maintain memory populations on depletion of effector T-cell populations. It has 
been described as the antigen-dependent maintenance of T-cell memory (Gray and Matzinger, 
1991), where re-exposure/extended exposure results in more robust CD4+ recall responses 
(Ravkov and Williams, 2009). 
Furthermore, memory responses to S. pneumoniae are best investigated in a longitudinal 
manner so that a time course of immune response can be followed. However, we have 
observed previously that the nature of a bronchoscopy and lavage induces a pro-inflammatory 
response which may perturb carriage acquisition rates (Wright et al., 2012). Therefore, 
repetitive lung sampling would not provide an accurate reflection of pulmonary recall cellular 
responses to the pneumococcus as BAL may prematurely clear carriage. In light of the 
restrictions on single time-point sampling, it is feasible the assay may respond to further 
optimisation, so we assess the conditions of the ex vivo intracellular cytokine staining assay. 
The limited availability of non-adherent cells for antigen stimulation (predominantly 
lymphocytes), resulted in conducting the BAL intracellular cytokine staining (ICS) assays with 
at most, half the number of non-adherent cells compared to PBMCs per test condition. 
Consequently, BAL-derived cell-antigen interactions may have differed from blood-derived 
PBMCs within a set reaction well. Furthermore, the nature of this mucosal sample (tendency 
of cells to clump together) resulted in fluctuations in acquisition rate and resultant potential of 
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more than a single cell passing through the cytometer at once. To maintain quality of single-
cell cytokine secretion data, we excluded samples displaying flow cytometry acquisition rate 
errors, therefore reducing numbers of an already limited dataset. 
It is important to note however, that the ICS assay used did not include a CD4+ effector 
memory marker e.g. CD45RO. Therefore, inferences made on the longevity of proportion of 
cytokine-secreting PspA-specific CD4+ T-cells, may be masking the specific cell population of 
interest. 
 
5.4.3 Questions posed: further work and study implications 
Our inability to detect a robust PspA-specific pulmonary CD4+ T-cell response to 
S. pneumoniae an average of 67 days post pneumococcal inoculation raises questions as to 
the role of PspA-specific T-cell memory responses in the adult lung. 
The lung is a complex and highly regulated immune environment, so emphasis must be placed 
on investigating additional immune cell subsets such as alveolar macrophages (AMs). AMs 
are one of the most abundant cell types in the lung (Balhara and Gounni, 2012), and impaired 
responses have been associated with pneumonia susceptibility in at risk populations. Burnham 
and co-workers (2011) have described a relationship between alcohol use disorders and 
perturbations in gene expression relating AM apoptosis, Wang et al. (2008) impaired AM 
pattern recognition and  S. pneumoniae clearance amongst morphine users, whereas no 
association was found between HIV and impaired AM phagocytic activity (Gordon et al., 2001). 
Of note is the demonstrated compartmentalisation of effector memory T-cell responses to 
S. pneumoniae (Jambo et al., 2011); this highlights the need to sample and assess cellular 
responses with a potential protective role against pneumonia, directly from lung and its 
surrounding tissue. 
Investigating pulmonary-specific immune responses to multiple widely expressed and 
immunogenic pneumococcal proteins, may reveal responses specific to other vaccine 
candidates: this causes us to re-visit the need to investigate multiple protein vaccine 
candidates. Nonetheless, the potential to dissect cellular responses elicited in the lung and 
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correlating experimental human pneumococcal carriage density and duration holds the 
prospect of aiding tissue-specific vaccine design and merits further study. 
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6 Systemic S. pneumoniae epitope-induced lymphoproliferation 
 
6.1 Introduction 
 
Current pneumococcal vaccine strategies target the variable surface polysaccharide of which 
there are over 90 serotypes: this has led to serotype replacement and vaccine escape. New 
approaches targeting virulence factors widely expressed across pneumococcal strains and of 
functional importance, would act to broadly target S. pneumoniae strains at a cost to fitness 
(Cobey and Lipsitch, 2012), hindering the mechanisms they use to survive and proliferate. 
Targeting multiple conserved virulence factors simultaneously is a strategy with the potential 
to avoid rapid vaccine escape, slowing vaccine-induced pneumococcal evolution and 
therefore the selective pressure now so globally prevalent as a result of polysaccharide-based 
vaccine introduction.  
Emerging pneumococcal vaccine strategies focus on immunisation eliciting broad protection 
across strains (Miyaji et al., 2013). One way to obtain broad coverage is to incorporate multiple 
widely expressed S. pneumoniae proteins. Leading candidates are conserved in nature and 
have demonstrated immunity against pneumococcal infection. Table 1.1 (Chapter 1, Section 
1.4.2.2) lists well-characterised candidates alongside their associated functions, and include 
the six top protein candidates tested in this study: 
 Pneumolysin (Ply): a 57 kDa thiol-activated cytolysin. Plays a key role in 
pneumococcal virulence, primarily by binding cholesterol, oligomerising, and forming 
large pores in eukaryotic cell membranes resulting in cell death (Steinfort et al., 1989, 
Ratner et al., 2006). Ply has been shown to contribute to pneumococcal pneumonia 
pathogenicity by promoting inflammation, impairing ciliary function and increasing 
alveolar permeability, in turn decreasing effective gaseous exchange (Mitchell and 
Dalziel, 2014).  
 Pneumococcal surface adhesin A (PsaA): a 37 kDa lipoprotein that plays a key role in 
virulence by mediating S. pneumoniae attachment to and colonisation of host cells 
(Berry and Paton, 1996). PsaA also acts to evade the host defence by binding 
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lactoferrin, competitively interfering with apolactoferrin deposition, and preventing host 
complement deposition (Shaper et al., 2004). 
 Plasmin and fibronectin binding protein A (PfbA): a 66 kDa polypeptide which exerts 
its virulence by binding to and invading host cells (Yamaguchi et al., 2008). 
 Choline-binding proteins: 
o Pneumococcal surface protein C (PspC): a 75 kDa protein which mediates 
both pneumococcal mucosal epithelial cell adherence to enable invasion, and 
evades clearance by binding host immune factors including complement 
factor H, C3 and secretory IgA (Dave et al., 2001, Kerr et al., 2006, 
Hammerschmidt et al., 1997); 
o Pneumococcal choline-binding protein A (PcpA): a 79 kDa surface antigen 
which plays a role in pneumococcal adhesion and colonisation (Sanchez-
Beato et al., 1998);  
o Pneumococcal surface protein A (PspA): an 80 kDa protein which inhibits 
complement deposition and binds lactoferrin to competitively inhibit 
apolactoferrin binding and killing (Ren et al., 2004). 
S. pneumoniae-specific CD4+ T-lymphocyte cellular responses are elevated post-
pneumococcal exposure (Wright et al., 2012) where elicitation of CD4+ T-cell responses 
requires binding and presentation of epitopes to a Major Histocompatibility Complex (MHC) 
class II molecule (Murphy and Weaver, 2017). Larger peptides of 13 – 18 amino acids 
preferentially bind MHC class II molecules over class I, promoting a CD4+ T-cell immune 
response over a CD8+ response. Our previous work sought to identify protective linear 
epitopes of a leading vaccine candidate, PspA, by probing both with serum of healthy adults 
both susceptible to or protected from pneumococcal carriage following nasal inoculation 
(EHPC model), and of older adults, a population more susceptible to pneumonia (Owugha et 
al., in preparation). We did not identify any linear epitopes differentially recognised in young 
compared to older adult cohorts, and therefore did not identify any potentially protective 
pneumococcal epitopes. Therefore, we sought to identify conserved and functionally important 
linear pneumococcal protein epitopes using a novel in silico approach, and test their 
immunogenicity ex vivo. 
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Coupling informatics approaches to epitope identification with immunological investigations 
has proven a useful tool for validating initial epitope selection, as predictions do not always 
directly correlate functional experimental data (Ip et al., 2015). A mainstay and initial screening 
stage to validate by immunogenicity is the wide-ranging lymphoproliferative assay: this 
enables immunological assessment of antigen-specific responses to informatics-identified 
epitopes. It is widely acknowledged however, that no single measure of lymphoproliferation 
captures the totality of the immune response to antigen (Roederer, 2011). Therefore, 
measures are often evaluated in tandem. Two employed in this study were: 
 Precursor Frequency (PF) as a marker of antigen-specific proliferating cell division 
probability 
 Upper generation proliferation index (UGPI) as a measure of true proliferating cell 
increase in cell number 
A sample dataset exemplifying calculations is as below: 
 
Table 6.1 Sample dataset for calculation of Precursor Frequency and Upper Generation Proliferation Index. 
 
PF     =     parent cell number (∑ generations 3 – 8)/parent cell number (∑ generations 1 - 8) 
          =     1070 /5470 
          =     0.20 
 
UGPI     =     total cell number (∑ generations 3 – 8)/parent cell number (∑ generations 3 – 8) 
  =     18500 /1070 
  =     17.29   
Table 6.1 Sample dataset for calculation of Precursor Frequency and Upper 
Generation Proliferation Index. 
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The potent mitogen Phaseolus vulgaris phytohaemagglutinin (PHA) (Quah et al., 2007) 
contains the major subunit leucoagglutinating phytohemagglutinin, PHA-L (Fitches et al., 
2001, Kumar et al., 2013). Frequently used as a positive control in lymphoproliferative assays, 
proliferative responses are monitored by staining of cells and monitoring the proportional 
decrease in visualised dye with increasing number of generations (Crumpton et al., 1975). 
Carboxyfluorescein succinimidyl ester (CFSE) is widely used as a cell dye due in part to high 
levels of cell permeability promoting homogeneity of staining, and stable covalent coupling to 
intracellular molecules enabling long-term tracking of cellular dynamics. Together, this allows 
for monitoring of cell division due to the reliable progressive halving in fluorescence intensity 
after up to an average of eight successive daughter generation divisions (Parish, 1999). 
Using a novel in silico computation method of selecting globally conserved peptide sequences 
of functional importance (fragility islands) (Bright et al., unpublished data), we aimed to identify 
pneumococcal protein targets with a cost to pathogen fitness, and assess their 
lymphoproliferative potential. We specifically set out to: 
1. Identify the most promising pneumococcal protein vaccine candidates by literature 
search 
2. Identify conserved peptide sequences of functional importance (fragility islands) within 
selected vaccine candidates, and fragment into 20 aa epitopes 
3. Optimise lymphoproliferation assay conditions 
4. Conduct the lymphoproliferation assay with single epitopes to select the 20 most 
proliferative. 
Ultimately, down-selection of immunogenic epitopes would go towards identification of a 
variety of epitopes inducing antigen-specific lymphocyte proliferation in healthy adults, and be 
fused to create novel protein constructs to test protective potential in murine models of 
pneumococcal infection. 
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6.2 Materials and methods 
 
6.2.1 Pneumococcal protein vaccine candidate identification 
A literature search was conducted to identify the 30 most promising pneumococcal protein 
vaccine candidates.  
 
6.2.2 Protein sequence identification and epitope generation 
An in silico approach to identifying regions of conserved amino acid sequence and functional 
relevance to S. pneumoniae (fragility islands), was taken to listed pneumococcal proteins 
(Table 1.1, Section 1.4.2.2). Briefly, an algorithm was developed (Blight et al., unpublished 
data) using Java SE Development Kit 8 software (Oracle) in which full length protein 
sequences were collected and queried for taxonomic identification using NCBI’s Entrez protein 
database (McEntyre, 1998) and Clustal Omega’s command line interface binary v.1.2.1 
(Sievers et al., 2011). Resultant sequences were aligned and conservation levels assessed 
using a sliding window approach. A conservation value between 0 and 1 was calculated for 
each window, and adjustments made to account for sequence collection bias. Fragility islands 
were defined as sequential windows with a conservation value deviating no more than 20% 
(window size = 15 amino acids; SD of conservation for fragility island ≦ 20%). 
Fragility island sequences were fragmented into 20 amino acid (aa) epitopes to promote MHC 
class II binding, and sequential sequences overlapped by 10 aa to prevent truncation of 
potentially immunogenic epitopes at fragment junctions. Resultant epitopes were synthesised: 
peptide purity and quality was assessed by high performance liquid chromatography and mass 
spectrometry, routinely scoring above 95% (Mimotopes, Clayton Victoria, Australia). 
 
6.2.3 Volunteer recruitment, ethical approval, sample collection and processing 
Healthy adult volunteers were recruited under ethical approval granted by The North West 3 
Research Ethics Committee, Liverpool East (REC 11/H1002/9) as previously described 
(Section 2.1.2). Samples were collected and processed as previously described (Section 
2.3.3). Briefly, donated heparinised venous blood samples were collected and peripheral blood 
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mononuclear cells (PBMCs) isolated by density-mediated centrifugation using Ficoll-Paque 
PLUS (GEHealthcare, Uppsala (Sweden)) according to the manufacturer’s instructions. Cells 
were washed twice in HBSS, re-suspended in RPMI + 20 mM L-glutamine supplemented with 
antibiotics (penicillin 40 U/mL, streptomycin 40 µg/mL, neomycin 80 µg/mL), seeded into a 24-
well plate in a volume of 1 mL and concentration of 1 x 106 PBMCs/mL and rested over night 
at 37°C, 5% CO2. 
 
6.2.4 Proliferation assay 
The potent lectin mitogen phytohaemagglutinin-L or leucoagglutinin (PHA-L), was used as a 
positive control and in optimising the lymphoproliferation assay. Volunteers (n = 5) were 
screened for a detectable PHA-L response, and the 2 highest responders selected for epitope-
induced lymphocyte proliferation testing. 
In optimisation experiments, rested PBMCs were stained with 1.0, 2.5 and 5.0 mM/test CFSE 
and stimulated with 1.0, 2.5 and 5 µg/test PHA-L in triplicate for 72, 120 and 168 hours.  
Optimal conditions selected were 2.5 mM CFSE staining, 1.0 µg PHA-L stimulation, and 120 
hours duration. Using these conditions, two randomly selected epitopes (epitopes 36 and 47) 
were titrated for optimisation of stimulant concentration: concentrations of 0.1, 0.5, 1.0, 2.5, 
5.0 and 10.0 µg/test were evaluated, and 10.0 µg/test selected. 
In epitope-induced proliferation experiments, rested PBMCs were collected and stained with 
2.5 mM carboxyfluorescein succinimidyl ester (CFSE) at a concentration of 1 x 107 PBMCs/mL 
and incubated in the dark with shaking (200 rpm) for 20 minutes. PBMCs were subsequently 
seeded into a 96-well plate in a volume of 200 µL, left unstimulated as a negative control, 
stimulated with 10 µg of epitope, or 1.0 µg of PHA-L positive control, and incubated at 37°C, 
5% CO2 for 120 hours. 
Cells were harvested and proliferation detected by fluorescence. 300,000 cell events were 
acquired using a BD LSRII Flow Cytometer (Becton Dickinson) and viewed using FacsDiva 
version 6.1 (BD Biosciences) software in the LSTM Flow Cytometry Facility. ModFit LT v.4.1 
was harnessed for proliferation analysis. 
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6.2.5 Statistical Analysis  
Lymphoproliferation in optimisation experiments was assessed using the parameter of 
Proliferation index (PI), and computed using FlowJo v7.65: 
PI   =   total number of divisions (∑ generations 2 - 7)/parent cell number (∑ generations 2 - 7) 
Lymphoproliferation in the subsequent epitope-induced lymphoproliferation pilot study was 
assessed via Precursor frequency (PF) and upper generation proliferation index (UGPI) 
computed using the ModFit LT v.4.1 software: 
PF        =      parent cell number (∑ generations 3 - 8)/parent cell number (∑ generations 1 - 8) 
UGPI    =     total cell number (∑ generations 3 - 8)/parent cell number (∑ generations 3 - 8) 
 
Descriptive measures for non-parametric data analysis were employed to analyse epitope-
induced proliferation conducted in triplicate, namely median and percentage values. 
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6.3 Results 
 
6.3.1 Identification of pneumococcal protein vaccine candidates  
We conducted a literature search of widely expressed immunogenic proteins with roles in 
pneumococcal virulence and identified leading vaccine candidates: surface proteins (1 - 18) 
and enzymes (18 - 30): 
1. Pneumococcal surface protein A 
2. Pneumococcal surface protein C 
3. Pneumococcal surface adhesin A 
4. Choline-binding protein A 
5. Polyhistidine triad proteins D & E 
6. Pneumococcal serine-rich repeat protein 
7. Pneumococcal choline-binding protein A 
8. Pneumococcal transformation pilus 
9. Pneumococcal pilus 1 proteins (RrgA & B) 
10. Pneumococcal pilus 2 
11. Polyamine transporter D 
12. Pneumococcal adhesion and virulence protein A & B 
13. Plasmin and fibronectin binding protein A 
14. Pneumococcal iron acquisition/uptake protein A 
15. Maltose/maltodextrin-binding protein 
16. ABC transporter, substrate-binding protein 
17. Hypothetical surface exposed protein 
18. Cell wall-associated serine protease 
19. Pneumolysin 
20. IgA1 protease 
21. Endonuclease A 
22. Neuraminidases A & B 
23. Glycosyl hydrolase 25 relating to invasion proteins 
24. Hyaluronate lyase 
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25. Pneumococcal protein endopeptidase O 
26. Large zinc metalloproteinase 
27. Autolysins B & C 
28. Protein for cell wall separation of group B streptococcus 
29. Serine-threonine protein kinase 
30. α-glycerophosphate oxidase 
We therefore identified the thirty most promising pneumococcal vaccine candidates for 
downstream epitope generation. 
 
6.3.2 Identification of conserved peptide sequences within fragility islands and 
fragmentation into epitopes  
Based upon protein consensus sequence availability and quality of sequence alignments, we 
down-selected 14 of the original 30 pneumococcal proteins for further analysis. We 
subsequently identified 36 sequences both of a conserved nature and of functional importance 
(fragility islands) from the 14 selected proteins (Appendix A).  
To promote downstream optimal binding of epitopes to MHC class II molecules in 
lymphoproliferation assays, we fragmented fragility islands into 20 amino acid (aa) epitopes 
(where the identified fragility island sequence was 20 aa or longer): we constructed 151 
epitope sequences in total. To ensure potential immunogenic linear epitopes were not 
truncated at fragment junctions, we defined epitopes to overlap by 10 aa (Appendix A). 
Epitopes not in fragility islands were designated highly diverse controls (HDCs).  
On sequence alignment of choline-binding proteins PspC, PcpA and PspA, we discovered that 
multiple sequence entries had been misnamed. To clearly distinguish between proteins, we 
re-aligned sequences and grouped them based on clades as revealed by cladistic analysis 
(Blight et al., unpublished data). Figure 6.1 illustrates the distinct branch formation on 
phylogenetic tree representation, and the three distinct groups (clades 1 - 3) of the newly 
designated protein 1_2_10: clade 3 divided into two further sub-clades (clades 3.1 and 3.2). 
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Figure 6.1 Radial cladogram of newly designated protein 1_2_10 illustrating sequence analysis to genetically 
distinguish between choline-binding proteins labelled PspC, PcpA and PspA. Sequences were aligned and 
grouped into distinct clades 1 - 3. Clade 3 was further divided into two sub-clades 3.1 and 3.2. Bar represents 
unit of genetic change.  
 
We removed sub-clade 3.1 from further analysis as domains of functional relevance from 
constituent sequences were diverse. Sub-clade 3.2 was further divided into clades 3.2.1 and 
3.2.2: clade 3.2.1 contained key fragility islands which were conserved (translocated promotor, 
TPR, and TATA-box regions), whereas clade 3.2.2 did not contain any islands of conservation. 
Furthermore, sub-clades 3.1 and 3.2.2 were more closely related to clades 1 and 2 compared 
to sub-clade 3.2.1, therefore we selected clade 3.2.1 as a distinct representative of clade 3 
choline binding proteins (Blight et al., unpublished data).  
We therefore identified conserved peptide sequences of functional importance (fragility 
islands) within selected vaccine candidates, and fragmented them into 20 aa linear epitopes. 
For this pilot study we selected epitopes listed 1 - 55 spanning 6 proteins to investigate 
pneumococcal epitope-induced lymphoproliferation in healthy adults (Appendix A).  
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6.3.3 Optimisation of lymphoproliferation assay conditions  
Due to the heterogeneity in volunteer responses, we selected 2 volunteers with the highest 
lymphoproliferation induced by positive control PHA-L, from an original screen of 5. This was 
to ensure we were working with detectable PHA-L responses for the optimisation of assay 
conditions. We tested PHA-L stimulation at 1.0, 2.5 and 5 µg/test, CFSE concentrations of 1.0, 
2.5 and 5.0 mM/test, assay durations of 72, 120 and 168 hours, and pneumococcal epitope 
concentrations of 0.1, 0.5, 1.0, 2.5 5.0 and 10.0 µg/test. 
We measured the greatest lymphocyte proliferation on stimulation of PBMCs with 1.0 µg/test 
of PHA-L (24.6% lymphocytes in total cell population): cell proliferation on stimulation with          
2.5 µg/test resulted in a 4-fold ±1.67 decrease in lymphocyte abundance relative to 
unstimulated control (10.3% lymphocytes), and stimulation with 5 µg/test a 9-fold ±0.90 loss 
in cell yield (2.6% lymphocytes) (Figure 6.2). On staining cells with 2.5 mM CFSE/test, we 
detected the highest resolution of daughter generations giving a proliferation index (PI) of 3.9, 
compared to 2.8 at 1 mM and 2.7 at 5 mM CFSE (Figure 6.3).  
We detected an increase in proliferation indices with duration of stimulation: 1.02 at 72 hours, 
1.26 at 120 hours and 2.21 at 168 hours. However, the marked increase in apoptotic 
lymphocytes at 168 hours resulted in 15% of the cell population identified as lymphocytes 
compared to 24.6% at 72 hours and 54.3% at 120 hours. We therefore selected 120 hours as 
the optimal assay duration (Figure 6.4). 
After we optimised assay conditions as 2.5 mM CFSE staining, 1.0 µg PHA-L stimulation, and 
120 hours duration, we titrated for epitope concentration. Epitopes 36 and 47 were randomly 
selected and lymphocyte proliferation measured at 0.1, 0.5, 1.0, 2.5 5.0 and 10.0 µg/test 
(Table 6.2).  
We did not detect lymphoproliferation on stimulation of PBMCs with epitope concentrations of 
0.1 to 5.0 µg/test: upper generation proliferation indices (UGPI) were below that of the 
unstimulated control (UGPI < 9.28). However, on stimulation with 10 µg/test, we detected 
proliferative activity: UGPIs were 15.07 for epitope 36 (background-corrected 5.5), and 12.07 
(background-corrected 2.5) for epitope 47. We consequently selected a final epitope assay 
concentration of 10 µg/test. 
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Therefore, lymphoproliferation assay conditions were optimised to 2.5 mM CFSE staining, 
10 µg epitope and 1 µg PHA-L stimulations over 120 hours duration. 
 
Table 6.2 Upper generation proliferation indices for optimisation of epitope stimulant 
concentration. 
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Figure 6.2 Lymphoproliferation assay PHA-L positive control stimulant concentration optimisation. Positive control PHA-L responses were assessed at 1.0, 2.5 and 5 µg/test. 
Percentage lymphocytes indicated within plot. FSC-A – forward scatter (measure of cell size); SSC-A – side scatter (measure of cell granularity/internal complexity).  
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Figure 6.3 Lymphoproliferation assay CFSE concentration optimisation. Positive control PHA-L responses at 1.0 µg/test used to titrate CFSE concentration. Percentage 
lymphocytes indicated within each dot plot. Histograms demonstrate daughter generation by colour, and Proliferation Index (PI) per CFSE dilution. FSC-A – forward scatter 
(measure of cell size); SSC-A – side scatter (measure of cell granularity/internal complexity); CFSE - carboxyfluorescein succinimidyl ester (lymphocyte stain). 
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Figure 6.4 Lymphoproliferation assay duration optimisation conditions. Positive control PHA-L proliferation potential assessed at 72, 120 and 168 hours. Percentage 
lymphocytes indicated within plot. Bold arrow denotes region of high lymphocyte apoptosis. Unstimulated and stimulated lymphocyte. FSC-A – forward scatter (measure of 
cell size); SSC-A – side scatter (measure of cell granularity/internal complexity).
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6.3.4 Selection of lymphoproliferative epitopes  
Immunogenic proteins in existing vaccines such as the tetanus toxoid (TT), are large and in 
the region of 150 kDa (Paoletti et al., 1990). This translates to > 1,300 amino acids and 
therefore a multiple-epitope protein made up of 20 aa fragility island epitopes could include up 
to sixty in number. As this pilot study measured lymphoproliferative responses in one third of 
an available 151 epitopes (n = 55), we evaluated the top 10 ranked epitope-induced 
lymphoproliferative responses in two volunteers (total n = 20), for selection towards a multiple-
epitope protein of a final size similar to the TT (total n = 60 epitopes).   
Our human adult volunteers elicited a range of recall proliferative responses to pneumococcal 
protein epitopes (Figure 6.4). Therefore, an epitope hit was defined as concurrent precursor 
frequency (PF) and upper generation proliferation index (UGPI) rankings within the twenty 
ranked most proliferative (Appendix B). The top ten epitopes per volunteer were selected to 
constitute the twenty suitable for down-selection, namely: 
 Volunteer 1: epitopes 1, 2, 3, 4, 37, 38, 44, 45, 50, 52 and 54 
 Volunteer 2: epitopes 14, 16, 18, 19, 20, 21, 22, 23, 24 and 25. 
 
Therefore, we selected the 20 most proliferative epitopes from a lymphoproliferation assay in 
a pilot of 55 epitopes.
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6.3.5 Lymphoproliferative epitopes  
On evaluating the top 20 ranked epitope-induced lymphoproliferative response rankings, 
epitope 3 of protein 1_2_10 clade 1 induced the highest cross-volunteer rankings of PF and 
UGPI (Appendix B).  
Epitope 3 stimulated PF responses ranking 20 in volunteer 1 and 5 in volunteer 2, where UGPI 
responses were 5 in volunteer 1 (54 in volunteer 2). This was closely followed by epitope 4 PF 
rankings of 19 for volunteer 1, and 27 for volunteer 2: UGPI rankings were 7 and 20 for 
volunteers 1 and 2 respectively. 
Epitopes 3 and 4 originated from consecutive regions of the same protein (choline binding 
protein 1_2_10 clade 1), therefore their consecutive high rankings in lymphoproliferation 
identified a highly immunogenic fragility island region. 
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Figure 6.5 Distribution of antigen-specific lymphoproliferative responses to pneumococcal protein epitopes. 
Unstimulated-corrected values presented for volunteer 1 (open bars) and volunteer 2 (filled bars) where (a) 
Precursor frequency (PF) probability of each cell dividing at least once (range; 0 to 1) (b) Upper generation 
proliferation index (UGPI): fold expansion of antigen-specific responding cells (proliferation index at 
generation 3 and above). Parent proteins from which epitopes derived indicated on the x-axis. HDCs – highly 
diverse controls, Ply – pneumolysin, PsaA – pneumococcal surface adhesion A, PfbA – plasmin and 
fibronectin binding protein A. 
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6.3.6 Lymphoproliferative protein identification 
Percentage epitope responses per parent protein were assessed to identify 
lymphoproliferative proteins. Where both PF and UGPI measurements were above the median 
parameter value, responses were defined as a positive. Volunteers 1 and 2 mounted an 
antigen-specific response to test epitopes from all proteins excluding PsaA in volunteer 2 (PF: 
50%, UGPI: 0%) and PfbA HDC responses in both volunteers (volunteer 1: UGPI = 0%; 
volunteer 2: PF = 0%) (Figure 6.5). This result indicated HDC PfbA epitope 55 as a 
pneumococcal-specific negative control for lymphoproliferative assays. The alternative HDC 
however, Ply epitope 54, induced a positive response in both volunteers (PF and UGPI = 
100%). 
The choline binding protein epitopes induced the greatest proportion of responses in both 
volunteers 1 and 2. Volunteer 1 responses were greatest to clades 2 (PF: 100%; UGPI: 89%) 
and 3.2.1 (PF: 100%; UGPI: 75%), whereas volunteer 2 responded highest to clade 1 epitopes 
(PF: 73%; UGPI: 67%) (Figure 6.5). 
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Figure 6.6 Percentage epitope response per parent protein. Proportion of protein epitopes with precursor 
frequency (top) or upper generation proliferation index (bottom) values above the median values graphed. 
Protein IDs on x-axis, with epitopes derived below. Number of lymphoproliferation-inducing epitopes (n) for 
volunteer 1 (open bars) and volunteer 2 (closed bars). HDC: highly diverse control; 1_2_10: choline binding 
protein 1_2_10. HDCs – highly diverse controls, Ply – pneumolysin, PsaA – pneumococcal surface adhesion 
A, PfbA – plasmin and fibronectin binding protein A.
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6.4 Discussion 
 
We optimised an assay for detection of S. pneumoniae protein linear epitope-induced 
lymphoproliferation and demonstrated that epitope 3 of in-study defined choline-binding 
protein 1_2_10 clade 1 induced the greatest proliferative activity in selected healthy adults. In 
this pilot study, lymphoproliferation was measured by precursor frequency (probability of 
antigen-specific proliferating cell division) and upper generation proliferation index (measure 
of increase in cell number of true proliferating cells). We also identified a pneumococcal-
specific highly diverse control linear epitope, number 55, originating from pneumococcal 
plasmin and fibronectin protein A (PfbA). 
 
6.4.1 Questions answered: study in field context 
The majority of pneumococcal vaccine candidates employed in this study were cell surface 
proteins, chosen due to studies in the field demonstrating them as protective against 
pneumococcal infection. Exposed to the host immune system on invasion, these polypeptides 
are a common target in vaccine design (Gamez and Hammerschmidt, 2012). Our in silico 
identification of a PsaA fragility island located within the zinc-uptake component (epitopes 52 
and 53), and its ability to induce lymphocyte proliferation, aligns with the findings of Lagousi 
and colleagues (2015). Their approach to identifying 10 immunodominant B-cell epitopes in 
patients with IPD yielded 10 immunodominant epitopes, 4 of which were within the zinc finger 
region. 
A reoccurring motif falling within our identified fragility islands and from which we selected 
conserved sequences, was the leucine rich repeat (LRR). These sequences form alternating 
alpha helix-beta strand motifs, which in succession build a ‘horse-shoe’-shaped molecule 
common on cell surface proteins, and play a role in providing a scaffold for protein-protein 
interactions necessary for host cell adherence (Kobe and Kajava, 2001, Glover et al., 2008).  
It is widely acknowledged that computational methods of epitope identification must be 
coupled with immunological techniques for maximum potential (Ip et al., 2015). We employed 
lymphoproliferation assays to compare proliferative potential of epitopes in two healthy adult 
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volunteers. Newly categorised choline binding protein 1_2_10 clade 1 (closest consensus 
homology to PspC) yielded epitopes with highly variant proliferation profiles in both volunteers. 
PspC is a polymorphic protein and is known to generate antibodies cross-reactive to choline 
binding protein PspA (Brooks-Walter et al., 1999). Furthermore, PspA has been shown to 
contain epitopes eliciting protection against infection (Daniels et al., 2010), and we have 
described PspA B-cell epitopes as a marker of pneumococcal exposure in adults (Owugha et 
al., in preparation), noting previous reports of PspA as a non-immunodominant protein antigen 
in paediatric cases of IPD (Lagousi et al., 2015).  
Our method of identifying conserved epitopes of functional importance is novel in its 
incorporation and weighting of global coverage of protein sequences. This accounts for any 
collection bias and therefore provides a truer reflection of global distribution and utility as a 
vaccine target (Blight et al., unpublished data). Chandra and Yadav (2016) acknowledge the 
importance of population bias in their identification of Mycobacterium immunogenum antigens, 
but we have utilised an algorithm described for the first time which integrates this factor into 
epitope discovery. 
 
6.4.2 Questions raised: study limitations  
Selecting virulence proteins to investigate based on prior studies promoting antigens as 
promising vaccine candidates poses its limitations. Proteins that may not play a major role in 
pneumococcal virulence but be highly expressed and therefore serve as an effective pathogen 
targeting mechanism, may be overlooked. Furthermore, if epitopes of poorly virulent yet 
densely expressed proteins were coupled to virulence epitopes, there is prospect of a 
combined effect of a target both highly expressed with a cost to pneumococcal fitness. 
Therefore, techniques which employ a non-selective approach to screening of the 
pneumococcal proteome to identify such peptides are favourable. An overview of high 
throughput T-cell epitope mapping techniques in vaccine development (Malherbe, 2009)  
includes: the mainstay enzyme-linked immunospot assays (ELISPOT) which monitors the 
cytokine secreting activity of antigen-induced PBMCs; and an alternative flow cytometry 
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method known as tetramer-guided epitope mapping, where MHC class II tetramers are used 
to label antigen-stimulated PBMCs to identify antigenic epitopes. 
We employed the long-standing lymphoproliferation technique as an initial basic method of 
screening epitope immunogenicity, harnessing measures of precursor frequency (PF) as a 
marker of probability that antigen-specific proliferating cells divide at least once, and upper 
generation proliferation index (UGPI) as a measure of increase in number of true proliferating 
cells. These two measures were evaluated in tandem because one alone does not give a full 
picture of lymphoproliferation and may have skewed analysis (Roederer, 2011). We did not 
incorporate the basic measure of number of epitope-induced daughter generations, as this 
parameter has the propensity to skew conclusions toward non-lymphoproliferative epitopes 
where few new generations are being formed. Biologically, this can be attributed to a 
propensity towards epitope-induced clonal expansion over division, a functional distinction 
worth consideration. The acquisition of various effector and memory phenotypes which 
promote functional immune responses would be beneficial in vaccine-induced protection, and 
is better reflected in parameters of PF and UGPI which incorporate total cell number and 
therefore the population size.   
A further complication to assessing lymphoproliferation responses lies in the variation between 
human responses. Differences in immune response to the same antigen across volunteers is 
an expected phenomenon due to the intrinsic host factor of human leucocyte antigen (HLA) 
variation. We therefore ranked lymphoproliferation per volunteer, and selected 10 different 
epitopes from each which were in the top twenty listed as no single epitope was cross-
volunteer lymphoproliferative (as measured by both top 20 PF and UGPI responses). Studies 
identifying immunogenic epitopes to other pathogens or allergens have human volunteer 
sample sets an order of magnitude greater than this pilot - n = 22 when investigating 
immunogenic Mycobacterium tuberculosis epitopes (Panigada et al., 2002) and n = 18 for 
peanut allergen epitope identification (Prickett et al., 2013) - yet require an epitope selection 
cut-off of 50% of volunteers with a positive CD4+ lymphoproliferative response to an epitope.  
Furthermore, the exogenous factor of unknown pneumococcal exposure history which affects 
variation: it is understood that individual responses to pneumococcal proteins vary across 
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individuals, and that this increases with age and exposure, measurable in infants as young as 
6 months but decreasing again in the elderly who have lower rates of colonisation and 
therefore pneumococcal exposure (Rapola et al., 2000). Therefore, exposing our volunteers 
to a controlled dose of pneumococci in our Experimental Human Pneumococcal Carriage 
(EHPC) model may serve to boost immune response and enable investigation of epitope 
responses due to recent exposure, eliciting a more pronounced and therefore comparison of 
epitope-induced lymphoproliferative response. An increased CD4+ T-cell response to hepatitis 
delta virus (HDV) was observed in volunteers with signs of inactive HDV-induced disease, 
compared to control subjects and patients with active disease (Nisini et al., 1997). 
 
6.4.3 Questions posed: further work and study implications  
Lymphoproliferation was utilised in this pilot study as an initial screen to assess epitope-
induced T-cell immunogenicity. To reduce the hurdles of volunteer HLA variation with this 
technique, computational selection of epitopes that bind promiscuously to MHC II molecules 
is an approach that has been harnessed to down-select epitopes (Diethelm-Okita et al., 1997). 
Tools exist to aid in their prediction and include the Immune Epitope Database and analysis 
resource (Vita et al., 2010): these aids have been used in selection of immune epitopes for 
other bacterial pathogens such as Staphylococcus aureus (Yu et al., 2015) and can be 
employed to improve future epitope selection screening.  
The data presented here represent a pilot dataset for the first stage in investigations to produce 
a multiple epitope vaccine protective against pneumococcal infection. Results demonstrated 
the ability to measure epitope-induced lymphoproliferation by PF and UGPI, but highlighted 
the need for larger datasets due to the variation in human responses.  
Going forward, the remaining 86 epitopes will be assayed in a similar manner with a larger 
sample size of ten volunteers (the pilot epitope dataset will be increased), and epitope pools 
screened and titrated to identify the optimal combination and concentration of 
lymphoproliferative epitopes. The method of pooling epitopes is an approach which has been 
taken to identification of immunogenic epitopes in HIV (Rubio-Infante et al., 2015) and hepatitis 
E (Aggarwal et al., 2007). Cytokine analysis of cell culture supernatants harvested from 
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lymphoproliferative assays can then be conducted to investigate polarisation in T-cell immune 
responses, and further select an epitope pool secreting cytokines toward a CD4+ T-cell profile.  
The end goal this project is the construction of a novel multiple-epitope protein that can be 
used to immunise mice and test for protection from a range of pneumococcal infections. 
However, Macmillan and co-workers' (2008) caution on construction of novel proteins must be 
heralded: they noted that the original ability of whole outer membrane fractions of Anaplasma 
marginale to elicit protection against disease due to complex structural interactions, may be 
abrogated on fusion of peptides that what would on the bacterial membrane have been distally 
located epitopes. We aim to decipher the optimal combination of peptides for fusion protein 
construction by initially investigating lymphoproliferation on stimulation with epitope pools. 
Epitopes from lymphoproliferative pools will be fused in a variety of sequences to identify the 
most protective novel protein, and address any potential sub-optimal peptide structural 
interactions. 
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CHAPTER 7 
 
General discussion 
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7 General discussion 
 
Currently licensed vaccines against pneumococcal infection are efficacious against invasive 
disease syndromes, but less so against mucosal infections including pneumonia. Furthermore, 
the serotype-targeted approach of pneumococcal conjugate vaccines (PCVs) to vaccination 
permits S. pneumoniae vaccine escape and proliferation of disease by non-vaccine serotypes. 
Therefore, there is a merited need for research into mucosally effective serotype-independent 
vaccination strategies against pneumococcal infection. 
The Experimental Human Pneumococcal Carriage model has been demonstrated as safe, 
efficient and cost-effective in testing the efficacy of PCV13 against pneumococcal colonisation. 
Using this platform, we investigated the relationship between the biological state of carriage 
as a prerequisite and proxy to infection in the natural host, and pneumococcal protein vaccine 
candidate immunity, with an emphasis on pneumococcal surface protein A (PspA). We aimed 
to: 
1. Further our current understanding of humoral PspA-specific responses to                        
S. pneumoniae 
2. Investigate blood PspA-specific CD4+ T-cell responses to S. pneumoniae 
3. Investigate BAL PspA-specific CD4+ T-cell responses to S. pneumoniae 
4. Investigate S. pneumoniae protein-specific systemic epitope-induced 
lymphoproliferation 
 
7.1 Questions answered: a summary of thesis findings and implications for new 
vaccines against pneumonia  
 
7.1.1 Humoral PspA-specific responses to S. pneumoniae 
We describe for the first time a suggested PspA family-specific protection against re-
colonisation with S. pneumoniae vaccine serotype 6B, in individuals who had a recent episode 
of natural carriage. Furthermore, controlled dosage exposure to S. pneumoniae induced 
cross-reactive IgG to homologous and heterologous PspA family types in individuals both 
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protected from and susceptible to carriage. Post-inoculation PspA-specific IgG binding 
functionality however, was greatest in carriage positive volunteers. 
These data highlight a potential role of PspA in protection from carriage: this observation is 
family-restricted, and therefore re-iterate the importance of inclusion of PspA family 1 and 2 
antigens in serotype-independent vaccine strategies. Humoral-specific observations of 
promiscuous PspA family binding demonstrates PspA-specific IgG as a marker of 
pneumococcal exposure, but not associated to prevention of carriage.   
 
7.1.2 Blood PspA-specific CD4+ T-cell responses to S. pneumoniae 
We have provided the first evidence of measurable CD4+ T-cell responses specific to an 
individual pneumococcal purified protein in the blood of healthy adults both before and after 
carriage. Post-inoculation, we observed a boost in PspA-specific (alpha helical domain 
Fragment 2 and proline-rich region Fragment 7) CD4+TNFα+ responses to S. pneumoniae, 
and a weak yet significant inverse correlation between PspA-specific CD4+TGFβ+ responses 
and colonisation intensity.  
Our observations highlight the role of CD4+TNFα+ responses to S. pneumoniae colonisation 
as markers of pneumococcal carriage, and CD4+TGFβ+ responses as playing a role in control 
of colonisation in healthy adults. Together, these data demonstrate PspA immunogenicity, and 
support a PspA vaccine effort in targeting pneumococcal blood infections and diseases. 
 
7.1.3 BAL PspA-specific CD4+ T-cell responses to S. pneumoniae 
We did not detect a robust PspA-specific CD4+ T-cell response to S. pneumoniae in BAL of 
healthy adults after pneumococcal exposure: levels were reduced compared to those in blood. 
These data suggest a compartmentalisation in immune response, and non-immunodominant 
role of PspA in response to pneumococcal exposure in the healthy adult lung. They do not 
support a PspA vaccine effort in targeting pneumococcal lung infections and diseases 
including pneumonia (subject to limitations discussed in Chapter 5), therefore merit research 
of alternative pneumococcal protein-induced immunity in the human lung. 
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7.1.4 Systemic S. pneumoniae epitope-induced lymphoproliferation 
In a pilot study of pneumococcal epitope-induced lymphoproliferation, we demonstrated an 
epitope within the conserved and functionally relevant fragility sequence of newly defined 
choline-binding protein 1_2_10 clade 1, induced the highest lymphoproliferative activity in 
healthy adults (Epitope 3). A highly diverse control (Epitope 55) from pneumococcal plasmin 
and fibronectin protein A (PfbA), was conversely universally poor as a lymphoproliferation 
inducer. The observation of cross-volunteer immunogenic Epitope 3 and non-immunogenic 
Epitope 55, showcase the optimisation of an assay with ability to discriminate 
lymphoproliferation levels on stimulation with 20 aa linear epitopes. 
These data preliminarily support the combination of in silico computational methods with 
immunological techniques to identify conserved pneumococcal epitopes of functional 
importance, and subsequently validate their immunogenicity in efforts towards design of a 
multiple pneumococcal protein vaccine. 
 
7.2 Conclusions and perspectives 
 
We have optimised a protocol for measurement of pneumococcal protein-specific CD4+ T-
lymphocyte responses to S. pneumoniae in the blood of healthy adults. With this we 
demonstrated PspA-specific CD4+TNFα+ responses to S. pneumoniae as markers of carriage, 
and PspA-specific CD4+TGFβ+ responses to S. pneumoniae as playing a role in regulation of 
colonisation in adults susceptible to carriage. We did not detect significant CD4+ T-cell PspA 
immune responses to S. pneumoniae in bronchoalveolar lavage, therefore suggest PspA is 
not an immunodominant pneumococcal antigen in the lung. Although the protective potential 
of PspA was emphasised on observing a role of homologous family protection from carriage 
re-acquisition, it is axiomatic that research into multiple pneumococcal proteins particularly at 
the relevant mucosal site of the lung, would support serotype independent pneumococcal 
vaccine design vaccines efforts against pneumococcal pneumonia. 
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Appendices 
 
Appendix A Fragmentation of conserved sequences within fragility islands 
Protein Epitope ID Sequence Amino acids (n) 
1_2_10 clade 1 1 KTVPDGAKLTGEAGKAYNET 20 
 2 GEAGKAYNETRTYAKEVVDK 20 
 3 RTYAKEVVDKSKKLLSQTAV 20 
 4 SKKLLSQTAVTMDELAMQLT 20 
 5 TMDELAMQLTKLNDAMSKLK 20 
 6 KLNDAMSKLKEAKAKLVPEV 20 
 7 EAKAKLVPEVKPQPENPEPK 20 
 8 KPQPENPEPKEAKAKLVPEV 20 
 9 EAKAKLVPEVKPQPENPEPK 20 
 10 KPQPENPEPKPQPEGEKPSV 20 
 11 PQPEGEKPSVPDINQEKEKA 20 
 12 PDINQEKEKAKLAIATYMSK 20 
 13 KLAIATYMSKILDDIKKHHL 20 
 14 ILDDIKKHHLKKEKHHQIVA 20 
 15 KKEKHHQIVALIKDLDKLKK 20 
 16 LIKDLDKLKKQALSEIDNVN 20 
 17 QALSEIDNVNTKVEIENTVH 20 
 18 TKVEIENTVHKVFADMDTVV 20 
 19 TVHKVFADMDTVVTKFQKGL 20 
 20 PFTIPTKITVGDKVFTVTEV 20 
 21 GDKVFTVTEVASQAFSYYPD 20 
 22 ASQAFSYYPDETGRIVYYPS 20 
 23 ETGRIVYYPSSITIPSSIKK 20 
 24 SITIPSSIKKIQKKGFHGSK 20 
 25 IQKKGFHGSKAKTIIFDKGS 20 
 26 AKTIIFDKGSQLEKIEDRAF 20 
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 27 QLEKIEDRAFDFSELEEIEL 20 
 28 DFSELEEIELPASLEYIGTS 20 
 29 PASLEYIGTSFSFSQKLKKL 20 
 30 FSFSQKLKKLTFSSSSKLEL 20 
 31 TFSSSSKLELISHEAFANLS 20 
 32 ISHEAFANLSNLEKLTLPKS 20 
 33 EAFANLSNLEKLTLPKSVKT 20 
1_2_10 clade 2 34 GNNINSLPSFFLSGVLDSLK 20 
 35 FLSGVLDSLKEIHIKNKSTE 20 
 36 EIHIKNKSTEFSVKKDTFAI 20 
 37 FSVKKDTFAIPETVKFYVTS 20 
 38 PETVKFYVTSEHIKDVLKSN 20 
 39 EHIKDVLKSNLSTSNDIIVE 20 
 40 LSTSNDIIVEKVDNIKQETD 20 
 41 KVDNIKQETDVAKPKKNSNQ 20 
 42 DVAKPKKNSNQGVVGWVKDK 20 
1_2_10 clade 
3.2.1 
43 AKKEVEAKELEIEKLQDEIS 20 
 44 EIEKLQDEISTLEQEVATAQ 20 
 45 DEISTLEQEVATAQHQVDNL 20 
 46 TELEKLLDSLDPEG 14 
Ply 47 AKWHQDYGQVNNVPARMQYE 20 
 48 NNVPARMQYEKITAHSMEQL 20 
 49 KITAHSMEQLKVKFGSDFEK 20 
 50 KVKFGSDFEKTGNSLDIDFN 20 
 51 NVRNLSVKIREC 12 
PsaA 52 ADLIFYNGINL 11 
 53 GAFKYFSKAYG 11 
Ply HDC (C01) 54 TSKSDEVEAAFEALIKG 17 
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PfbA HDC 
(C06i) 
55 DNNSSLSTDNNGGVSINQNK 20 
PotD 56 AIILVLWGIATHLDSKINSR 20 
 57 LWGIATHLDSKINSRDSQKL 20 
 58 FDSNEAMYTKIKQGGTTYDI 20 
 59 EAMYTKIKQGGTTYDIAIPS 20 
 60 QQLEETVDKLYKLTPNIKA 19 
 61 AIGVTFSGEASQMLEKNENL 20 
 62 SGEASQMLEKNENLRYVVPT 20 
NanA 63 TWHAGEAVNDNRQVDGQKIH 20 
 64 NRQVDGQKIHSSTMNNRRAQ 20 
 65 SSTMNNRRAQNTESTVVQLN 20 
 66 NTESTVVQLNNGDVKLFMRG 20 
 67 TESTVVQLNNGDVKLFMRGL 20 
 68 PKRENGMVHLARVEENGELT 20 
 69 ARVEENGELTWLKHNPIQKG 20 
 70 WLKHNPIQKGEFAYNSLQEL 20 
 71 EFAYNSLQELGNGEYGILYE 20 
 72 GNGEYGILYEHTEKGQNAYT 20 
 73 NGEYGILYEHTEKGQNAYTL 20 
NanB 74 NYFRIPTLYTFSNGRVFSSI 20 
 75 TFSNGRVFSSIDARYGGTHD 20 
 76 KINIATSYSDDNGKTW 16 
 77 SYGTQLSAIKYSQLIDGKEA 20 
 78 IKYSQLIDGKEAVILSTPNS 20 
 79 VPMNVFYKDSLFKVTPTNYI 20 
 80 LFKVTPTNYIAMTTSQNRGE 20 
 81 AMTTSQNRGESWEQFKLLPP 20 
 82 MTTSQNRGESWEQFKLLPPF 20 
 83 VHMNIFYKDALFKVVPTNYI 20 
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 84 LFKVVPTNYIAYISSNDHGE 20 
 85 AYISSNDHGESWSAPTLLPP 20 
 86 YISSNDHGESWSAPTLLPPI 20 
PepO 87 SWSKWNQPVDYKEWGMPAHM 20 
 88 YKEWGMPAHMVNAYYNPQKN 20 
 89 VNAYYNPQKNLIVFPAAILQ 20 
 90 LIVFPAAILQAPFYDLHQSS 20 
 91 APFYDLHQSSSANYGGIGAV 20 
 92 SSSANYGGIGAVIAHEISHA 20 
PfbA 93 TGLFTDDGAQVEWGP 15 
 94 MNGALNEEGTKAKNLPLINS 20 
 95 PLTRKGFPYALNDDGKKS 18 
GlpO 96 DLLIIGGGITGAGVALQAAA 20 
 97 GAGVALQAAASGLETGLIEM 20 
 98 SGLETGLIEMQDFAEGTSSR 20 
 99 QDFAEGTSSRSTKLVHGGLR 20 
 100 STKLVHGGLRYLKQFDVEVV 20 
 101 GLRYLKQFDVEVVSDTVSER 20 
 102 DIESSWAGLRPLIA 14 
 103 SKEKTREDVESAVSKLESST 20 
 104 SAVSKLESSTSEKHLDPSAV 20 
 105 SEKHLDPSAVSRGSSLDRDD 20 
 106 SRGSSLDRDDNGLLTLAGGK 20 
 107 NGLLTLAGGKITDYRKMAEG 20 
 108 ITDYRKMAEGAMERVVDILK 20 
 109 TDYRKMAEGAMERVVDILKA 20 
MalX 110 KTDDTTKSLVTAANGKVYGA 20 
 111 TAANGKVYGAPAVIESLVMY 20 
 112 PAVIESLVMYYNKDLVKDAP 20 
 113 YNKDLVKDAPKTFADLENLA 20 
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 114 KTFADLENLAKDSKYAFAGE 20 
 115 KDSKYAFAGEDGKTTAFLAD 20 
 116 DGKTTAFLADWTNFYYTYGL 20 
 117 GKTTAFLADWTNFYYTYGLL 20 
 118 FQEGKTAAIIDGPWKAQAFK 20 
 119 DGPWKAQAFKDAKVNYGVAT 20 
 120 DAKVNYGVATIPTLPNGKEY 20 
 121 GVATIPTLPNGKEYAAFGGG 20 
 122 IPANTEARSYAEGKNDELTT 20 
 123 AEGKNDELTTAVIKQFKNTQ 20 
 124 AVIKQFKNTQPLPNISQMSA 20 
 125 PLPNISQMSAVWDPAKNMLF 20 
 126 TSKSDEVEAAFEALIKG 17 
IgA1 HDC 
(C02) 
127 YDRYRSSEYPKGEKLNKFVE 20 
 128 KGEKLNKFVEENAHEAAKRF 20 
 129 ENAHEAAKRFRNHYDYWYKI 20 
 130 RNHYDYWYKILDNDNKEKLF 20 
 131 LDNDNKEKLFRSVLVYDAFR 20 
 132 RSVLVYDAFRFGNDKNDKIQ 20 
 133 VLVYDAFRFGNDKNDKIQEA 20 
IgA1 HDC 
(C03) 
134 NMFDLIYTLEILEGRAVAKL 20 
 135 ILEGRAVAKLGYNEKNDLLR 20 
 136 GYNEKNDLLRKIENIYKKDP 20 
 137 KIENIYKKDPDGNQVYATNA 20 
 138 KKDPDGNQVYATNAIRRLTP 20 
ZmpB HDC 
(C04) 
139 QLPTFVKTMFENEWLHINGE 20 
 140 ENEWLHINGESSGAVAALRQ 20 
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 141 SSGAVAALRQKIMDNKTAIL 20 
 142 KIMDNKTAILLALTYINRYY 20 
 143 NKTAILLALTYINRYYDVKF 20 
ZmpB HDC 
(C05) 
144 WYAYHGYGAHAGGRNRVNYE 20 
 145 AGGRNRVNYEVFDVLSEYGI 20 
 146 VFDVLSEYGISVFTHELTHV 20 
 147 SVFTHELTHVNDTWIYLGGY 20 
 148 FTHELTHVNDTWIYLGGYGR 20 
PfbA HDC (C06 
ii - iv) 
149 NGGVSINQNKPDITNDTMMG 20 
 150 PDITNDTMMGNISGMEVNTI 20 
 151 TMMGNISGMEVNTILSTNLN 20 
 C – control (followed by identification number); HDC – highly diverse control 
 
 
 
 
 
 
 
 
 
 
 
 - 171 - 
 
Appendix B Epitope lymphoproliferative response rankings 
 Volunteer 1 Volunteer 2 
Ranking Epitope PF Epitope UGPI Epitope PF Epitope UGPI 
1 32 0.46 1 18.92 25 0.33 22 6.63 
2 50 0.44 38 17.07 24 0.29 21 6.57 
3 2 0.43 28 15.54 23 0.28 23 6.41 
4 54 0.42 36 15.07 21 0.25 20 6.35 
5 44 0.41 30 15.06 3 0.24 24 5.50 
6 46 0.41 29 14.53 16 0.24 19 5.43 
7 42 0.41 4 13.92 20 0.22 18 4.96 
8 45 0.41 3 13.70 22 0.21 25 4.90 
9 1 0.41 45 13.67 19 0.21 17 3.64 
10 52 0.40 47 13.57 15 0.21 16 3.62 
11 51 0.40 26 13.57 17 0.19 15 2.11 
12 48 0.40 50 13.48 18 0.19 9 1.66 
13 43 0.39 35 13.46 14 0.17 14 1.53 
14 31 0.38 44 13.28 13 0.17 11 1.42 
15 55 0.38 2 13.15 12 0.14 10 0.90 
16 53 0.38 37 12.89 11 0.14 12 0.89 
17 38 0.37 54 12.59 9 0.12 13 0.85 
18 37 0.37 41 12.43 8 0.11 30 0.20 
19 4 0.37 52 12.41 10 0.09 29 0.08 
20 3 0.35 49 12.30 7 0.07 4 0.03 
21 40 0.35 27 12.23 50 0.03 36 -0.01 
22 47 0.33 34 12.05 32 0.02 47 -0.09 
23 39 0.33 42 12.03 36 0.01 2 -0.10 
24 49 0.32 40 12.00 2 0.01 39 -0.11 
25 36 0.32 33 11.92 52 0.01 28 -0.12 
26 41 0.31 48 11.88 44 0.01 54 -0.14 
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27 34 0.30 43 11.48 4 0.01 41 -0.15 
28 35 0.28 32 11.42 1 0.00 49 -0.16 
29 26 0.26 53 11.37 46 0.00 26 -0.17 
30 33 0.26 39 11.36 33 0.00 7 -0.18 
31 29 0.20 55 11.20 6 0.00 43 -0.19 
32 28 0.09 51 11.03 5 -0.02 45 -0.20 
33 27 0.09 46 10.81 45 -0.02 51 -0.20 
34 30 0.06 31 10.49 34 -0.02 42 -0.21 
35 13 -0.03 25 2.33 38 -0.02 35 -0.23 
36 16 -0.03 21 1.90 39 -0.03 37 -0.23 
37 24 -0.03 20 1.61 40 -0.04 55 -0.23 
38 12 -0.04 22 1.35 51 -0.04 48 -0.25 
39 17 -0.04 23 1.15 42 -0.06 27 -0.27 
40 23 -0.04 17 1.04 43 -0.07 1 -0.30 
41 22 -0.05 24 1.02 41 -0.07 38 -0.33 
42 15 -0.05 19 0.82 54 -0.07 31 -0.34 
43 21 -0.05 5 0.66 37 -0.08 34 -0.34 
44 25 -0.05 16 0.63 55 -0.08 44 -0.34 
45 19 -0.06 18 0.23 53 -0.09 53 -0.39 
46 10 -0.06 15 0.21 27 -0.09 32 -0.41 
47 20 -0.06 9 0.08 35 -0.09 50 -0.42 
48 7 -0.06 13 -0.04 49 -0.10 46 -0.47 
49 11 -0.06 14 -0.07 48 -0.10 33 -0.49 
50 18 -0.07 8 -0.14 47 -0.10 8 -0.50 
51 14 -0.07 7 -0.43 31 -0.12 40 -0.56 
52 6 -0.07 12 -0.46 28 -0.12 5 -0.57 
53 8 -0.08 11 -0.62 26 -0.13 52 -0.62 
54 5 -0.19 10 -0.68 29 -0.13 3 -1.02 
55 9 -0.20 6 -0.71 30 -0.23 6 -1.28 
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- US 0.66 US 12.58 US 0.37 US 6.95 
- PHA-L -0.08 PHA-L 60.47 PHA-L 0.29 PHA-L 0.29 
 
Top twenty epitopes coloured per volunteer: volunteer 1 (green) and volunteer 2 (blue). PF = precursor frequency; 
UGPI = upper generation proliferation index; PHA-L = leucoagglutinating phytohemagglutinin. 
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